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Abstract 
 
One key hallmark of cancer is its ability to evade apoptotic cell death. In normal cells, the 
apoptotic intrinsic and extrinsic pathways converge on the activation of executioner cysteine 
aspartate proteases caspases-3 and -7. However, cancer cells are able to escape apoptosis through 
mutations which render the key apoptotic proteins inactive or aberrantly expressed.  
Paradoxically, procaspases are generally upregulated and rarely mutated in cancers. Therefore, a 
small molecule that directly activates executioner procaspase-3/-7 to caspase-3/-7 to induce 
apoptosis in cancer cells could circumvent the defective apoptotic machinery and serve as an 
effective personalized anti-cancer therapy. Described herein are the in vitro mechanisms and the 
in vivo anticancer application of procaspase activators PAC-1 and S-PAC-1, the identification of 
novel procaspase activating compounds, and the evaluation of procaspase-3 levels in human 
cancers.     
Several procaspase activating compounds have been discovered in the Hergenrother 
laboratory through high-throughput screening and will be discussed in this thesis. PAC-1 
activates procaspase-3/-7 in vitro through the chelation and sequestration of inhibitory zinc ions. 
In cells, PAC-1 is capable of inducing a decreased signal of an intracellular zinc sensor, 
suggesting that PAC-1 chelates zinc in the cytosol. Transcript profiling of PAC-1 reveals that the 
compound concentration has a very dramatic effect on the gene expression signature in 
lymphoma and leukemia cell lines. At high concentrations, PAC-1 may act by an ER stress 
mechanism, evidenced by Connectivity Map analysis, decreased ER calcium levels, and cellular 
morphology.   
Also described in this thesis are the efforts to translate procaspase activating compounds 
PAC-1 and S-PAC-1 to the clinic, using cell culture and animal studies. PAC-1 and S-PAC-1 are 
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potently cytotoxic in a variety of cancer cell lines. The in vivo safety, pharmacokinetics, and 
efficacy of PAC-1 and S-PAC-1 have been assessed in murine and canine models. S-PAC-1 has 
been found to be well-tolerated in mice, research dogs, as well as client-owned patient pet dogs 
with lymphoma. A continuous i.v. S-PAC-1 regimen led to a reduction or stabilization of tumor 
progression in some of the patient dogs after 4 weeks. PAC-1 has the unique ability to induce a 
strong cytotoxic response in cell culture with exposure times as short as 4 hours. The short 
exposure cytotoxicity would allow for a more attractive and simplified dosing regimen in vivo, 
compared to a continuous administration of the drug. However, PAC-1 is neurotoxic in vivo; 
therefore ~860 PAC-1 derivatives were synthesized in parallel, and compound L28R8 was 
identified as a compound that is safe and induces short exposure cytotoxicity.  
Efforts have been made to discover novel procaspase-3/-7 activating compounds through 
high-throughput screening. The lead compounds from a high-throughput screen for procaspase-7 
activators are likely zinc chelators, like PAC-1. Another high-throughput screening campaign 
was developed for non-zinc chelating procaspase-3/-7 activating compounds. The campaign 
resulted in promising compounds that are currently being characterized. Finally, the initial 
studies toward the characterization of procaspase-3 levels in human cancer tissue will be 
presented. The immunohistochemical analysis of procaspase-3 in colon, lung, and breast tissue 
may lead to the identification of a human cancer patient population that would most benefit from 
treatment with a procaspase activating compound.   
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Chapter 1: Mechanisms of caspase-dependent apoptotic cell 
death 
 
1.1. Introduction  
 Apoptosis, or programmed cell death, is an essential process for all multicellular 
organisms and plays a critical role in many cellular processes such as embryogenesis, the 
maintenance of cellular homeostasis, and the immune system.1-3 There are two classical 
pathways, the intrinsic and the extrinsic pathways, by which the cell undergoes apoptotic death.  
Both pathways converge on the activation of executioner caspases, which in turn cleave 
numerous intracellular substrates leading to the breakdown and packaging of cellular 
components. Surrounding cells uptake the dead cell, or apoptotic body, and recycle its cellular 
material.  
 The dysregulation of the apoptotic pathways is implicated in cancer and 
neurodegenerative diseases. Cancer cells evade apoptotic cell death through mutations that either 
inactivate or lead to abnormal protein expression of key proteins along the apoptotic pathway, 
thus facilitating the uncontrolled proliferation of the cells. Cancer research efforts, including 
those conducted in the laboratory of Paul Hergenrother, seek to develop novel anticancer agents 
that will induce apoptotic death in cancer cells.  
 Described in this chapter is a background on apoptosis and cancer. First, the classical 
pathways of apoptosis will be discussed, followed by a background about the caspases 
themselves and their role in apoptosis. Next, the role of ER stress as an apoptotic trigger will be 
addressed, including putative roles of caspases during these processes.  Finally, the mechanisms 
by which cancer evades apoptotic death and research goals to target apoptotic pathways as an 
anticancer strategy will be presented.    
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1.2. Classical caspase-dependent apoptotic pathways 
 Apoptosis plays a crucial role in processes such as cellular homeostasis, embryogenesis, 
and cellular differentiation generally through two classical pathways, the extrinsic and intrinsic 
apoptotic pathways.2 Both pathways utilize caspases, which are proteases that exist as inactive or 
low-activity zymogen precursors in the cell. In the extrinsic pathway, the binding of extracellular 
apoptotic ligands with various death receptors leads to the activation of initiator procaspases-8 
and -10. The initiator procaspases then activate the executioner procaspases-3 and -7. In the 
intrinsic pathway, cellular stresses trigger mitochondrial-mediated initiator caspase-9 activation. 
The executioner caspases-3 and -7 are activated by caspase-9. Therefore, both the intrinsic and 
extrinsic pathways lead to the activation of the executioner caspases, which then cleave scores of 
intracellular substrates leading to cell death and packaging of cellular components (Figure 1.1). 
1.2.1. Extrinsic pathway 
 In the extrinsic pathway, various extracellular apoptotic ligands trigger cell death when 
they bind to membrane-bound receptors on the cell. Some of the most characterized receptors 
include TRAIL receptors 1 and 2 (TRAILR1 and TRAILR2),4, 5 Fas,6 TNFR1,7 DR6,8 and 
TRAMP.9 Ligands such as TRAIL, Fas-ligand, and TNF bind to the receptors causing the death 
domain (DD), the intracellular portion of the receptor, to recruit initiator procaspase-8 or -10.10, 11 
Once the procaspase monomers are complexed with the ligand-bound receptors in the various 
death-inducing signaling complexes (DISCs), they are activated to caspase-8 or -10.12 These 
active initiator caspases proteolyze the large and small subunits of procaspase-3 and -7, leading 
to activation of the executioner caspases.  
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1.2.2. Intrinsic pathway 
 The intrinsic apoptotic pathway, or mitochondrial-dependent pathway, is one where an 
intracellular signal triggers apoptotic cell death. Intracellular stresses such as the buildup of 
reactive oxygen species (ROS) and DNA damage13 or endoplasmic reticulum (ER) stress14 can 
all lead to intrinsic apoptotic death. DNA-damage sensors such as kinases ATM/ATR, and 
checkpoint response proteins lead to the activation of p53.15 p53 tumor suppressor induces the 
transcriptional and non-transcriptional regulation of several pro-apoptotic factors, most notably 
bcl-2 family proteins.16 These factors induce the formation of pro-apoptotic bcl-2 proteins, such 
as Bad, Bax, and Bid to associate and form pores on the mitochondrial membrane.17-23  The 
depolarization of the mitochondria results in the release of cytochrome c and other factors such 
as endonuclease G, dATP/ATP, and apoptosis inducing factor (AIF).24, 25 The association of 
cytochrome c, Apaf-1, and procaspase-9 into the apoptosome protein complex leads to the 
activation of procaspase-9.26-29 Caspase-9 then activates procaspase-3 and procaspase-7 by 
proteolyzing the large and small subunits of the executioner caspases.  
1.2.3. Inhibition of the intrinsic and extrinsic pathways 
 The apoptotic pathways are inhibited by a number of endogenous proteins. In the intrinsic 
pathway, anti-apoptotic bcl-2 prevents mitochondrial depolarization by binding to the pro-
apoptotic bcl-2 proteins, preventing their dimerization and subsequent mitochondrial 
depolarization.30  Downstream in both intrinsic and extrinsic pathways, active caspases are 
inhibited by inhibitor of apoptosis proteins (IAPs)31 such as XIAP and Survivin.32, 33 In the case 
of XIAP, the pro-apoptotic Smac/DIABLO complex rescues XIAP-mediated inhibition of the 
caspases.34  
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Figure 1.1. Classical apoptotic pathways converge on the activation of 
executioner caspase-3/-7. The intrinsic pathway is depicted on the left. Intracellular 
stress such as DNA damage lead to p53 induced activation of pro-apoptotic bcl-2 family 
proteins that form mitochondrial transition pores. Upon depolarization of the 
mitochondria, released cytochrome c associates with procaspase-9 and Apaf-1 to from 
the apoptosome to activate caspase-9. Caspase-9 then activates procaspase-3/-7 to 
active caspase-3/-7. On the right, the extrinsic pathway is initiated by the binding of 
ligands to various membrane-bound receptors which recruit procaspase-8/-10 into the 
DISC. Following caspase-8/-10 activation, procaspase-3/-7 are activated to caspase-3/-
7. Executioner caspase-3/-7 cleave intracellular substrates and resign the cell to 
apoptotic death. 
 
1.2.4. Interrelated characteristics of the intrinsic and extrinsic pathways  
 The “intrinsic” and “extrinsic” classification of the two classical apoptotic pathways does 
not adequately describe the considerable cross-talk between the pathways. Intracellular stresses 
are thought to engage p53 in the regulation of the bcl-2 family in the intrinsic pathway, however, 
p53 also regulates the expression of death receptors such as TRAILR2 and Fas to employ the 
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extrinsic pathway.35-37 Furthermore, extrinsic initiator caspase-8 activates executioner caspases-3 
and -7, and also cleaves Bid forming truncated Bid (tBid), which associates with itself and other 
pro-apopototic bcl-2 proteins to engage the intrinsic pathway through mitochondrial 
depolarization.38 Procaspase-2 and procaspase-6 play somewhat unknown roles in apoptosis. 
Procaspase-2 has been reported to autoactivate to caspase-2 when complexed in an apoptosome-
like complex, called the PIDDosome, when it associates with PIDD and RAIDD. It is believed 
that PIDDosome-related procaspase-2 activation is triggered by p53, not necessarily 
mitochondrial depolarization.39 Further detailed work to understand procaspase-6 is necessary to 
determine its intracellular role. Procaspase-6 is known to be activated when it associates with the 
protein DEDD, caspase-8, and FADD and translocates to the nucleus for activation.40 It is also 
thought that caspase-7, once activated through the classical apoptotic pathways, will activate 
procaspase-6.41  Caspase-3 and -7 cleave hundreds of intracellular substrates, and are capable of 
proteolysis between the large and small subunits in the initiator and executioner caspases, thus 
contributing in a feedback mechanism to both apoptotic pathways.42 Therefore, no matter which 
way cell death is triggered, is possible that intrinsic and extrinsic-associated caspases play a role 
in the cell’s ultimate demise.  
1.3. Apoptotic caspases 
 Caspases (named from cysteine aspartate proteases), are cysteine endopeptidases that 
cleave after aspartate residues in numerous protein substrates.43 In the various caspases, a 
cysteine-histadine dyad exists in the active site to cleave after aspartic acids in substrates. To 
date, ten human caspases and eleven murine homologs (caspase-1 to -10, and caspase-12, -14) 
have been identified.3 Some caspases are involved in inflammatory pathways (Caspase-1, -4, -5, 
and possibly caspase-12) and caspase-14 is involved in skin cell differentiation.44  The remaining 
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caspases play a critical role to initiate and execute apoptotic pathways, and are hence grouped as 
initiator and executioner caspases. Initiator caspases, caspase-2, -8, -9, and -10, generally have 
prodomains that contain death effector domains (DED) or caspase activation recruitment 
domains (CARD) and act at the early stages of apoptosis. Executioner caspase-3, -6, and -7 have 
shorter prodomains; executioners caspase-3 and -7 in particular have a numerous known 
intracellular substrates and are considered to be the “workhorses” in apoptosis.3 All of the 
caspases exist as inactive or low activity zymogens and the cleavage between the large and small 
subunits allows for activation; in the active conformation there is greater accessibility in the 
active site for a substrate to interact with the cysteine-histidine dyad.  
1.3.1. Initiator caspases 
 Initiator caspases-8 and -10 are associated with the extrinsic apoptotic pathway; they 
exist as monomer precursors with death effector domains (DED). These domains facilitate their 
recruitment to the DISC formed with apoptotic ligands that bind to membrane-bound death 
receptors.45 After recruitment to the death receptor complex, caspase-8/-10 are autoactivated 
either by their close proximity, yielding the active caspase as a homodimer of two 
heterodimers.46 Associated with the intrinsic pathway is procaspase-9; this initiator forms the 
apoptosome complex with Apaf-1 and cytochrome c (released from the mitochondria).26-29  Once 
complexed with the apoptosome, procaspase-9 is activated to caspase-9. Caspase-2 is an initiator 
caspase in which its mechanism in apoptosis is not fully elucidated. However, as described 
above, procaspase-2 is activated when it is associated with the proteins PIDD and RAIDD to 
form the PIDDosome.39  
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1.3.2. Executioner caspases 
The three classified executioner caspases are caspase-3, -6, and -7. The lesser known and 
least characterized executioner caspase-6 has a short prodomain and a recognition sequence of 
VEID,47 unique from caspase-3/-7, which generally prefer DEVD.48 Once activated in the 
nucleus,40 caspase-6 is known to cleave nuclear membrane maintenance proteins Lamin A and 
C,49 assisting in apoptotic chromatin condensation.50 Furthermore, knock-out studies suggest that 
caspase-6 may not be critical for inducing apoptotic death; caspase-6 actvation of Lamin A 
cleavage is not necessary for apoptosis,50, 51 but rather may be more involved in cellular 
differentiation pathways and immune responses.52, 53 Other details about the role of caspase-6 in 
the cell remain to be elucidated, however, since Lamin A and C cleavage are relatively late stage 
events in apoptosis, it appears to act secondary to caspase-3 and caspase-7.41  
Different models of executioner caspase activation exist for procaspase-3 and procaspase-
7. The generally accepted mechanism, based predominantly on crystallographic data of the 
proenzyme and active caspase-7, has been postulated in which the zymogen procaspase-3/-7 
exists as a dimer containing two catalytic units as a core, out of which four loops project.54, 55 
Each monomer is comprised of two main subdomains, a large N-terminal subdomain and a small 
C-terminal subdomain. During apoptosis, initiator caspases typically cleave after the conserved 
aspartic acid that joins the large and small subunits in procaspase-3 (Asp175) and procaspase-7 
(Asp198). The proteolytic cleavage allows surface loops to adapt a conformation in which a fully 
functional active site forms. Afterward, the N-terminal prodomain (28aa for caspase-3 or 23aa 
for caspase-7) is cleaved. The role of the prodomain remains unknown, but it is speculated that it 
serves to sterically hinder access to the active site in the caspase-3/-7 zymogen.56 Active caspase-
3 and -7 exist as a dimer of the two cleaved heterodimers.  
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The two main executioner caspases, caspase-3 and -7 share a high degree of homology 
and a sequence identity of 54%.57, 58 Caspase-3 and -7 also cleave many of the same substrates as 
they both recognize similar tetrapeptide recognition sequences, preferentially cleaving the 
DEVD tetrapeptide recognition sequence after the last aspartic acid.48 Because of their high 
homology and their shared intracellular substrates, many studies have suggested that caspase-3 
and caspase-7 play redundant roles in the cell.59 There is evidence that support and refute this 
hypothesis. A murine knock-out study in the B6 mouse strain supports this hypothesis; caspase-3 
or caspase-7 knock-out mice are viable, and the caspase-3 and caspase-7 B6 double knock-out 
mouse died after birth, suggesting that caspase-3 or caspase-7 compensated for the lack of one 
caspase in the single knock-out B6 transgenic mouse.60-62 However, there is evidence that 
caspase-3 and caspase-7 are indeed distinct. In a different knock-out study on the 129 mouse 
strain, caspase-3 knock-out mice were embryonic lethal, while caspase-7 knock-out mice were 
viable.60, 61, 63 This suggests that caspase-3 and caspase-7 play different roles in vivo in that 
particular mouse strain. Furthermore, Martin and co-workers have shown that various caspase 
substrates were not cleaved when caspase-3-depleted Jurkat human lymphoma cell extracts were 
treated with cyt-c/dATP, yet proteolysis of these substrates was not affected in caspase-7-
depleted cell extracts.64 In a different  report, Martin and co-workers found recombinant caspase-
3 and caspase-7 cleave some substrates with similar catalytic efficiency, such as ROCK 1 
(cleaved ROCK-1 is responsible for chromatin condensation), PARP-1 (cleaved PARP-1 is 
inactivated and unable to facilitate DNA repair), and RhoGDI (regulator of Rho GTPases that 
control cell morphology), however caspase-3 cleaved more substrates than caspase-7 in the cell 
extracts from two different cell lines.65 In this study caspase-7 did selectively cleave chaperone 
p23 (modulator of Hsp90), as well. These data show that while caspase-3 and caspase-7 may 
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have some different roles in the cell, but the spectrum of intracellular substrates cleaved by 
caspase-3 suggests that caspase-3 is indeed the major executioner caspase.65 
 Regardless of the apoptotic pathway, procaspase-3 activation has been considered by 
many as the “point of no return” for a cancer cell because proteolytic cleavage of intracellular 
substrates inactives several proteins involved in cellular repair and function.66 However, there 
have been reports of transient caspase-3 activation in cell differentiation processes,67, 68 
quiescence,69 cell dispersal70 and expansion71 without leading to apoptotic death. The role and 
mechanism of transient caspase-3 activation for cell fate remains to be elucidated. Megeney and 
co-workers have reported that caspase-3 cleavage to release caspase-activated DNase (CAD) 
from its inhibitory complex (CAD/ICAD) allowed the DNase to function in skeletal muscle cell 
differentiation.72 Furthermore, caspase-3/-7 is degraded by the proteasome, and caspase-3 
cleaves substrates leading to proteasome inhibition; therefore, the balance between the 
proteasome and executioner caspases may play a role in whether apoptotic death occurs.73, 74  
1.4. Endoplasmic reticulum stress as a trigger for apoptotic death 
 Apoptotic death can be triggered through DNA damage (caused by chemical insult, 
radiation, or ROS),15 serum starvation, ER stress, among other factors. The particular factors that 
link ER stress to apoptosis will be discussed in this section.  
1.4.1. The ER as an apoptotic stimulating organelle  
 The endoplasmic reticulum is responsible for protein synthesis and folding, Ca2+ storage 
and signaling, biosynthesis of various lipids and steroids, and is involved in the maintenance of 
Ca2+ homeostasis.75 ER stress occurs when there are dramatic changes in Ca2+ levels, cellular 
glucose depletion, or build up of unfolded or misfolded proteins in the ER. When there is a 
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disruption in ER function, the cell responds with the Unfolded Protein Response (UPR), which 
attempts to decrease protein synthesis and increase the degradation of misfolded proteins. The 
UPR is triggered by three transmembrane sensors: PERK (inhibits additional protein translation), 
IRE1, and ATF6 (both signal proteins that aid the folding of the proteins).76 The UPR also leads 
to the ER-associated degradation (ERAD) and autophagic protein degradation pathways in order 
to remove and recycle excess accumulated proteins and for cell survival.77 However, when the 
ER stress is prolonged or severe, the ER becomes a source of apoptotic initiation. In the case of 
acute ER stress, the PERK and IRE1 pathways leads to the transcriptional activation of 
transcription factor CHOP.76 The upregulation of CHOP leads to the expression of proapoptotic 
factors such as TRAILR2, which is a membrane-bound death receptor that acts in the extrinsic 
apoptotic pathway. CHOP also attenuates the expression of anti-apoptotic Bcl-2 to promote an 
apoptotic response.76  
1.4.2. ER stress and ion homeostasis 
 Since the ER is a storage organelle that regulates Ca2+ homeostasis in the cell, changes in 
Ca2+ homeostasis is tied to the apoptotic response in ER stress. Ca2+ is pumped into the ER 
through the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA). Thapsigargin, a small 
molecule SERCA inhibitor, causes ER Ca2+ stores to be depleted and an increase in intracellular 
Ca2+.78 Upon acute ER stress, a conformation change in ER membrane-associated Bak and Bax 
can also lead to an efflux of Ca2+.79 The release of Ca2+ from the ER can lead to the 
depolarization of the mitochondrial membrane mitochondria-dependent (intrinsic) apoptosis. 
Furthermore, Ca2+ is thought to also lead to caspase activation through calcium-dependent 
protease m-calpain, described below.  
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 Zinc homeostasis has been associated with cell function and apoptosis, notably, zinc 
inhibits active caspase-3,-6,-7, and -8.80-82 Because of its importance in protein folding, there is 
also evidence that Zn2+ might be associated with ER stress as well. Eide and coworkers found 
ER stress and the UPR were engaged in zinc-deficient yeast and mammalian cells.83 Zinc 
transporters have been observed to effect ER function in two studies: Msc2 zinc transporter 
protein in yeast,83 and the ZnT5/ZnT6 complex in vertebrate cells.84 Furthermore, Zn2+ was 
observed to be released along with calcium in cells treated with SERCA inhibitor thapsigargin, 
suggesting that SERCA may be a mode of Zn2+ transport into the ER.85 Future studies are 
necessary to further elucidate the roles that calcium and zinc play in ER-stress associated 
apoptosis.  
1.4.3. ER stress and caspases 
 There is emerging evidence that ER stress is related to the caspases (Figure 1.2).86 As 
mentioned above, ER stress triggers and the efflux of Ca2+ from the ER. This increase in 
cytosolic Ca2+ has been observed to activate calcium-dependent protease m-calpain, leading to 
the activation of procaspase-12 (murine homolog of human procaspase-4/-5), which in turn 
activates procaspase-9; this results in an apoptotic cascade independent of mitochondrial 
depolarization.87, 88  There is other evidence that caspase-7 translocates to the ER membrane 
during ER stress and activates murine procaspase-12,88 however the mechanism behind caspase-
7’s activity is not well understood. Furthermore, caspase-12 itself may be associated with the ER 
directly; caspase-12-deficient cells are resistant to ER stress-mediated apoptosis,87 caspase-12 
knock-out mice are not protected from ER stress death.89 VCP, an ATPase modulator of ER 
stress is thought to form a putative 600 kDa caspase-9/12-activating complex called the 
“eraptosome” independent of the mitochondria.75 Finally, human caspase-4 and caspase-5 are 
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thought to be implicated in ER stress as well.90-93 They both share a relatively high homology 
>40% with murine caspase-12, and may play a similar role as caspase-12 in ER stress because 
human caspase-12 is expressed at low levels or is inactive.86,3  
 
Figure 1.2. Putative relationships between ER stress and caspase activation. Left, 
the classical intrinsic pathway. Right, the ER leads to caspase activation through four 
putative pathways. In one pathway, procaspase-4/-12 associates with the ER and is 
directly activated to caspase-4/-12, which then activates procaspase-9, leading to 
executioner caspase activation. In two additional pathways, ER stress causes an efflux 
of Ca2+, leading to either direct mitochondrial membrane depolarization (and engage the 
intrinsic pathway) or activation of m-calpain, which activates procaspase-4/-12. Finally, 
there is evidence that procaspase-7 itself may be activated at the ER membrane by ER 
stress and also participate in the activation of caspase-4/-12.   
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1.5. Apoptosis in cancer  
1.5.1. Evasion of apoptosis in cancer 
 One hallmark of cancer is the evasion of apoptosis.94 The build-up of mutations in cancer 
cells leads to aberrant expression levels or inactivating mutations of key proteins in the apoptotic 
cascade. In cases where levels of key pro-apoptotic proteins such as p53,95 Bim,96 Bax,96 Apaf-
1,97 and FLIP98 are either mutated or downregulated, the apoptotic cascade is incapable of 
signaling the downstream activation of executioner caspases. Furthermore, anti-apoptotic 
proteins, such as Bcl-2,99-101 and the IAP caspase inhibitors102-105 have been found to be 
upregulated in cancers. These aberrations, whether the downregulation of pro-apoptotic proteins 
or the upregulation of anti-apoptotic proteins, lead to defective apoptotic pathways in cancer, 
allowing the activation of the caspases to be evaded (Figure 1.3).  
1.5.2 Mutations and paradoxical elevation of procaspase/caspase levels in cancer 
 Mutations in the caspases in cancers are surprisingly rare; some mutations have been 
identified with low incidence for caspase-3,106 caspase-6,107, 108 caspase-7,109 caspase-8,110, 111 
caspase-9,112 as well as caspase-10.113 Furthermore, in many cancers, procaspase levels are 
paradoxically elevated. A number of procaspases were found to have elevated levels in a panel of 
cancer cell lines that were examined.114 Numerous studies of human tissue from various cancers 
have shown that procaspases are upregulated. For example, executioner procaspase-3 has been 
found to have upregulated levels in leukemias and lymphomas,115-119 lung cancers,120, 121 colon 
cancers,122, 123 hepatocarcinomas,124, 125 esophagus and tongue cancers,126-128 pancreatic 
cancers,129 prostate cancers,130 breast cancers,131-133 endometrial cancers,134 stomach cancers,135  
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skin cancers,136, 137 and cancers of the central nervous system.138, 139 A comprehensive description 
of these studies can be found in Chapter 5. 
Figure 1.3. Evasion of apoptotic death in cancer. A hallmark of cancer is its ability to 
evade apoptosis through various inactivating mutations and aberrant protein expression 
levels. The intrinsic pathway in some cancers is altered through mutations in p53, the 
upregulation of anti-apoptotic Bcl-2, and/or the inactivation of Apaf-1. These alterations 
prevent the triggering of the apoptosis either through the mitochondria or caspase-9 
activation. Aberrant expression of the death receptors alter the extrinisic pathway, 
leading to a failure to activate caspase-8/-10. Cancers are able to prevent the activation 
of executioner caspase-3/-7, and thus apoptotic death is evaded.   
 
1.6. Executioner caspases as an anticancer target 
 Anticancer compounds developed to target proteins along the intrinsic and extrinsic 
apoptotic pathways have shown promising therapeutic potential. However, as described above, 
many cancers have alterations in proteins downstream from currently targeted proteins, limiting 
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the therapeutic power of these strategies. For example, compounds which target p53 are 
ineffective in >50% of cancers in which p53 is mutated.140 Nevertheless, compounds such as 
inhibitors of bcl-2141 and XIAP142, 143 or activators of p53144 and the apoptosome145 have been 
developed and show considerable promise as anticancer therapies.  
 Since the activation of procaspases, is critical to the implementation of apoptotic cell 
death, efforts have been made to develop compounds that activate procaspases as an anticancer 
strategy by the Hergenrother laboratory and others. This strategy would also be considered a 
personalized anticancer treatment because procaspases are paradoxically elevated in cancers (see 
above), affording a basis for selectivity of a procaspase activating compound for cancer cells 
over non-cancerous cells. 
 In 2006, the first small molecule activator of procaspase-3/-7, procaspase activating 
compound 1 (PAC-1), was discovered in the Hergenrother laboratory through a high-throughput 
screening campaign. PAC-1 was found to activate procaspase-3 and -7 in a dose dependent 
manner in vitro, induce apoptotic death in cancer cell lines as well as in live cells isolated from 
primary resected colon and lung cancer tissue from human patients.146 Furthermore, PAC-1 was 
effective in three different mouse xenograft models. In 2009, Wells and co-workers reported the 
discovery of additional procaspase activating compounds. Procaspase-3/-6 activators 1541 and 
1541B, are thought to enhance the proenzymes’ conformation to allow for greater proteolysis to 
active caspase-3/-6.147 Together, these efforts show that procaspases are targetable by small 
molecules and indicate that procaspases may serve as worthy anticancer targets. 
 Described in this dissertation is the further development of PAC-1, PAC-1 derivatives, 
and novel procaspase activating compounds as potential anticancer therapies. In Chapter 2, the in 
vitro mechanism of PAC-1 and PAC-1 derivative S-PAC-1 will be elucidated. In Chapter 3, the 
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in vivo implications of various in silico, in vitro, cell culture and animal studies of PAC-1 will be 
discussed, as well as goals for future PAC-1-like anticancer agents. In Chapter 4, the efforts 
toward the identification of novel procaspase activating compounds and two high-throughput 
screening campaigns will be presented. Included in Chapter 5 are the initial studies toward 
evaluating procaspase-3 levels in human cancer tissue in order to identify a patient population 
that might benefit the most from procaspase activating compounds.    
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Chapter 2: In vitro and cell culture mechanisms of 
procaspase activating compounds PAC-1 and S-PAC-1 
 
Portions of this chapter were taken from: J. Mol. Biol. 2009, 388, 144-158., Nat. Protocols. 2010, 
5, 294-302., Cancer Res. 2010;70:7232-41. All experiments, unless otherwise noted in the 
chapter, were performed in full by Diana West. Experimental methods from experiments 
performed by colleagues other than myself are not included in the Materials and Methods 
section.  
 
2.1. Introduction 
 The first effort toward the discovery of compounds that directly activate procaspase-3 to 
caspase-3 was performed by the Hergenrother laboratory. A ~22,000-member compound library 
was constructed of ~14,000 purchased compounds from ChemBridge corporation, ~2000 
synthesized compounds, and ~4000 compounds collected from the Marvel storeroom at the 
University of Illinois Department of Chemistry. This library was screened with recombinant 
procaspase-3. The increase in activity of procaspase-3 activated to caspase-3 by a small molecule 
could be monitored in an in vitro caspase-3/-7 activity assay.  As a result of the screen and 
secondary assays, a compound named PAC-1 (procaspase activating compound 1) was 
forwarded as a lead dose-dependent activator (Figure 2.1.A).146  
 
Figure 2.1. Chemical structures of procaspase activating compound 1 (PAC-1) 
and derivative (S-PAC-1). 
PAC-1 S-PAC-1
A B
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 PAC-1 was reported to activate procaspase-3/-7 in vitro. Caspase-3/-7 activity was 
observed before mitochondrial membrane depolarization in cells treated with PAC-1 (compared 
to etoposide), where caspase activity was monitored in cell lysate and mitochondrial membrane 
potential was measured by mitochondrial stain by flow cytometry.146 PAC-1 induced apoptotic 
death in cancer cell lines and cells isolated from primary tumor resections. Notably, PAC-1 
cytotoxicity correlated with levels of procaspase-3 in the various cell lines tested.146 A 
fluorescent AlexaFluor-350-conjugated derivative of PAC-1, AF-350-PAC-1, was developed to 
study the effect of PAC-1 by confocal microscopy. Indeed, when live HeLa cells were treated 
with AF-350-PAC-1, the fluorescent compound co-localized with fluorescence from caspase-3/-
7 probe FAM-DEVD-FMK, placing this PAC-1 derivative at sites of active caspase-3/-7 
activity.148  
One notable PAC-1 derivative, S-PAC-1, was developed through a structure-activity-
relationship study and has been characterized along with PAC-1 as another potential anticancer 
drug.148, 149 Both PAC-1 and S-PAC-1 have been forwarded into a clinical trial of patient pet 
dogs with lymphoma and the strong clinical potential of these compounds prompted further 
investigation into the compounds’ mode of procaspase activation in order for its development as 
a personalized anticancer drug.  
Described in this chapter are efforts toward the elucidation of the in vitro and cell culture 
mechanism of PAC-1 and its derivative S-PAC-1. First, in order to evaluate procaspase 
activating compounds in vitro, a recombinant expression system for procaspase-3/-7 and a 
colorimetric caspase activity assay was utilized. An optimized solution-phase synthesis for the 
colorimetric caspase substrate was developed.  Secondly, the experiments outlined in this chapter 
demonstrate that procaspase-3/-7 and caspase-3/-7 are inhibited by zinc, and that procaspase 
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activating compounds PAC-1 and S-PAC-1 chelate the inhibitory zinc to restore the activity of 
the enzymes in vitro. Lastly, cell culture experiments show that both compounds are cytotoxic 
and chelate intracellular zinc, and have similar expression profiles and cellular phenotypes at 
concentrations lower than 50 µM; however, at high concentrations, PAC-1 appears to act by a 
unique ER stress mechanism. The data lends evidence that procaspases, zinc, and perhaps ER 
stress are related in the cell. These results impact the translation of PAC-1 and S-PAC-1 to the 
clinic.  
2.2. Monitoring in vitro caspase activity  
2.2.1. Recombinant expression of procaspase-3/-7, caspase-3/-7 
The most efficient way to obtain large quantities of procaspase-3/-7 for screening and 
testing is through recombinant expression of the enzymes in a bacterial system. Procaspase-3 and 
procaspase-7 have been reported in various expression protocols, including the expression of 
full-length affinity-tagged procaspases.150 The expression of procaspase-3 and procaspase-7 as a 
His6-tagged low-activity zymogen in E.coli has been employed in the Hergenrother laboratory; 
as procaspases are capable of autoactivating, longer expression induction duration leads to active 
caspases-3/-7 from the same plasmid as their respective precursor.150  
Plasmids encoding C-terminal His6-tagged procaspase-3 (pHC332 plasmid) and 
procaspase-7 (PET23b plasmid) were transformed into the E.coli strain BL21 DE3. Sterile Luria-
Burtani (LB) broth pre-treated with ampicillin was inoculated with a starter culture grown from a 
single colony of transformed cells. Once the cells reached an optical density (O.D.) of 0.6, they 
were induced with IPTG. Following induction, pelleting, and cell lysis, the clarified lysate was 
treated with Ni-NTA resin and the His6-tagged caspases were eluted with a high concentration of 
imidazole. The elution buffer was then exchanged with a sodium/HEPES caspase assay buffer 
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from which divalent metals were removed by Chelex® resin. The protein concentration was 
quantified with the Edelhoch method, taking into account the molar absorptivities of the 
enzymes. The enzymatic activity was further evaluated with a caspase activity assay, and correct 
molecular weight was confirmed by SDS-PAGE.  
2.2.2. Monitoring caspase activity in vitro with substrate Ac-DEVD-pNA 
Once purified, one of the most widely used in vitro assays for monitoring 
procaspase/caspase-3/-7 activity is use of the peptidic substrate DEVD conjugated to a 
fluorophore (such as AMC or AFC) or a chromophore (such as p-nitroaniline, pNA). DEVD is 
the consensus cleavage site sequence for caspase-3 and -7, and is found in shared cellular 
substrate PARP-1.151-153  
  The caspase activity assay most utilized in the Hergenrother lab uses the colorimetric 
substrate Ac-DEVD-pNA. Both caspase-3/-7 cleave after the last aspartate, releasing p-
nitroaniline; once cleaved pNA absorbs light at 405 nm (Figure 2.2). An increase in absorbance 
can be tracked over time, and is indicative of increase caspase activity. This is useful assay that 
has been employed in screens for caspase inhibitors and activators. Ac-DEVD-pNA, for 
example, is commercially available at a cost of about $70 for 5 mg (Enzo Life Sciences; at the 
time of this writing). The size of the publically accessible screening libraries has increased at 
least 10-fold since the initial discovery of PAC-1: the ~200,000 compound library at the High-
Throughput Screening Facility (HTSF, UIUC) or the ~330,000 compound library through the 
NIHC Molecular Libraries Probe Centers Network (MLPCN) are some examples of accessible 
compound libraries. The commercial acquisition of Ac-DEVD-pNA for high-throughput 
caspase-3/-7 activity assays in large high-throughput screening efforts is a major hindrance due 
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to cost. Therefore, an efficient and facile synthesis of Ac-DEVD-pNA is needed for the in-house 
production of large quantities of caspase substrate.  
Figure 2.2. Caspase activity assay with colorimetric substrate Ac-DEVD-pNA. 
Caspase and procaspase-3/-7 cleave substrate Ac-DEVD-pNA after the last aspartic 
acid, releasing p-nitroaniline, which absorbs light at 405nm.  The change in the intensity 
of the absorbance is measured over time with a spectrophotometer. For an example, a 
progress curve of procaspase-7 activity is shown with increasing amounts of 
procaspase-7 inhibitor, ZnSO4.  
 
2.2.3. Solution phase peptide synthesis of tetrameric peptide substrates 
Standard solid-phase peptide syntheses involve coupling to a resin, followed by C- to N-
terminal peptide construction in an iterative sequence involving deprotection, purification and 
coupling. Purification of products is achieved by filtration, where impurities are washed through 
a filter, which retains the solid support and the growing peptide chain. The ability to filter the 
product is advantageous when synthesizing longer peptides and facilitates automation of solid-
phase peptide synthesis. As the peptide is formed on a solid support and not in solution, coupling 
reactions are not as efficient and require large excess of each amino acid (as high as 5–40 
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equivalents). Furthermore, owing to low loading efficiency on the solid support, a large amount 
of resin is often required to produce gram quantities of the final peptide.  
Colleagues Dr. David Goode and Dr. Anil Sharma in the Hergenrother laboratory 
developed a synthetic scheme for the small-scale solution phase synthesis of caspase substrates 
and inhibitors.154 The solution-phase synthesis described in this chapter is an optimization of the 
synthetic protocol in order to obtain large quantities of a relatively short peptide. Gram quantities 
of the Ac-DEVD-pNA caspase-3/7 substrate can be synthesized, in good overall yield, using 
nearly stoichiometric quantities of reagents (the amino acids are used in only slight excess, 1.1 
equivalents). This route also allows for the addition of the chromophore before couplings, 
thereby enabling the purification of this product to be carried out early in the synthesis. In 
contrast, in solid-phase synthesis the protected peptide is typically cleaved from the resin before 
being coupled to the chromophore. 
This technique could be extended for the synthesis of other colorimetric tetrapeptide 
substrates for other caspases, such as Ac-IETD-pNA, the substrate for procaspase-8 (IETD is the 
cleavage site in procaspase-3).155, 156 Indeed, three additional peptide substrates were 
synthesized: Ac-NSVD-pNA, Ac-DSVD-pNA, and Ac-ESMD-pNA, which are the tetrameric 
cleavage sites in procaspase-3 and procaspase-7. Furthermore, this technique could also be 
applied to the synthesis of caspase inhibitors such as Ac-DEVD-fmk and Ac-DEVD-CHO. 
However, for the purposes of this chapter the use of Ac-DEVD-pNA for caspase activity assays 
will be discussed.  
2.3. Zinc inhibition of procaspase-7 and caspase-7  
Executioner caspase-7 shares a high degree of structural homology with caspase-3.57, 58 
Both procaspase-3 and procaspase-7 zymogens are expressed with a short prodomain (23 amino 
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acids) followed by large and small subunits.157 Furthermore, procaspase-3 and procaspase-7 are 
activated by upstream initiator caspases,158 and caspase-3 and caspase-7 are inhibited by zinc.82 
Both executioner caspases exist latently as low activity zyomogens that are homodimers. Once 
processed (either autocatalytically or by other proteases), the large and small subunits 
reconfigure into a heterodimer, and caspase-3/-7 both are homodimers of two heterodimers. 
Active caspase-3/-7 are known to be inhibited by zinc in vitro, and share some of the same 
intracellular substrates in the induction of apoptosis.65, 82 Since PAC-1 is an activator of both 
procaspase-3 and procaspase-7, I sought to study the in vitro mechanism of PAC-1 activation of 
procaspase-7 specifically.  
2.3.1. Development of a novel procaspase-7 uncleavable triple mutant 
 The evaluation of the activity of procaspase-7 is complicated by the heterogenous 
mixture of procaspase-7 and caspase-7.  Since procaspase-7 is capable of autoprocessing itself to 
caspase-7, it is a challenge to monitor pure procaspase-7 activity with the caspase activity assay 
because the enzyme tested may become a mixture of precursor and active caspase-7.  In an effort 
to evaluate only the activity of the procaspase-7 form of the protein, we sought to develop an 
uncleavable mutant of procaspase-7. An analogous uncleavable mutant of procaspase-3 
(procaspase-3 triple mutant “D3A” D9A/D28A/D175A) has been developed previously to study 
the proenzyme without the limitation of contaminating active caspase-3.159 Therefore, to study 
procaspase-7, the triple mutant of procaspase-7 was created for an autoproteolysis-resistant and 
catalytically active proenzyme. Formed by successive quickchange site-directed mutagenesis, the 
procaspase-7 triple mutant has the aspartic acids of two canonical caspase cleavage sites altered 
(D23 and D198), in addition to a third site (D206) that is known to be a substrate for further 
processing.56, 160 Analysis of this triple mutant by SDS-PAGE shows it to be fully stable over the 
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course of 4 h (Figure 2.3). The procaspase-7 (D23A/D198A/D206A) mutant is thus analogous to 
the procaspase-3(D9A/D28A/D175A) triple mutant and provides a version of procaspase-7 that 
is stable during the time course of the biochemical experiments described in this chapter. 
Figure 2.3. Procaspase-7 and procaspase-7 D23A/D198A/D206A. A) Representative 
SDS-PAGE gel of recombinantly expressed procaspase-7 over 4h at 37 ºC. 
Autoproteolysis of the prodomain occurs readily. B) Representative SDS-PAGE gel of 
recombinantly expressed uncleavable mutant procaspase-7 D23A/D198A/D206A over 
4h at 37 ºC. No significant autoproteolysis  is observed.  
 
2.3.2. Zinc inhibition of caspase-7, wt-PC7, and PC7 D3A 
Zinc has been shown to inhibit active caspase-7 in vitro.82 The inhibitory effect of zinc 
was tested for the first time in both procaspase-7 species (procaspase-7 and uncleavable mutant 
procaspase-7 D23A/D198A/D206A) as well as confirmed in active caspase-7. As shown in 
Figure 2.4A-C, 1 µM caspase-7 and procaspase-7 were treated with increasing concentrations of 
ZnSO4. As expected, 1-10 µM ZnSO4 was sufficient to inhibit active caspase-7. Furthermore, 10-
100µM ZnSO4 potently inhibited the uncleavable procaspase-7 D23A/D198A/D206A mutant (at 
enzyme concentration of 5 µM). To the best of our knowledge, this is the first demonstration that 
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zinc inhibits procaspase-7 activity in vitro. It should be noted that analogous experiments with 
procaspase-3, not shown here, were performed by Quinn Peterson. Indeed, zinc also inhibited all 
tested species of caspase-3: active caspase-3, procaspase-3, and uncleavable procaspase-3 D3A 
mutant.161 
2.4. PAC-1 as a zinc chelator in vitro 
2.4.1. PAC-1 chelates Zn2+  
The structure of PAC-1 contains an ortho-hydroxy-N-acyl hydrazone motif that is known 
to be a divalent metal-binding motif. Compounds containing o-hydroxy-N-acyl hydrazones motif 
have been shown to bind to metals,162 and some of these compounds bind Zn2+ with Kd values in 
the nanomolar  to micromolar range.163 Colleague Dr. David Goode determined the affinity of 
PAC-1 for zinc through two methods.161 To determine the stoichiometry and dissociation 
constant of PAC-1–Zn2+ binding, PAC-1 was titrated with increasing amounts of ZnSO4, leading 
to a change in the UV–visible spectrum of this compound. A modified version of the method of 
continuous variations was used for this determination.164 Application of the continuous variations 
method revealed that PAC-1 binds Zn2+ in a 1:1 stoichiometry, and at this stoichiometry, the 
absorption of PAC-1 was almost entirely shifted that of the zinc-bound state (96% of PAC-1 is 
Zn2+ bound at a 1:1 ratio of PAC-1–Zn2+). Using this 96% value and the obtained a Kd = 42nM 
for the PAC-1–Zn2+ interaction. In a second confirmatory experiment, Dr. Goode titrated a 
preformed complex of PAC-1 and Zn2+ with ethylene glycol bis(β-aminoethyl ether) N,N′-
tetraacetic acid (EGTA, a metal binder with a known affinity for Zn2+), and the absorbance at 
410 nm was monitored. Using the literature value for the EGTA–Zn2+ association constant,165 the 
PAC-1–Zn2+ dissociation constant was calculated to be 55 nM, in general agreement with Kd of 
42 nM calculated through the method of continuous variations. 
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Figure 2.4. PAC-1 rescue of zinc-mediated inhibition of caspase-7, procaspase-7,  
and  procaspase-7 D23A/D198A/D206A.  A-C) 1 µM caspase-7, procaspase-7, and 5 
µM procaspase-7 triple mutant is inhibited by ZnSO4 (red curve), and upon addition of 
50 µM PAC-1, the inhibition curve is shifted (blue curve), indicative of PAC-1 rescue of 
zinc-mediated enzyme inhibition. D-F) ZnSO4 effectively inhibits the DEVDase activity of 
all three caspase-7 species, and the catalytic activity is restored to varying levels upon 
addition of increasing amounts of PAC-1 (blue curve). In the absence of zinc, PAC-1 
does not affect the activity of caspase-7 species significantly (red curve).  
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2.4.2. Restoration of procaspase-7/caspase-7 activity   
 Since PAC-1 is capable of chelating zinc, experiments were conducted to assess the 
ability of PAC-1 to relieve the zinc-mediated inhibition of caspase-7 and procaspase-7 activity. 
A concentration of 50 μM PAC-1 was used for these experiments. The results from these 
experiments are displayed in Figure 2.4D-F for caspase-7, procaspase-7, and the procaspase-
7(D23A/D198A/D206A) mutant, respectively. PAC-1 relieves the zinc-mediated inhibition of 
caspase-7, procaspase-7, and the procaspase-7(D23A/D198A/D206A) mutant, as indicated by 
the shift in the ZnSO4 inhibition curves in the presence of PAC-1. Likewise, this experiment was 
performed by Quinn Peterson for caspase-3 and procaspase-3 (cleavable and uncleavable forms) 
and PAC-1 was also able to relieve the zinc-mediated inhibition of the enzymes.161 
The ability of PAC-1 to activate procaspase-7 and caspase-7 in a dose-dependent manner 
was assessed in the presence and absence of zinc. For these experiments, concentrations of PAC-
1 from 0.025 to 100 μM were evaluated, and all buffers were treated with Chelex® resin prior to 
addition of PAC-1 or zinc. The results of these experiments are displayed in Fig. 2.4 for caspase-
7, procaspase-7, and the procaspase-7(D23A/D198A/D206A) mutant, respectively. As expected, 
in the presence of zinc and very low concentrations of PAC-1, the procaspase-7 and caspase-7 
enzymes are powerfully inhibited. However, as PAC-1 concentration is increased, the activity of 
the enzymes in the buffer containing zinc is increased to 40–100% of the maximal rate (i.e., the 
rate of the enzyme in the absence of zinc). This effect was also seen with caspase-3 species in an 
experiment performed by Quinn Peterson, with one notable difference: Interestingly, very high 
concentrations of PAC-1 (~50-100 µM) inhibited procaspase-3/caspase-3 activity, this inhibition 
was not observed with the procaspase-7/caspase-7 enzymes.161  
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In addition to the use of the caspase activity assay to examine zinc inhibition of caspase-7 
species, SDS-PAGE analysis also indicates that zinc inhibits automaturation and proteolytic 
activity of the enzyme, as well as PAC-1 relief of zinc-mediated inhibition. In one study, 
increasing concentrations of ZnSO4 inhibited the ability of procaspase-7 to autoproteolyze its 
prodomain. Upon addition of PAC-1, the enzyme’s activity was restored (Figure 2.5A). In 
another study, a catalytically inactive mutant of procaspase-7, C186A, was made by site-directed 
mutagenesis. SDS-PAGE analysis revealed that active caspase-7, in the presence of ZnSO4, 
proteolyzed subunits of procaspase-7 C186A more readily when co-treated with PAC-1 than 
with vehicle alone (Figure 2.5B). Together these results indicate that zinc inhibits procaspase-7 
and caspase-7 autoproteolysis and activity, and PAC-1 activates procaspase-7 in vitro through 
the chelation of the inhibitory zinc to restore enzyme activity.  
Figure 2.5. Effect of PAC-1 (pro)caspase-7 by SDS PAGE. A) Procaspase-7 treated 
with varying amounts of ZnSO4. At 10 µM and higher, ZnSO4 inhibits procaspase-7 
autoproteolysis of the prodomain. Upon 100µM PAC-1 treatment, procaspase-7 ability 
to cleave its prodomain is restored. B) In the presence of 50 µM ZnSO4, 50 µM 
catalytically inactive procaspase-7 mutant C186A is cleaved by 10 µM active caspase-7 
more quickly over the course of 6h when treated with PAC-1, indicating that PAC-1 
rescues the ability of caspase-7 to cleave substrate procaspase-7 C186A.  
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2.5. PAC-1 and PAC-1 derivative S-PAC-1 as a zinc chelator in cell culture 
2.5.1. S-PAC-1 is similar to PAC-1 in vitro.  
PAC-1 derivatives were synthesized and evaluated by colleagues Quinn Peterson and Dr. 
Danny Hsu to determine the structure-activity relationship.148 Of the ~50 synthesized derivatives, 
many of the compounds bearing the o-hydroxy-N-acyl hydrazone motif were capable of binding 
zinc with comparable affinities to PAC-1, restoring PC3 activity through chelation of inhibitory 
zinc ions, and inducing cytotoxicity with comparable potencies as PAC-1. One derivative, S-
PAC-1, was identified among these compounds to have very similar in vitro characteristics to 
PAC-1 and was selected for further testing as it had a favorable predicted in vivo safety (this will 
be addressed in detail in Chapter 3).  
2.5.2. S-PAC-1 binds zinc and relieves zinc-mediated inhibition of procaspase-3 
The activity of S-PAC-1 was characterized in several biochemical assays analogous to 
previously performed PAC-1 studies.148, 161 Dr. Danny Hsu used an EGTA competition titration 
experiment166 to determine the Kd of the S-PAC-1-Zn2+ complex. This complex has a Kd of 46 ± 
5 nM compared with 52 ± 2 nM for PAC-1–Zn2+.148 The ability of S-PAC-1 to activate 
recombinantly expressed procaspase-3 in the presence of exogenous zinc was assessed in vitro 
by Quinn Peterson. S-PAC-1 was found to rapidly (within 5 minutes) enhance the enzymatic 
activity of the procaspase-3 D3A mutant by relief of zinc-mediated inhibition, although to a 
lesser degree than PAC-1.149 
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2.5.3. PAC-1 and S-PAC-1 continuous cytotoxicity in cancer cell lines. 
Having confirmed that S-PAC-1 chelates zinc and activates procaspase-3 in vitro, I 
assessed the cytotoxicity of S-PAC-1 against a panel of human, canine, and murine cancer cell 
lines using the sulforhodamine B assay,167 a measurement of remaining cellular biomass, and the 
MTS assay (Promega), a measurement of living cells’ ability to reduce a formazan dye. The 24-
72-hour IC50 values for PAC-1 and S-PAC-1 are reported in Table 2.1 along with data collected 
by Quinn Peterson. Both PAC-1 and S-PAC-1 have micromolar cytotoxic IC50 values against all 
lymphoma cell lines tested regardless of the species of origin. While the IC50 values of the 
compounds generally correlated between the two cytotoxicity assays, it was surprising that S-
PAC-1 was about 13-fold less potent in OSW canine lymphoma cells when assessed by the MTS 
assay at 24 and 48 h, compared to the SRB assay results in the exact same cell line. This may be 
Table 2.1. Summary of cytotoxicity data for PAC-1 and S-PAC-1. 
Cell Line Species Cancer type
Exposure Time 
(h) PAC-1 IC50 (µM)* PAC-1 IC50 (µM)† S-PAC-1 IC50 (µM)* S-PAC-1 IC50 (µM)†
HeLa Human Cervical 72 15.5 ± 3.8 - 28.4 ± 7.7 -
MDA-MB-231 Human Breast 72 9.9 ± 1.0 - 11.7 ± 5.3 -
SK-MEL-5 Human Melanoma 72 11.5 ± 3.6 - 8.6 ± 1.3 -
Jurkat Human Leukemia 72 5.7 ± 2.8 - 4.5 ± 1.1 -
U-937 Human Lymphoma 72 9.3 ± 0.5 - 6.4 ± 0.8 -
EL4 Murine Lymphoma 72 3.8 ± 0.9 - 7.1 ± 1.3 -
OSW Canine Lymphoma 24 - 6.5 ± 2.3 - 21.2 ± 6.6
48 - 2.8 ± 0.7 - 25.4 ± 4.4
72 8.6 ± 1.3 2.3 ± 0.9 11.0 ± 0.9 26.2 ± 3.3
GL-1 Canine Lymphoma 24 - 3.0 ± 0.9 - 2.5 ± 0.5
48 - 2.1 ± 1.1 - 4.9 ± 2.1
72 4.9 ± 0.3 2.2 ± 0.5 7.1 ± 0.3 4.6 ± 0.5
17-71 Canine Lymphoma 24 - 0.8 ± 0.3 - 1.9 ± 0.8
48 - 2.5 ± 0.6 - 6.0 ± 1.7
72 - 2.5 ± 0.9 - 2.7 ± 0.8
* IC50 values determined using the SRB assay by Quinn Peterson, error shown is standard error of the mean of at least 3 experiments
† IC50 values determined using the MTS assay by Diana West, error shown is standard error of the mean of at least 3 experiments
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due to differences in the metabolic activity while the cells are alive, and the remaining biomass 
after cell death in that particular cell line.   
The use of isogenic cell lines that selectively overexpress one protein is useful for 
determining the effect of a compound on cells on particular pathways. In apoptosis, bcl-2 is an 
anti-apoptotic member of the bcl-2 family that prevents apoptosis by binding to APAF-1 or by 
inhibiting the release of cytochrome c from the mitochondria.30 Bcl-2 levels are typically 
elevated in cancer cells as a way of evading apoptosis.168, 169 PAC-1 cytotoxicity was tested in 
two pairs of isogenic cell lines where bcl-2 is overexpressed through transfection: lymphomas 
Jurkat/bcl-2 and CEM/bcl-2 (compared to the vector-only controls Jurkat/neo and CEM/neo).19 It 
was predicted that if PAC-1 acted upstream bcl-2 action, then two cell lines overexpressing bcl-2 
would be less sensitive to PAC-1 treatment. Cytotoxicity was assessed by the MTS assay and, as 
expected, both the bcl-2 overexpressing cell lines and their vector-only isogenic pair were almost 
equally responsive to PAC-1 treatment for 72h: 3.6 ± 1.8 µM (neo) and 2.6 ± 0.8 µM (bcl-2) in 
the CEM cells, and 2.8 ± 0.9 µM (neo) and 2.6 ± 1.0 µM (bcl-2) in Jurkat cells, respectively 
(Figure 2.6). Together, cytotoxicity data show that PAC-1 and S-PAC-1 are potent with low 
micromolar IC50 values at 24, 48, and 72h in multiple cell lines, and comparable cytotoxicities in 
two different bcl-2 overexpressing isogenic pairs of cell lines indicate that PAC-1 most likely 
functions downstream of bcl-2 activity.   
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Figure 2.6. PAC-1 is equally cytotoxic in bcl-2 overexpressing cells as in vector 
control cells. A)  Left, Representative IC50 curves for CEM/neo and CEM/bcl cell lines 
treated with PAC-1, Right: Average IC50 values and western blot confirmation of bcl-2 
(or lack thereof) in the isogenic pair.  B) Left, Representative IC50 curves for Jurkat/neo 
and Jurkat/bcl-2 cell lines treated with PAC-1, Right: Average IC50 values and western 
blot confirmation of bcl-2 (or lack thereof) in the isogenic pair.  
 
2.5.4. Effect of PAC-1 and S-PAC-1 at low concentrations on global gene expression. 
Global transcript profiling is a useful tool to observe how compounds elicit cellular 
changes on the transcriptional level. Since PAC-1 and S-PAC-1 share a very similar compound 
structure, and many in vitro properties, it was suspected that the compounds would induce a 
similar transcript profile as well. To compare the effects of PAC-1 and S-PAC-1 on global gene 
expression, mRNA was isolated by colleague Karen Morrison from HL-60 cells that were treated 
with PAC-1 and S-PAC-1 (25 µM for each) for 6 hours, and a transcript profile was generated 
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using the Illumina human HT-12 array. PAC-1 and S-PAC-1 at 25 µM have a very similar 
pattern of up- and downregulated transcripts. DDIT4, IL8, STC2, JUN, SLC25A24, ATF3, TNF 
were all among the most highly upregulated transcripts in both treatment groups compared to 
DMSO control (Figure 2.7A). The Spearman rank correlation value,170 a measure of similarity, is 
0.928 for PAC-1 and S-PAC-1 profiles (using the top 200 up- and downregulated genes). These 
results indicate that at 25 µM, PAC-1 and S-PAC-1 act on cancer cells in a remarkably similar 
manner. The transcript profile for 25 µM PAC-1 was also carried out in U-937 cells by colleague 
Rahul Palchaudhuri, and the results largely matched that obtained in HL-60 cells; numerous 
significantly up- and downregulated genes with a p-value cut-off of 0.05 were shared between 
transcript profiles in the two cell lines (Figure 2.7B). 
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Figure 2.7. Expression profiles for PAC-1 and S-PAC-1.  A) HL-60 cells were treated 
with PAC-1 or S-PAC-1 at 25 μM for 6 hours.  Shown are the most up- or down-
regulated transcripts (p < 0.05) compared to DMSO control cells.  White text: Fold-
change values, black text: the ranks of transcripts in individual profiles. B)  Comparison 
of the expression profiles of PAC-1 in U937 and HL-60 cells.  Cells were treated with 
PAC-1 at 25 μM for 6 hours. Shown are the most up- or down-regulated transcripts (p < 
0.05) compared to DMSO control cells.  Fold-change values are shown in white. The 
ranks of transcripts in individual profiles are to the right in black text. Spearman rank 
correlation value of top 200 up- and downregulated genes is 0.701. 
PAC‐1 S‐PAC‐1 Rank
DDIT4 10.4 14.9 1,1
IL8 6.5 6.0 2,3
STC2 4.5 6.4 3,2
JUN 4.3 4.2 4,4
SLC25A24 4.0 3.9 5,6
ATF3 3.5 4.1 11,5
TNF 3.7 3.6 10,7
IL1B 3.8 3.3 8,11
CCL3 4.0 3.0 6,19
ADM 3.5 3.3 12,12
RGS16 3.4 3.3 13,10
CDKN1A 3.3 3.5 14,8
CCL3L3 4.0 2.6 7,30
CCL4L2 3.8 2.5 9,31
PMAIP1 3.0 3.2 20,13
TNFAIP3 3.1 3.0 18,17
NFKBIA 3.2 2.9 15,23
SLC2A3 3.0 3.0 21,16
CYP4B1 3.1 2.8 19,25
MAFF 2.8 3.0 25,15
EGR1 2.7 2.9 26,22
CD83 3.1 2.5 17,32
CCNE2 2.9 2.6 22,29
CCL4L1 3.1 2.4 16,41
PCK2 2.2 3.4 43,9
CTH 2.5 2.9 30,21
NFKBIZ 2.5 2.7 29,26
INHBE 2.2 3.2 41,14
CHAC1 2.4 2.9 34,24
GPT2 2.3 2.9 37,20
KIFC1 ‐2.2 ‐2.3 ‐38,‐37
GTSE1 ‐2.2 ‐2.3 ‐33,‐41
AURKB ‐2.1 ‐2.5 ‐39,‐31
CDCA8 ‐2.2 ‐2.5 ‐34,‐32
BUB1 ‐2.1 ‐2.5 ‐40,‐25
MYBPH ‐2.3 ‐2.4 ‐31,‐33
RACGAP1 ‐2.4 ‐2.4 ‐25,‐35
TPX2 ‐2.4 ‐2.4 ‐26,‐34
KPNA2 ‐2.4 ‐2.5 ‐28,‐27
FAM72D ‐2.4 ‐2.5 ‐22,‐29
CENPF ‐2.5 ‐2.5 ‐20,‐28
AURKA ‐2.4 ‐2.6 ‐24,‐24
MGC40489 ‐2.5 ‐2.6 ‐19,‐23
DLGAP5 ‐2.3 ‐2.9 ‐30,‐15
H1F0 ‐2.8 ‐2.6 ‐10,‐22
HMMR ‐2.7 ‐2.7 ‐11,‐21
CDC20 ‐2.7 ‐2.8 ‐12,‐16
DEPDC1 ‐2.6 ‐2.9 ‐17,‐12
CDCA3 ‐2.6 ‐3.0 ‐18,‐10
CCNF ‐2.7 ‐2.9 ‐14,‐14
UBE2C ‐2.7 ‐2.9 ‐15,‐13
ASPM ‐2.7 ‐3.0 ‐13,‐11
CCNB1 ‐2.9 ‐3.0 ‐9,‐9
PSRC1 ‐3.1 ‐3.0 ‐8,‐8
PLK1 ‐3.3 ‐3.4 ‐7,‐7
FAM83D ‐3.3 ‐3.7 ‐6,‐4
CENPA ‐3.6 ‐3.7 ‐5,‐5
CENPE ‐3.9 ‐3.7 ‐3,‐3
PSRC1 ‐3.9 ‐3.9 ‐2,‐2
KIF20A ‐4.1 ‐4.7 ‐1,‐1
HL60 U937 Rank
DDIT4 5.5 10.4 1,1
IL8 2.4 6.5 7,2
ADM 4.5 3.5 2,9
CDKN1A 2.7 3.3 5,10
JUN 2.0 4.3 14,3
ATF3 2.2 3.5 10,8
SLC2A3 2.4 3.0 6,12
CCL3 1.8 4.0 26,4
CCL3L3 1.7 4.0 27,5
FOSB 2.4 2.6 8,15
PFKFB4 3.1 1.8 3,39
NDRG1 2.9 1.8 4,35
IL1B 1.4 3.8 61,6
TNF 1.4 3.7 56,7
PMAIP1 1.8 3.0 25,11
CTH 2.1 2.5 11,16
ANKRD37 2.0 2.4 13,17
EGR1 1.8 2.7 21,14
ADM2 2.1 2.2 12,20
CCL3L1 1.6 2.8 42,13
GPT2 1.9 2.3 19,18
FOS 1.9 2.1 17,23
HERPUD1 2.4 1.7 9,41
DDIT3 2.0 1.8 15,37
CCL2 1.5 2.3 45,19
VLDLR 1.8 1.9 20,33
NLRP12 1.9 1.7 16,40
AXUD1 1.6 2.1 39,22
PCK2 1.5 2.2 47,21
PPP1R15A 1.7 2.0 33,25
IER3 1.7 1.9 30,29
PSAT1 1.7 1.9 34,27
VEGFA 1.6 2.0 38,24
TSC22D3 1.7 1.9 32,30
ATF4 1.9 1.6 18,49
BNIP3L 1.7 1.8 31,38
SESN2 1.6 1.9 40,31
PTPRE 1.5 2.0 49,26
PSMC3IP 1.5 1.9 48,32
SMOX 1.8 1.6 22,52
BHLHB2 1.6 1.6 36,43
ZFP36 1.4 1.9 58,34
IRF1 1.8 1.5 24,60
HK2 1.8 1.5 23,64
DUSP5 1.3 1.9 71,28
JMJD1A 1.6 1.5 37,55
DNAJB9 1.7 1.4 28,66
LGALS8 1.7 1.5 29,65
BTG1 1.3 1.8 77,36
MTHFD2 1.5 1.6 46,54
CXCR4 1.5 1.6 51,45
BRF2 1.5 1.6 54,46
RRM2 1.4 1.6 57,42
ASNS 1.6 1.4 35,69
TUBE1 1.5 1.5 50,56
RPS6KA2 1.6 1.4 43,67
SLC3A2 1.4 1.6 60,48
SLC2A1 1.6 1.4 41,68
PRNP 1.4 1.6 59,50
MXD1 1.5 1.5 52,57
EIF1 1.3 1.6 70,44
LOC255783 1.6 1.4 44,70
CBS 1.4 1.6 66,53
SLFN11 1.5 1.5 53,63
PEA15 1.3 1.6 73,47
S100P 1.3 1.6 74,51
CHD2 1.4 1.5 62,61
PLAU 1.3 1.5 72,58
EIF2AK3 1.3 1.5 68,62
MASTL 1.3 1.5 76,59
MTP18 1.4 1.4 64,71
PDRG1 1.4 1.4 65,72
GARS 1.4 1.3 55,77
ZNF419 1.4 1.3 63,74
C10orf32 1.3 1.4 78,73
MAFF 1.3 1.3 75,75
ATG12 1.3 1.3 69,76
PHGDH 1.4 1.3 67,78
MS4A6A ‐1.4 ‐1.3 81,79
BCL11A ‐1.3 ‐1.5 79,80
HIST1H2AC ‐1.6 ‐1.5 83,81
HIST1H2BF ‐1.7 ‐1.8 84,82
PIF1 ‐1.5 ‐2.0 82,83
CENPA ‐1.3 ‐2.4 80,84
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2.5.5. Effect of PAC-1 and S-PAC-1 on intracellular Zn2+ concentration. 
While PAC-1 and S-PAC-1 have been shown to activate procaspase-3 in vitro through 
the chelation of inhibitory zinc ions,149, 161 and both compounds chelate zinc with comparable Kd 
values (52 nM for PAC-1 and 46 nM for S-PAC-1),148, 149 a study of the effect of these 
compounds on the cellular zinc pool was warranted. Genetically-encoded Zn2+ sensors have been 
developed to study changes in intracellular Zn2+ concentrations in live cells.171, 172 A 
conformational change in the sensor upon Zn2+-binding leads to increased fluorescence 
resonance energy transfer (FRET), offering an opportunity to visualize the changes in the cellular 
labile zinc pool upon treatment with PAC-1 or S-PAC-1. Zn2+ levels are proportional to the 
FRET ratio (FRET/CFP signal) which can be measured by fluorescence microscopy. In a 
collaboration with Professor Amy Palmer, HeLa cells were  transfected with the ZapCY2 sensor 
(apparent Kd’ for Zn2+: 811 pM171), and were exposed to PAC-1 or S-PAC-1 at 10 µM for 15 
min. The FRET ratio decreased, indicating a decrease in intracellular free Zn2+ (Figure 2.8A,B). 
The FRET ratio decreased further upon exposure to 50 µM PAC-1 or S-PAC-1 for 15 min 
(Figure 2.8A,B). To demonstrate that the decrease in FRET was due to chelation of labile zinc, 
cells were washed and exposed to 150 µM N,N,N',N'-Tetrakis(2-pyridylmethyl)ethylenediamine 
(TPEN), a cell permeable Zn2+ chelator with a Kd of 2.6 x 10-16 M.173 The FRET ratio of the 
sensor decreased further upon treatment with this powerful Zn2+ chelator. Finally, cells were 
permeabilized with digitonin and treated with a solution containing 9.5 nM Zn2+, the FRET ratio 
of the sensor increased. Together, these experiments suggest that PAC-1 and S-PAC-1 penetrate 
cells and chelate intracellular Zn2+. 
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Figure 2.8. Changes in intracellular zinc concentration upon PAC-1 and S-PAC-1 
treatment. FRET ratio changes in HeLa cells using the genetically-encoded zinc sensor 
ZapCY2. Graphs of a representative individual experiment show a decrease in 
intracellular free zinc in five cells treated with A)10 µM PAC-1 followed by 50 µM PAC-1, 
or B) 10 µM S-PAC-1 followed by 50 µM S-PAC-1. C) The decrease in intracellular zinc 
for both PAC-1 and S-PAC-1 is significant over multiple experiments. Error bars are 
standard error of the mean, p-values are from DMSO (10 cells or n=2 experiments), 
PAC-1 (21 cells or n=4 experiments), S-PAC-1 (14 cells or n=3 experiments).  
 
2.6. PAC-1 at high concentrations as an ER stress inducer in cell culture 
2.6.1. Transcript profile of high concentration of PAC-1 points to ER stress 
The effects of high (100 µM) and low (25 µM) concentrations of PAC-1 on the global 
gene expression were compared. U-937 cells were treated with both concentrations of PAC-1 for 
6h, and after mRNA isolation by Rahul Palchaudhuri, the transcript profile was performed with 
the Illumina HT-12 array. The transcript profiles between 25 µM and 100 µM PAC-1 (both in U-
937 cells) are quite different: when compared to DMSO control treated cells, only three genes, 
DDIT4, ATF3, and JUN, are shared in the top 30 most upregulated genes for both high and low 
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PAC-1 treatments. Furthermore, TNF, which is among the top 30 most upregulated genes for 25 
µM PAC-1-treated cells, is among the top 30 most downregulated transcripts in the 100 µM 
PAC-1 profile (Figure 2.9A). The Spearman rank coefficient comparing these two profiles is 
0.483. The transcript profiling data also suggests potential pathways and mechanisms of the 
compound. DDIT3, PI3KIP1, and HERPUD1 are among the top 10 most highly upregulated 
transcripts and are associated with ER stress and unfolded protein response (UPR) pathways.174-
176 
2.6.2. CMAP analysis and thapsigargin CMAP hit 
The Connectivity Map database contains transcript profiles from 7000 expression profiles 
representing about 1300 individual compounds.177 Comparing a transcript profile to those 
collected in the Connectivity Map can suggest potential mechanisms and pathways for a 
compound. Taking multiple profile data into account, thapsigargin was the top permuted 
compound that has the most similar gene expression signature to that of PAC-1 at 100 µM 
(Figure 2.9B). Interestingly, thapsigargin is a known ER stress inducer; as a sarco/endoplasmic 
reticulum calcium ATPase (SERCA) inhibitor, cells treated with thapsigargin experience ER 
stress as the ER calcium stores are depleted by an inhibition of the ability of the ER to pump 
Ca2+.78 Thus, this similar profile to thapsigargin suggests ER stress as a possible mechanism for 
PAC-1 at high concentrations.  
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Figure 2.9. Gene expression profile for 100 µM PAC-1 and Connectivity Map 
analysis. A) U-937 cells were treated with PAC-1 at 100 μM for 6 hours.  Shown are the 
30 most up- or down-regulated transcripts compared to DMSO control cells.  White text: 
fold change values, red text: common genes with PAC-1 treatments at low (25 μM) 
concentrations.  TNF (indicated with an *) is downregulated at high PAC-1 
concentrations but shows upregulation at low PAC-1 concentrations. B) Top five 
permuted results for Connectivity Map analysis of 100 µM PAC-1.  
 
 
PAC‐1
DDIT3 13.8
PIK3IP1 9.2
ARHGEF3 7.8
HERPUD1 7.1
FBXO32 7.0
TSC22D3 5.9
PPP1R15A 5.7
ADFP 5.7
DNAJB9 5.5
DDIT4 5.1
STARD5 4.8
KLF6 4.8
ZFAND2A 4.7
TRIB3 4.5
PLAU 4.5
ATF3 4.5
KLHL24 4.3
TXNIP 4.2
CCNG2 4.1
ANG 4.1
JUN 4.0
GADD45B 4.0
HPS4 3.9
CTH 3.9
HBP1 3.9
NFIL3 3.9
TIPARP 3.8
FICD 3.6
LRP5L 3.6
BCL11A ‐2.2
IGSF3 ‐2.3
RUNX1 ‐2.3
IL1B ‐2.3
SBF1 ‐2.3
TNF* ‐2.3
INTS1 ‐2.3
SLCO4A1 ‐2.3
FZD9 ‐2.3
P15RS ‐2.3
MAT2A ‐2.4
GEMIN6 ‐2.4
ZNF576 ‐2.5
NETO2 ‐2.6
RXRA ‐2.6
MARS2 ‐2.6
CCND2 ‐2.7
HSPA8 ‐2.7
HSPA1A ‐2.7
ABCE1 ‐2.7
HSPA8 ‐2.7
RPL29 ‐2.8
GPR84 ‐2.8
B3GALT6 ‐2.8
HSPA1B ‐2.8
SLC39A10 ‐2.9
NIP7 ‐3.2
CBX6 ‐3.2
TMEM158 ‐4.8
CCL2 ‐5.2
Rank Perturbugen Mean Score n
1 thapsigargin 0.798 3
2 emetine 0.718 4
3 cephaeline 0.705 5
4 niclosamide 0.678 5
5 astemizole 0.718 5
A B
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2.6.3. Cellular and mitochondrial morphology of PAC-1 
Given the intriguing information gathered from the transcript profile of a high 
concentration of PAC-1, transmission electron microscopy was utilized to study the effect of a 
PAC-1 on general cellular morphology. U-937 lymphoma cells were harvested and incubated in 
the presence of 100 µM PAC-1, 100 µM S-PAC-1, or DMSO for 1h, 2h, or 3h. Following 
treatment, the cells were immediately washed, fixed, and imaged by transmission electron 
microscopy. Compared to DMSO control cells, some remarkable changes to cellular morphology 
upon 100 µM PAC-1 treatment were observed, including: large lysosome-like structures 
surrounded with myelin-like membrane, dilated ER, and myelin-like inclusions in the 
mitochondria (Figure 2.10B-E). Some cells undergoing apoptosis or apoptotic bodies were 
observed in the 3h 100 µM PAC-1 treatment sample (Figure 2.10F,G). The cells treated with 100 
µM S-PAC-1 for up to 3h resembled the DMSO control cells (Figure 2.10A,H-J).  
The morphological changes visualized by electron microscopy in PAC-1-treated cells, 
especially mitochondrial changes, motivated further investigation of the effect of PAC-1 on 
mitochondrial morphology by confocal microscopy. HeLa cells were treated with 25 µM and 
100 µM PAC-1, 10 µM thapsigargin (top permuted Connectivity Map hit), and 100 µM S-PAC-
1 in HBSS. The mitochondria were stained with Mitotracker Red and visualized by confocal 
microscopy. After a 60 min exposure of 100 µM PAC-1 and 10 µM thapsigargin, the 
mitochondrial morphology was punctate, compared to the diffuse mitochondrial staining 
observed in 25 µM PAC-1-treated, 100 µM S-PAC-1-treated, and untreated control cells (Figure 
2.11A-E). Indeed, punctate mitochondrial staining was observed with 100 µM PAC-1 treatment 
at exposure times as early as 30 min. Cell viability was diagnostically estimated at various 
exposure times by FITC-annexin V/propidium iodide staining and cell flow cytometry of a 
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sample population of 5,000 cells. Even at 12h, when ~50% viable HeLa cells remained in 
treatment groups exposed to 25 µM PAC-1 and 100 µM S-PAC-1, no changes in mitochondrial 
morphology were noted (Figure 2.11F). Together, these data suggest that at 100 µM PAC-1 
induces a unique cellular morphology compared to control and 100 µM S-PAC-1-treated cells. 
Also, cells treated with 100 µM PAC-1 rapidly display a punctate mitochondrial phenotype 
similar to thapsigargin. The staining of the mitochondria remained diffused and unaltered with a 
low concentration of 25 µM PAC-1 or high 100 µM S-PAC-1, even at longer exposure times 
when the cell population was undergoing death, indicating that 100 µM PAC-1 behaves very 
differently than it does at lower doses or compared to equimolar amounts of S-PAC-1.  
2.6.4. Effect of PAC-1 (and S-PAC-1) on cytosolic and ER calcium levels 
The similarity of thapsigargin and high concentrations of PAC-1 in both the expression 
profile and mitochondrial morphology experiments suggests that both compounds may be acting 
by a similar mechanism.  Thapsigargin is known to cause an increase in cytosolic Ca2+ as the 
calcium stores in the ER are released.78 Thus, Professor Amy Palmer utilized genetically-
encoded calcium sensors to examine whether PAC-1 induced changes in intracellular Ca2+ levels 
in live cells.178 Treatment of HeLa cells expressing the calcium sensor D3cpv with 100 µM 
PAC-1 in calcium-free media led to an increase in cytosolic Ca2+ (Figure 2.12A). However, 
under the same experimental conditions 100 µM S-PAC-1 showed no significant change in the 
FRET of the sensor.  
The increase in cytosolic Ca2+ induced by 100 µM PAC-1 was observed in absence of 
extracellular calcium, suggesting that PAC-1 induced release of Ca2+ from the ER. To test this 
hypothesis, a genetically-encoded calcium sensor that localizes to the ER, D1ER, was used to 
measure calcium levels within the ER.179 Treatment of HeLa cells with 100 µM PAC-1 for 15 
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minutes caused the FRET ratio of the ER-localized calcium sensor to decrease, indicating a 
decrease in ER Ca2+ (Figure 2.12B,C). A less significant decrease was noted for 100 µM S-PAC-
1 treatments. Together, the data from both cytosolic and ER Ca2+ sensors demonstrate that a high 
concentration of PAC-1, but not S-PAC-1, triggers a marked decrease in ER Ca2+, and a 
concomitant increase in cytosolic Ca2+.  The release of Ca2+ from the ER is an indicator of an 
acute ER stress response, and leads to ER stress-related apoptosis,180 indicating that PAC-1 may 
behave as an ER stress inducing compound at high concentrations. 
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Figure 2.10. Changes in cellular morphology. T.E.M. images of U-937 cells treated 
with A) Control DMSO 1h, 4kx magnification B) 100 µM PAC-1 for 1h, 5kx, C) 100 µM 
PAC-1 for 1h, 4kx (black arrows: large lysosome-like structures, white arrows: dilated 
ER), and D) 100 µM PAC-1 for 1h, 15kx (arrows: dark myelin-like mitochondrial 
inclusions)., all scale bars indicate 1 micron. E) 100 µM PAC-1 for 2h, 5kx magnification 
with large lysosome structures, F) 100 µM PAC-1 for 3h undergoing apoptosis, 3.5kx 
magnification, G) 100 µM PAC-1 for 3h apoptotic body, 5kx magnification, H) 100 µM S-
PAC-1 for 1h, 4kx magnification, I) 100 µM S-PAC-1 for 2h, 5kx magnification, J) 100 
µM S-PAC-1 for 3h, 5kx magnification. Images are representative of several cells, n = 1 
experiment.    
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Figure 2.11. Mitochondrial morphology  and cell viability of HeLa cells. Confocal 
images at 40x of HeLa cells stained with Mitotracker Red (false-colored red) and SYBR 
Green (false-colored blue) show no changes in mitochondria morphology at 60 min in 
A) untreated control, B) 100 µM S-PAC-1, C) 25 µM PAC-1, but punctate mitochondrial 
staining with D) 100 µM PAC-1, and E) 10µM thapsigargin (Tg), F) Diffuse mitochondrial 
staining in untreated, 25µM PAC-1, and 100 µM S-PAC-1 treated cells at 6h and at 12h, 
all confocal images are representative of n ≥ 3 experiments, scale bar represents 10 µm 
in F, and can be applied to all confocal images. G) Diagnostic cell viablity by FITC-
annexin V/propidium iodide from a population of 5,000 HeLa cells treated with various 
compounds assessed at completion of exposure time (n=3, error bars indicate standard 
deviation)  
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Figure 2.12. Changes in cytosolic and ER calcium levels upon PAC-1 and S-PAC-1 
treatment. Graphs of single representative experiments show A) an increase in the 
FRET ratio in four individual HeLa cells expressing genetically-encoded cytosolic 
calcium sensor D3cpV upon treatment with 100 µM PAC-1 but not S-PAC-1. Following 
treatment with PAC-1 or S-PAC-1, cells were washed and treated with ionomycin/Ca2+ 
to demonstrate the maximum FRET ratio and confirm sensor functionality in each cell. 
B) A greater decrease in the FRET ratio of genetically-encoded ER calcium sensor 
D1ER was observed upon treatment of 100 µM PAC-1 compared to S-PAC-1 (average 
of at least 9 cells or n=3 experiments) and C) the absolute change in FRET value is 
shown to demonstrate that 100 µM PAC-1 elicits a significantly different ER calcium 
response than S-PAC-1. Error bars represent standard deviation, p < 0.0001.       
 
2.7. Conclusions 
PAC-1 and S-PAC-1 are two structurally similar procaspase activating compounds that 
chelate inhibitory zinc and restore procaspase (and active caspase) activity in vitro. At low 
concentrations (50 µM or lower), the evidence supports the hypothesis that PAC-1 and S-PAC-1 
serve as zinc-chelating procaspase activating compounds in the cell. In addition to their ability to 
activate procaspase-3 and induce apoptotic death, PAC-1 and S-PAC-1 have comparable zinc-
binding Kd values and cytotoxic IC50 values.148, 149 The global transcript profiles for HL-60 cells 
treated with 25 µM PAC-1 and 25 µM S-PAC-1 were highly correlated, suggesting that both 
compounds elicit similar cellular response. Furthermore, both compounds cause a decrease in 
intracellular zinc concentrations, detected with genetically-encoded FRET-based zinc sensors. 
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These studies contribute additional evidence that both compounds chelate labile zinc to activate 
procaspase-3 in the cell. 
PAC-1, at high concentrations (greater than 50 µM), has a very distinct gene expression 
profile, cellular and mitochondrial morphology, and effect on intracellular calcium 
concentrations, suggesting that a unique ER-stress mechanism for the compound. A high 
concentration of PAC-1 produces a distinct gene expression signature that is highly similar to ER 
stress inducer thapsigargin. Cellular morphology is altered in cells treated with a high 
concentration of PAC-1, in particular the dilated ER,181, 182 and enlarged lysosomes, indicative of 
an ER stress-related response.183 The release of Ca2+ through thapsigargin treatment has been 
shown to promote the hemolytic fusion of multiple lysosomes into large lysosomes in 
fibroblasts.184 Comparisons of mitochondrial morphology show that a high concentration of 
PAC-1 induces punctuate mitochondrial staining also observed in thapsigargin treatment, as 
shown in Figure 2.11 and in other studies.185, 186 The rapid mitochondrial changes may be due to 
mitochondrial Ca2+ uptake, leading to mitochondrial membrane depolarization and apoptosis 
through apoptosome formation,79, 187, 188 and this has been observed in thapsigargin treatment.189 
PAC-1 at high concentrations causes an increase in cytosolic calcium concentration within 
minutes of treatment, a hallmark of many ER stress inducing compounds, including 
thapsigargin78 and tunicamycin.190  
The induction of ER stress holds strong potential as an anticancer strategy. It has been 
proposed that cancer cells are already in a general state of ER stress due to accumulation of 
mutated and misfolded proteins, hypoxic tumor environment, and general dysregulation of 
cellular homeostasis.191 Therefore ER stress inducing compounds could cause a more acute stress 
response in tumor cells than normal cells. Indeed, ER stress inducers, such as tunicamycin and 
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bortezomib, have been investigated as novel anticancer drugs as single entity agents or combined 
with other chemotherapeutics.77, 192 
Among other initiators, alterations in Ca2+ concentrations in the ER lead to an increased 
expression and accumulation of unfolded, misfolded, or mutant proteins, thus prompting an 
unfolded protein response (UPR). ER transmembrane proteins such as PERK, IRE1, and ATF6 
are activated to begin UPR signaling pathways. When the ER encounters a severe or prolonged 
UPR, the UPR signaling pathways lead to ER stress-associated apoptosis; however, there may be 
significant cross-talk between specific UPR pathways and traditional apoptotic pathways as well. 
Furthermore, bcl-2 family proteins Bak and Bax associate with the ER membrane and allow Ca2+ 
efflux. It is thought that released Ca2+ leads to a variety of apoptotic changes: Ca2+ activates m-
calpain, which then cleaves and activates procaspases-12 as well as executioner procaspase-3; 
Ca2+ also leads to mitochondrial membrane depolarization and apoptosis through apoptosome 
formation,79, 187, 188 as mentioned above.  
It remains to be seen if PAC-1’s mechanism of chelating zinc and/or relief of zinc 
inhibition of caspases is related to its role as a potential ER stress inducing compound. About ten 
percent of cellular zinc content is loosely bound, and mammalian cells treated with zinc chelator 
TPEN have been reported to undergo UPR.83, 193 Caspases have been found to be directly 
associated with the ER during UPR. For example, caspase-8 is thought to cleave ER membrane 
protein BAP31 to induce a release of Ca2+ from the ER,194, 195 procaspase-12 may accumulate 
and activate near the ER in the IRE1 pathway,196 or executioner procaspase-7 may activate 
procaspase-12 near the ER.187 ER stress may also induce caspase-2 cleavage of BID.197 Since S-
PAC-1 is a zinc chelator that does not appear to induce ER-stress related cell death, zinc 
chelation and subsequent caspase activation are not likely primary contributors to PAC-1’s ER 
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stress mechanism at high concentrations, however, further investigation of the relationship 
between zinc, caspases, and ER stress is warranted. 
2.8. Materials and Methods 
2.8.1. Reagents, Buffers, and Cell Lines 
All reagents, unless otherwise noted, were purchased from Sigma-Aldrich. Compounds 
purchased from other suppliers include: Fmoc-protected amino acid building blocks (EMD), Ac-
Asp(OtBu)-OH (ChemImpex), digitonin (Calbiochem). Compounds were dissolved in DMSO 
(Sigma) for in vitro and cell culture studies. PAC-1 and S-PAC-1 were synthesized by colleagues 
Dr. Danny Hsu, Dr. David Goode, Howard Roth, and others as reported.146, 148 
For recombinant protein expression and purification, the following buffers were used: Ni 
NTA Binding Buffer (50 mM Tris pH 8.0, 300 mM NaCl, 10 mM imidazole), Ni NTA Wash 
Buffer (50 mM Tris pH 8.0, 300 mM NaCl, 20 mM imidazole), and Ni NTA Elution Buffer (50 
mM Tris pH 8.0, 300 mM NaCl, 500 mM imidazole). Zinc-free assay HEPES buffer (50 mM 
Hepes, 300 mM NaCl pH 7.4) treated for 1h with Chelex® resin to remove divalent ions, such as 
zinc. 
Cell lines U-937, Jurkat, SK-MEL-5, HeLa, HL-60, MDA-MB-231, and EL4 were 
obtained from the American Type Culture Collection (ATCC) and maintained at low passage 
number. Two canine B-cell lymphoma lines (17-71 and GL-1) were provided by Dr. Steve Suter 
(North Carolina State University, Raleigh, NC). Isogenic pairs Jurkat neo/bcl-2 and CEM 
neo/bcl-2 were provided by Dr. John Reed (Sanford-Burnham Medical Institute, La Jolla, CA). 
All cell lines grown in a 37 °C, 5% CO2, humidified environment, in media containing 1% 
penicillin/streptomycin. All cell lines were grown in RPMI 1640 or DMEM growth media with 
10% fetal bovine serum (FBS), with the exception of HL-60 human leukemia, which was grown 
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in IMEM with 20% FBS, and the isogenic bcl-2 cell line pairs, which were grown in RPMI 1640 
with 10% FBS, supplemented with 500 mg/L G418.  
2.8.2. Synthesis of Ac-DEVD-pNA and related tetrameric peptide substrates 
The general method is described as follows: The reactions were performed in dry 
glassware open to air for Ac-DEVD-pNA synthesis, and under a positive atmosphere of nitrogen 
for the other tetrapetides, and the starting materials from commercial suppliers were used without 
purification, except for p-nitroaniline. The TLC development solvent system used was 1:9 
MeOH:EtOAc.  1H NMR spectra were obtained on a Varian Unity Inova 500NB spectrometer 
and chemical shifts are reported in parts per million (ppm) with multiplicities designated as s 
(singlet), d (doublet), t (triplet), q (quartet), or m (multiplet). The spectra were referenced to 
TMS. Mass spectra were acquired by the UIUC Mass Spectrometry Center. 
Large-scale synthesis of Ac-DEVD-pNA (Ac-Asp-Glu-Val-Asp-pNA): p-nitroaniline 
(10g) was recrystallized in H2O. (Coupling) Fmoc-Asp(Ot-Bu)OH (4.115 g, 10 mmoles), and 
pNA (1.381 g, 10 mmoles) were stirred in 30 ml of pyridine, in a salt-ice bath (−10 to −15 °C).  
POCl3 (1.02 ml, 11 mmoles) was slowly added through a syringe and stirred for 30 min at −10 to 
−15 °C. The reaction was quenched with ice water, and the product was extracted three times 
with EtOAc (150 mL). The combined organic layers were washed with a saturated bicarbonate 
solution, and then with brine, and then dried with 20-30g of solid anhydrous sodium sulfate, and 
concentrated by rotary evaporation. The product was purified through a 2′′ high silica plug and 
eluted with 3:1 hexane–EtOAc under vacuum. To remove residual pyridine, the concentrated 
product was co-evaporated sequentially with 50mL toluene, EtOAc, and MeOH. (Deprotection)  
Fmoc-Asp(Ot-Bu)-pNA (2.658 g, 5 mmoles) was dissolved in 30 ml of methylene chloride 
(CH2Cl2). TAEA (30 ml, 200 mmoles) was slowly added and the reaction mixture was stirred 
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for 30 min. Formation of the deprotected amine was monitored by TLC (10% MeOH in EtOAc), 
which was stained with Ninhydrin. The reaction was quenched and extracted with 60mL EtOAc, 
and the organic layer and washed once with 50mL brine, three times with 50mL of phosphate 
buffer, dried over sodium sulfate, and concentrated to a powder. (Coupling)  Asp(Ot-Bu)-pNA 
and Fmoc-Val-OH (1.867 g, 5.5 mmoles) were dissolved in 30mL CH2Cl2. DIEA (1.3mL, 7.5 
mmoles) was added dropwise by syringe, and PyBOP (2.861g, 5.5 mmoles) was added to the 
reaction mixture. After stirring for 30 minutes, formation of the protected amine product was 
monitored by TLC and Ninhydrin staining (the spot for the free amine disappeared as the 
coupling with the protected amine occurred). (Deprotection) To the stirring reaction mixture, 40 
equivalents of TAEA (200 mmoles, 30 ml) were added through syringe to deprotect the N-
terminal amino acid. After stirring at room temperature for 30 min, the appearance of a free 
amine by TLC (via Ninhydrin) was observed. The coupling and deprotection steps were repeated 
with appropriately protected amino acids to give the desired sidechain protected peptide. The 
final coupling step consisted of the coupling of Glu(Ot-Bu)-Val-Asp(Ot-Bu)-pNA to Ac-Asp(Ot-
Bu)-OH. The Ac-DEVD-pNA product with protected sidechains was precipitated as a white 
solid in the organic layer during the final washings. The precipitate was washed with 15 ml of 
diethyl ether and was dried under vacuum overnight. (Global deprotection) With the protected 
product in a round bottom flask, 30 ml of TFA was added by syringe to the solid product and 
stirred for 30 min. The TFA was then removed by rotary evaporation, and the solid was triturated 
and decanted with 30 mL diethyl ether three times. The final deprotected product was dried 
overnight by vacuum, the light tan solid (40% yield) was characterized by 1H NMR and mass 
spectrometry to verify proper synthesis and complete sidechain deprotection. 1H NMR (500 
MHz, CDCl3): δH 8.23 (m, 2H), 7.95 (dd, J = 9.2 Hz, J = 2.7 Hz, 2H), 4.61 (m, 1H), 4.50-4.30 
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(m, 1H), 4.06-3.91 (m, 1H), 3.03 (m, 1H), 2.92-2.66 (m, 3H), 2.49-2.36 (m, 2H), 2.16 (m, 2H), 
2.00 (m, 3H), 1.97-1.88 (m, 1H), 0.99 (m, 6H). HRMS(ESI) (m/z) calculated for C26H34N6O13, 
639.22; found, 639.2254 
Small-scale synthesis of Ac-DSVD-pNA (Ac-Asp-Ser-Val-Asp-pNA) and Ac-NSVD-
pNA (Ac-Asn-Ser-Val-Asp-pNA): To a solution of Fmoc-Asp(OtBu)-pNA (1.2 mmol, 1 eq) in 
25 mL CH2Cl2, ~7 mL of tris(aminoethyl)amine (TAEA) (excess) was added. After 40 minutes, 
the reaction was diluted to 50 mL with EtOAc, washed with brine (25 mL), pH 5.5 10% 
phosphate buffer (5x25mL), and brine (25 mL) once more. The organic layer was dried over 
sodium sulfate and then concentrated with a rotavaporator to achieve a yellow residue. (Coupling 
step) 25 mL CH2Cl2, N-Fmoc-Valine (1.32 mmol, 1 eq), and diisopropylethylamine (DIEA) (1.8 
mmol, 1.5 eq) was added to the residue. PYBOP (1.32 mmol, 1.1 eq) was then added. The 
reaction stirred at room temperature at least 30 minutes until the presence of the amine was no 
longer detected by TLC (Ninhydrin stain). (Deprotection step) Next, ~7 mL TAEA (excess) was 
added to the reaction mixture and stirred for ~30 minutes until the presence of the deprotected 
amine was detected by TLC (Ninhydrin stain). The reaction was diluted to 50 mL with EtOAc, 
washed with brine (25 mL), pH 5.5 10% phosphate buffer (5 x 25 mL), and brine (25 mL). The 
organic layer was dried over sodium sulfate and then concentrated to dryness by rotavaporator. 
The coupling and deprotection steps were repeated with appropriately protected amino acids to 
give the desired sidechain protected peptide which precipitated as a white solid in the organic 
layer during the final washings. The organic layer was filtered via vacuum filtration and washed 
with ~30 mL diethyl ether to obtain the white powder. To recover any unprecipitated peptide, the 
mother liquor was concentrated to dryness, and the residue was washed with ~30 mL diethyl 
ether to obtain a white powder. (Global Deprotection) All precipitate was collected and taken up 
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in ~4-5 mL trifluoroacetic acid (TFA) and stirred at room temperature for 10-15 min. The 
reaction mixture was concentrated by rotavaporator, and the residue was washed with diethyl 
ether (2x25 mL) and the white solid product was collected after vacuum filtration. The product 
was dissolved in ~5 mL of MeOH, then the solvent was removed by rotavaporator and high 
vacuum to give the final white powder in 25% yield. Ac-DSVD-pNA: 1H-NMR (500 MHz) ppm 
8.24 (d, 1H, J=9.3Hz) ppm 7.99 (d, 2H, J=9.3Hz) ppm 4.75 (t, 1H, J=6.6Hz) ppm 4.43 (t, 1H, 
J=5.3Hz) ppm 4.15 (t, 1H, J=6.4Hz) ppm 3.85 (ddd, 1H, J=5.4Hz, J=11.0Hz, J=67.5Hz) ppm 
3.03 (dd, 1H, J=5.6Hz, J=16.8Hz) ppm 2.91 (dd, 1H, J=6.5Hz, J=17.0Hz) ppm 2.80 (t, 2H, 
J=24.1Hz) ppm 2.22 (td, 1H, J=6.8Hz, J=13.6Hz) ppm 2.00 (s, 3H) ppm 1.02 (d, 6H, J=6.9Hz) 
MS m/e 597 (M+H); HRMS (ESI) calcd for C24H33N6O12 597.2156, found 597.2168. 
The synthesis of Ac-NSVD-pNA followed the exact same protocol as Ac-DSVD-pNA, with 
appropriate amino acids. Ac-NSVD-pNA: 5% yield. 1H-NMR (500 MHz) ppm 8.21 (d, 2H, 
J=9.3Hz) ppm 7.95 (d, 2H, J=9.3Hz) ppm 4.72 (dd, 1H, J=6.0Hz, J=6.8Hz) ppm 4.35 (t, 1H, 
J=5.0Hz) ppm 4.12 (d, 1H, J=6.9Hz) ppm 3.85 (ddd, 2H, J=5.0Hz, J=11.1Hz, J=59.3Hz) ppm 
2.97 (dd, 1H, J=5.5Hz, J=16.8Hz) ppm 2.76 (dd, 3H, J=6.5Hz, J=21.6Hz) ppm 2.20 (qd, 1H, 
J=6.8Hz, J=13.6Hz) ppm 1.95 (s, 3H) ppm 1.36 (dd, 1H, J=3.2Hz, J=7.0Hz) ppm 0.98 (dd, 6H, 
J=3.7Hz, J=6.8Hz) MS m/e 596 (M+H); HRMS (ESI) calcd for C24H34N7O11 596.2316, found 
596.2310. 
Small-scale synthesis of Ac-ESMD-pNA (Ac-Glu-Ser-Met-Asp-pNA): To a solution of 
Fmoc-Asp(OtBu)-pNA (1.2 mmol, 1 eq) in 25 mL CH2Cl2, ~7 mL of tris(aminoethyl)amine 
(TAEA) (excess) was added. After 40 minutes, the reaction was diluted to 50 mL with EtOAc, 
washed with brine (25 mL), pH 5.5 10% phosphate buffer (5x25mL), and brine (25 mL) once 
more. The organic layer was dried over sodium sulfate and then concentrated with a 
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rotavaporator to achieve a yellow residue. (Coupling step) 25 mL CH2Cl2, N-Fmoc-Methionine 
(1.32 mmol, 1 eq), and diisopropylethylamine (DIEA) (1.8 mmol, 1.5 eq) was added to the 
residue. PYBOP (1.32 mmol, 1.1 eq) was then added. The reaction stirred at room temperature at 
least 30 minutes until the presence of the amine was no longer detected by TLC (Ninhydrin 
stain). (Deprotection step) Next, ~7 mL TAEA (excess) was added to the reaction mixture and 
stirred for ~30 minutes until the presence of the deprotected amine was detected by TLC 
(Ninhydrin stain). The reaction was diluted to 50 mL with EtOAc, washed with brine (25 mL), 
pH 5.5 10% phosphate buffer (5 x 25 mL), and brine (25 mL). The organic layer was dried over 
sodium sulfate and then concentrated to dryness by rotavapor. The coupling and deprotect steps 
were repeated with appropriately protected amino acids to give the desired sidechain protected 
peptide which precipitated as a white solid in the organic layer during the final washings. The 
remainder of the protocol follows that which was used for the synthesis of Ac-DSVD-pNA and 
Ac-NSVD-pNA. 6% yield. 1H-NMR (500 MHz) ppm 8.22 (d, 2H, J=9.3Hz) ppm 7.95 (d, 2H, 
J=9.3Hz) ppm 4.45 (dd, 1H, J=4.7Hz, J=9.1Hz) ppm 4.38 (t, 1H, J=5.8Hz) ppm 4.34 (dd, 1H, 
J=6.0Hz, J=8.3Hz) ppm 3.82 (ddd, 2H, J=5.8Hz, J=10.8Hz, J=65.4Hz) ppm 2.89 (ddd, 2H, 
J=6.8Hz, J=16.8Hz, J=24.8Hz) ppm 2.59 (dd, 2H, J=28.5Hz, J=39.6Hz) ppm 2.42 (t, 2H, 
J=7.6Hz) ppm 2.08 (s, 4H) ppm 1.99 (s, 4H) ppm 1.58 (d, 1H, J=5.3Hz) MS m/e 643 (M+H); 
HRMS (ESI) calcd for C25H35N6O12S 643.2034, found 643.2044. 
2.8.3. Recombinant expression of procaspase-3/-7 and caspase-3/-7  
Procaspase-3 and caspase-3 were expressed using the pHC332 expression plasmid. The 
uncleavable mutant (D9A/D28A/D175A) of procaspase-3 was created by successive quick-
change mutations on pHC332 as previously described.159 Procaspase-7 and caspase-7 were 
expressed from a pET23b plasmid. The uncleavable mutant (D23A/D198A/D206A) of 
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procaspase-7 was created by successive quick-change mutations using the following primers:  
gcaaatgaagattcagtggctgctaagccagaccg for D23A, ggcatccaggccgctagcgggcccatcaatg for D198A, 
and ccatcaatgacacggccgctaatcctc for D206A.56 The catalytically inactive mutant was also made 
through a single quick-change mutation using the following primer: cttcattcaggctgcccgagggacc.  
 Expression of procaspase-3/-7 was performed in the BL21(DE3) strain of Escherichia 
coli (Novagen). Plasmids encoding for the C-terminally 6×His-tagged procaspase-3/-7 protein 
were transformed into electrocompetent BL21. The transformants were selected for by growth in 
ampicillin. Individual colonies were picked and used to inoculate 10-mL seed cultures of LB 
with ampicillin (100 μg/mL) for expression. Seed cultures were used to inoculate 2-L cultures of 
LB, which were grown at 37 °C to an OD600=0.6. Protein expression was induced via the 
addition of IPTG to a final concentration of 0.5 mM. The following induction times were used 
for the various caspase species: 20 min induction for procaspase-3, procaspase-
3(D9A/D28A/D175A), procaspase-7, and procaspase-7(D23A/D198A/D206A) and 4 hr 
induction for active caspase-3/-7. After addition of IPTG, the culture was incubated at 37 °C 
with shaking for the duration of the induction time. Bacterial cultures were then pelleted by 
centrifugation (at 5000g, 5 min, 4 °C) and lysed by pulse sonication on ice for 5 min in the 
presence of 30 mL Ni NTA binding buffer. Bacterial debris was removed by centrifugation (at 
35,000g, 30 min, 4 °C) and the 6×His-tagged protein was purified from the supernatant with 1 
mL 50% slurry Ni NTA resin (Qiagen). Protein was batch loaded onto the resin for 1 h at 4 °C. 
The bound resin was applied to a disposable column and the resin was washed with 15 mL of Ni 
NTAWash Buffer. The protein was then eluted from the column with 10 mL of Ni NTA Elution 
Buffer. Fractions (׽1 mL) were collected and the presence of protein was determined by 
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reaction with the Bradford reagent (BioRad). Fractions containing protein were pooled and flash-
frozen in liquid nitrogen. Protein was stored at −80 °C. 
In order to prepare protein in zinc-free conditions, the protein was expressed and purified 
as above until fractions were pooled. Protein was not flash-frozen at this point, but fractions 
containing protein were pooled and applied to a PD-10 column (GE Healthcare) charged with 
Hepes buffer that had been treated with Chelex® resin. The pH was monitored after treatment 
with the Chelex® resin and was found to have not changed. The protein was eluted using an 
additional 3.5 mL of Chelex®-treated Hepes buffer and the concentration was determined using 
the Edelhoch method for protein quantitation by absorbance at 280 nm. The extinction 
coefficient, Ɛ, used for procaspase-7 was 24220 M-1cm-1 and for procaspase-3 was 26150 M-1cm-
1. Protein isolated directly from the column typically had a concentration of ׽50 μM; for 
experiments described requiring zinc-free conditions, the protein was typically diluted to the 
desired concentration in Hepes buffer that had been treated with Chelex® resin. Protein was 
flash-frozen in 500-μL aliquots in liquid nitrogen and stored at −80 °C. 
2.8.4. Caspase activity assay 
Stocks of zinc-free enzyme were prepared with or without the appropriate amount of zinc 
and were incubated at room temperature for at least 30 min prior to addition to compound. 
Compound dilutions were made from the 10 mM dimethyl sulfoxide (DMSO) stock to the 
appropriate concentration in the specified assay buffer and DMSO to maintain a constant amount 
of DMSO in every well (never above 5%). These were placed into wells of a 384-well plate (20 
μL), and then 25 μL of an appropriately diluted enzyme stock in assay buffer was added to the 
compound wells (1 μM procaspase-3, 1 μM caspase-3, or 5 μM D9A/D28A/D175A procaspase-
3, 2 μM procaspase-7, 2 μM caspase-7, or 10 μM D23A/D198A/D206A procaspase-7). Controls 
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containing DMSO and assay buffer without compound or without both compound and enzyme 
were included for each experiment.  
For experiments in the presence of zinc, a control containing no zinc was also included. 
The plates were then incubated for 2 h at 37 °C. Then, to each well of the plate was added 5 μL 
of a 2 mM stock of Ac-DEVD-pNA in assay buffer and the absorbance at 405 nm was read every 
minute for 1 h using a Spectra Max Plus 384 plate reader (Molecular Devices, Sunny Vale, CA). 
The slope of each well was used to determine the activity as compared to the controls. The data 
were plotted as percent activity versus compound concentration and fitted to a logistic dose– 
response curve using Table Curve (SYSTAT Software, Richmond, CA). Data were generated in 
triplicate and repeated at least three times.  
To test the ability of procaspase activating compounds to relieve zinc-mediated inhibition 
of caspases, aliquots of frozen zinc-free protein were thawed and diluted in Hepes buffer (that 
had been treated with Chelex® resin) to the appropriate concentration. A 40-μL solution of 
protein was added to each well of a 384-well plate and 5 μL of various concentrations of zinc 
were added. Appropriate wells also received PAC-1161 or S-PAC-1148 to a final concentration of 
50 μM. The plate was incubated at 37 °C for 2 h. A 5-μL solution of a 2mMstock of Ac-DEVD-
pNA was added to each well to a final concentration of 200 μM. The absorbance at 405 nm was 
monitored every minute for 60 min and the initial slope was determined from the linear portion 
of the progress curve. The slopes were converted to percent of maximal activity (the slope in the 
absence of zinc) and the data were fitted with a logistical dose–response curve. Data were 
generated in triplicate and repeated at least three times. The data presented are the averages of 
the triplicate data points and are representative of the replicate experiments. 
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2.8.5. SDS-PAGE and Western blot 
 Protein solutions (either 20 µg recombinant protein or 80 µg clarified cell lysate) were 
denatured with SDS loading dye (with b-mercaptoethanol) and ran on a 4-20% pre-cast gradient 
polyacrylamide gel for about 45 min at about 145V in SDS running buffer. Following gel 
electrophoresis, the gel was transferred into Commassie Brilliant Blue staining solution. In order 
to assure that bcl-2 was present in the Jurkat/bcl2 and CEM/bcl2 cell lines, a Western blot was 
performed: following SDS-PAGE of the cell lysate (collected from ~10 x 106 cells), protein was 
transferred to a PVDF membrane at 60V for 120 min in Towbin transfer buffer. The membrane 
was blocked overnight at 4 ºC with 1% w/v powdered milk in TBST, then incubated with bcl-2 
or actin primary antibody (Santa Cruz Biotechnologies) for 1h at room temperature. Following 
another 1h incubation with HRP-conjugated secondary antibody, the blot was treated with HRP 
substrate (Pierce) and imaged by autoradiography.  
2.8.6. Cytotoxicity in cell culture 
Cancer cell lines were cultured in their respective growth media with 10% fetal bovine 
serum and 1% Pen-Strep. Cells were harvested for plate-based cytotoxicity assays as follows: 
10,000 cells/well for 48 and 72h experiments, and 40,000 cells/well for 24h experiments. The 
cells were transferred to 96-well plates. If the cells were adherent, then the cells were incubated 
at 37 ºC in order for cell attachment to the plate. Next, the cells were exposed to compounds at 
half-log dilutions in respective growth media, so that the final volume of the well was 200 µM 
(SRB assay) or 100 µM (MTS assay). The cells were exposed to the compounds for 24, 48, or 
72h, after which the SRB assay was performed as described,167 or the MTS assay was performed 
according to manufacturers protocol (Promega). Each compound concentration was tested five 
times in one experiment, and the experiment was performed at least three times. The IC50 values 
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were determined after fitting a logistical dose-response curve to the absorbance values obtained 
from each assay.   
2.8.7. Electron and confocal microscopy 
Transmission electron microscopy (TEM). U-937 cells were harvested and transferred to 
a 24-well plate at 500,000 cells/well in 500 µL RPMI 1640 media with 10% FBS. DMSO, PAC-
1, or S-PAC-1, were dissolved from DMSO stocks in RPMI 1640 with 10% FBS as pre-mixed 
concentrated solutions. Compound solutions of 500 µL were added to the wells with cells, so that 
the final concentration of compound was 100 µM PAC-1 or S-PAC-1 (1% v/v DMSO) for a 
compound exposure of 1, 2, and 3 hours for PAC-1 and S-PAC-1, and 1h for DMSO. The cells 
were washed once with PBS, and pelleted. Karnovsky’s fixative (500 µL/sample) was filtered 
through a 0.22 micron filter and fixative was added directly to the cell pellet. The preparation 
and imaging of samples by TEM were carried out in part by the Center for Microanalysis of 
Materials of the Frederick Seitz Materials Research Laboratory Central Facilities, University of 
Illinois. Images of several cells in each sample were taken by film and scanned. Shown are 
representative images of a single experiment. 
Confocal microscopy. HeLa cells were harvested and grown in Lab-Tek 4-well 
chambered 1.0 borosilicate coverglass (Nunc) dishes to ~50% confluency in RPMI 1640 media. 
The cells were washed with Hanks’ Balanced Salt Solution (HBSS). The cells were treated with 
25 and 100 µM PAC-1, 100 µM S-PAC-1, and 10 µM thapsigargin pre-mixed in 500µM HBSS 
for exposure times up to 12h, and stained with Mitotracker Red CMXRos (Invitrogen) and 
SYBR Green I (Invitrogen) in HBSS. Order of addition to cells: For >1h compound exposures, 
the compounds were dissolved from DMSO stocks into 500 µL HBSS to the final concentration 
of 10 µM thapsigargin, 25 µM PAC-1, 100 µM PAC-1, and 100 µM S-PAC-1 (with 1% DMSO 
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content) and added to the cells and incubated at 37 ºC for exposure times of 6h and 12h. 
Following the incubation time, the cells were sequentially stained with Mitotracker Red 
CMXRos (Invitrogen) mitochondrial stain and SYBR Green I (Invitrogen) in HBSS. To image 
the cells at shorter exposure times of 10-60 min, the cells were first stained with Mitotracker Red 
and SYBR Green as described above. After the last wash step in HBSS, the cells were treated 
with compounds that were pre-mixed in 500 µL HBSS and imaged at the various exposure times. 
The cells, in 500 µL HBSS, were imaged on a LSM700 confocal microscope (Zeiss) using a 40X 
oil immersion objective. Microscope settings include a 2.55 µs dwell time and an average of four 
lines allowed images of live cells. Shown cell images are representative of the cell population 
over at least three experiments. Cell viability of each treatment group was diagnostically 
assessed. In a 24-well plate, HeLa cells were treated with the same procedure as the confocal 
samples. Following compound exposure for 1, 6, and 12h, the cells were scraped and stained 
with FITC-annexin-V/propidium iodide (AV/PI), and cell viability was assessed for a population 
of 5,000 cells by flow cytometry.    
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Chapter 3: In vivo applications of PAC-1 and PAC-1 
derivatives 
 
Portions of this chapter were taken from: Cancer Res. 2010;70:7232-41, Invest. New Drugs. 
2010, in press (published on web May 25, 2010; DOI 10.1007/s10637-010-9445-z). All 
experiments, unless otherwise noted in the chapter, were performed in full by Diana West. 
Experimental methods from experiments performed by colleagues other than myself are not 
included in the Materials and Methods section.  
 
 
3.1. Introduction 
Procaspase activating compound PAC-1 was found to be effective in three mouse models 
in the initial report of its discovery: Mice bearing subcutaneous ACHN renal cancer tumors had a 
decrease in tumor volume when treated with an implanted cholesterol pellet with up to 5mg 
PAC-1; mice with subcutaneous NCI-H226 lung cancer tumors also experienced a decrease in 
tumor volume upon PAC-1 treatment, administered by oral gavage at 50 and 100 mg/kg; finally, 
mice injected with the NCI-H226 cell lines did not develop tumors as remarkably upon treatment 
with 100 mg/kg PAC-1 by oral gavage, compared to control.146 Since these initial findings, more 
detailed studies into the safety, pharmacokinetics, dosing strategies, and efficacy have been 
necessary to forward procaspase activating compounds PAC-1 and PAC-1 derivatives as 
potential anticancer drugs.  
In this chapter, a summary of the in vivo safety, pharmacokinetics, and efficacy of PAC-1 
and PAC-1 derivatives will be described. While S-PAC-1 is well-tolerated in mice and canine 
models, PAC-1 elicits a neurotoxic response in the animals. The logBB value, an in silico tool 
for predicting blood:brain barrier penetrance, is useful for the selection of PAC-1 derivatives for 
further investigation. Furthermore, cell culture studies, such as measurements of compound 
cytotoxicities, not only serve as predictors for in vivo efficacy, but also can be used suggest 
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dosing strategies and concentrations for in vivo use. These data can inform the development of 
novel PAC-1 derivatives that are safe, potent, and are easily translated to the clinic.  
3.2. Safety, pharmacokinetics, and efficacy of PAC-1 and S-PAC-1 
 In order to determine the feasibility of PAC-1 and S-PAC-1 as anticancer drugs, murine 
and canine models were employed to study drug-like properties of the compounds. First, the 
safety of the compounds and their adverse side effects were noted. Next, pharmacokinetic studies 
were performed in order to determine the concentration of PAC-1 and S-PAC-1 in the blood as 
well as the elimination half-life in the animals. Finally, the efficacy of compounds was explored 
in client-owned patient pet dogs with lymphoma.  
3.2.1. In vivo safety of PAC-1 and S-PAC-1 
Collaborator Prof. Tim Fan tested PAC-1 in C57/BL6 mice to determine if an intravenous 
(i.v.) administration would be safe in animals. Tail vain injections are commonly used i.v. 
injections for mice. Summarized in Table 3.1 are the observed adverse effects of PAC-1 and S-
PAC-1 in mice that were administered the compounds formulated in 200 mg/kg 2-
hydroxypropyl-beta-cyclodextrin (HPβCD), and as a 1:1 drug to saline solution by tail vein 
injection. Mice that received PAC-1 exhibited transient neurotoxicity which was displayed as 
loss of muscle function (ataxia) and convulsions, with onset occurring within 5 minutes of drug 
administration and resolution occurring within 2 hours. The severity of the adverse effect 
increased with increase dose from 20 mg/kg to 50 mg/kg PAC-1. Mice that received only the 
HPβCD vehicle or S-PAC-1 (up to 350 mg/kg) did not exhibit any clinically observable toxicity.  
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To determine the peak serum concentrations of the compounds in the blood, mice that 
were treated with 20 mg/kg PAC-1 (the dose at which significant neurologic symptoms first 
appear), 50 mg/kg PAC-1 (the dose where acute neurologic symptoms are present), and 350 
mg/kg S-PAC-1 (the highest dose tested) via tail vein injection. The serum from the mice was 
analyzed by high-performance liquid chromatography (HPLC) to provide the pharmacokinetic 
profiles for S-PAC-1 and PAC-1. At the PAC-1 dose that induced mild neurotoxicity (20 mg/kg), 
peak plasma concentrations were ׽50 μM and concentrations of ~100 µM were obtained at a 
neurotoxic dose of 50 mg/kg. In contrast, a 350 mg/kg dose of S-PAC-1 provided peak plasma 
levels of ׽3,500 μM without any signs of neurotoxicity.149   
Dogs are frequently used in preclinical toxicity studies for investigating experimental 
therapeutics including anticancer agents. Serving as a large mammalian experimental system, 
dogs more closely mimic the body size, physiology, and metabolism of humans in comparison to 
Table 3.1. Observed neurotoxicity of PAC-1 and S-PAC-1 in C57/BL6 mice
Dose 
(mg/kg)
PAC-1 
Toxicity
PAC-1 peak 
plasma 
concentration 
(µM) 
S-PAC-1 
Toxicity
S-PAC-1 peak 
plasma
concentration 
(µM)
10 None - - -
12.5 - - None -
20 Yes, mild 50 - -
25 - - None -
30 Yes, overt - - -
37.5 - - None -
50 Yes, severe 100 - -
350 - - None 3500
(-) Not determined
n=3 mice for each condition
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rodents.198 Healthy research hound dogs were also i.v. administered PAC-1 and S-PAC-1 to 
determine the safety of the compounds. The observed neurotoxicity of PAC-1 in mice did not 
seem to be species specific, as grand mal seizure activity in one healthy dog was elicited when 
administered 25 mg/kg of PAC-1 as a 5-minute i.v. infusion. Adverse side effects in this dog 
were transient and not life limiting.149 It should be noted that lower doses of PAC-1 can be 
administered safely in the dogs (see below).199 S-PAC-1, when administered in HPβCD via tail 
vein injection, exhibited no observable toxicity at any dose tested. Given the dramatically 
reduced neurotoxic effect of S-PAC-1, pharmacokinetic analysis was performed to compare the 
plasma concentrations achievable with PAC-1 and S-PAC-1.  
3.2.2. Pharmacokinetics of PAC-1 and S-PAC-1 in healthy dogs 
Cytotoxicity studies for PAC-1 and S-PAC-1 have been performed in several cell lines 
using the SRB, MTS, and annexin-V/propidium iodide assays (see Chapter 2).146, 148, 149, 199 PAC-
1 and S-PAC-1 are cytotoxic with IC50 values generally ~10 µM or less. Preliminary studies of 
pharmacokinetics in mice (above) show that these concentrations can be surpassed in that animal 
model. Therefore, barring any unforeseen toxicity, a goal plasma concentration of PAC-1 and S-
PAC-1 was ~10 µM for 24 h. Similar to the toxicity experiments performed (above), the 
pharmacokinetic parameters of PAC-1 or S-PAC-1 in healthy research hound dogs were 
determined with i.v. administration by collaborators Dr. Tim Fan, Dr. Pamela Lucas, and Dr. 
Joanna Schmidt, with occasional support and plasma sample preparation from myself and Quinn 
Peterson.149, 199  
PAC-1 elicits overt neurotoxicity in mice at doses higher than 30 mg/kg; however, this 
compound may be clinically useful if treated at safe low doses over a continuous period of time. 
As such, the i.v. pharmacokinetic profiles of PAC-1 in six healthy research dogs were 
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determined through the conductance of a crossover design. Following single-dose, bolus i.v. 
administered PAC-1 at a dosage of 1.0 mg/kg over 10 minutes, the average maximal plasma 
concentration achieved immediately following the completion of drug infusion was 2.8 ± 0.6 
μM, with the mean terminal elimination half-life of 3.1 ± 0.7 hours (error is standard deviation). 
To obtain a pharmacokinetic profile for S-PAC-1, four research hound dogs were treated with 25 
mg/kg S-PAC-1 via i.v. injection over 10 minutes. The peak plasma concentration resulting from 
this 25 mg/kg i.v. bolus dose was ׽150 μM. From analysis of the pharmacokinetic profile, the 
half-life of S-PAC-1 in dogs was calculated to be 1.09 ± 0.02 hours. Additionally, single-dose, 
i.v. S-PAC-1 treatment was well tolerated by all four research dogs, and no short- or long-term 
adverse events were observed with these animals as a result of treatment. 
An i.v. constant rate infusion pharmacokinetic profile was generated for PAC-1 and S-
PAC-1 using a “personalized” protocol for research dogs based upon their individualized 
volumes of distribution, systemic clearance, elimination half-life, and body weights. The 
protocol tested in our investigation included a 10-minute loading dose, followed by a constant 
rate infusion maintenance dosage administered for 24 h (S-PAC-1) and 48 h (PAC-1) (Figure 
3.1). Using this pharmacokinetically derived dosing protocol in four research dogs, plasma 
concentrations of PAC-1 after 6h of infusion were 10.7 ± 2.0 μM, and remained equal to or 
greater than this concentration for approximately 36 h. PAC-1 concentrations appeared to plateau 
off following completion of the first 24 h of the constant rate infusion, with plasma 
concentrations ׽18 μM. Three healthy research dogs were used to determine if S-PAC-1 could 
be safely administered via a constant rate infusion regimen, and to determine appropriate dosing 
levels to maintain plasma concentrations above 10 μM. I was present and assisted for this testing 
for two of the research hound dogs for S-PAC-1. Following PAC-1 or S-PAC-1 constant rate 
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infusion, dogs were reevaluated weekly for 4 consecutive weeks. Weekly serial blood tests and 
physical examinations documented the absence of any clinically meaningful hematologic and 
nonhematologic toxicity, and no clinically overt gastrointestinal toxicity was reported by animal 
care givers throughout the 4 week duration of monitoring. Thus, both PAC-1 and S-PAC-1 
administered as a continuous-rate infusion can be safely given to research dogs and easily reach 
desired micromolar steady-state plasma concentrations.  
Figure 3.1. Constant rate infusion protocol for the pharmacokinetic study of  PAC-
1 and S-PAC-1 in healthy research hound dogs. The research dog pictured here was 
administered S-PAC-1 by Dr. Tim Fan. A) Front and back leg peripheral catheters 
inserted. Basal blood sample taken before the introduction of the drug. B) Bolus loading 
dose over 10 min (5.1 mg/kg; 189 mg total; rate 1mL/40 sec “personalized” for this 
research dog, C) First pharmacokinetic sample: blood drawn at t = 10 min, D) Constant 
rate infusion via syringe pump (65 mg/hr; 5.75 ml/hr over 24h), blood drawings took 
place at t = 1, 6, 12, and 24h).  
 
3.2.3. Assessment of PAC-1 and S-PAC-1 in pet dogs with lymphoma 
PAC-1 and S-PAC-1 could be safely administered to research dogs through a constant 
rate infusion dosing regimen, therefore client-owned pet dogs with spontaneous lymphoma were 
enrolled into clinical trials for both compounds as single-entity agents. Summarized in Table 3.2 
are the clinical responses for the dogs that have received treatment to date. Pet dogs that entered 
the study received treatment with PAC-1 or S-PAC-1 as a single entity drug for 4 weeks and 
were followed for an additional 2 weeks after drug withdrawal. Four patient dogs received PAC-
1 via a once-a-week 48 h constant rate infusion for four weeks; 11 patient dogs received 
A B C D
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treatment with S-PAC-1 via a once-a-week 24 h constant rate infusion for four weeks, and 3 
patient dogs received S-PAC-1 every other week in a 72 h constant rate infusion for four weeks. 
To date, PAC-1-treated dogs were enrolled as follows: one dog received a 1X PAC-1 treatment 
(2 mg/kg loading dose, 0.6 mg/kg/h maintenance does), two dogs received a 2X PAC-1 
treatment (twice the amount in both loading and maintenance dose), and one dog received a 3.3X 
PAC-1 treatment (3.3 times the amount of PAC-1). S-PAC-1-treated dogs were enrolled in a 
more extensive dose escalation study as follows: the first cohort (n=6) received 1X S-PAC-1 (7 
mg/kg bolus loading dose, 3 mg/kg/h maintenance dose), the second cohort (n=3) received 2X S-
PAC-1, the third cohort (n=5) received 3.3X S-PAC-1, and one dog was administered 2.25X S-
PAC-1.   
The safety of the drug administration was monitored during treatments by clinical staff 
and in between treatments by pet owners. Since only four patient dogs have enrolled in the PAC-
1 trial to date, more information is necessary to fully characterize whether the treatment elicits 
adverse side effects. Notably, however, 3.3X PAC-1 treated dog patient 4 died following the 
second compound treatment, and it appear this death was due to a neurological comatose 
response (not hyperexcitation/seizure seen in the healthy dogs with higher doses of PAC-1). 
While initial work with PAC-1 in healthy research dogs demonstrated that PAC-1 is predicted to 
be safe at low doses (see above), the presence of neurological response in the patient dogs may 
suggest that these ill dogs may have a more compromised blood-brain barrier or a general 
increase sensitivity to side effects. Steady-state plasma concentrations in the 1X S-PAC-1 
treatment cohort were >10 μM in the majority of treatments. In the 2X and 3.3X S-PAC-1 
treatment groups, some of the dogs showed signs of mild to severe gastrointestinal irritation 
during the treatment, and some patients were co-treated with anti-nausea drugs to offset the 
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discomfort with this side effect. With these generally short-lived side effects, it was a surprise 
that dog patient 14 died during the 2.25X S-PAC-1 treatment, especially pharmacokinetic 
analysis reveals that patient 14 obtained plasma concentrations of S-PAC-1 that were comparable 
to patient 9, a dog that experience no adverse side effects (Table 3.2). It is possible that 
differences in breed and extent of illness may play a role in the differences in side effects in the 
various patients. 
Figure 3.2. Anti-tumor effect of S-PAC-1 treatment for patient dog 1.  A)  RECIST 
scores for patient 1 over the course of 7 weeks.  Arrows indicate treatment days.  
During the course of treatment patient 1 experienced a 27% decrease in RECIST score.  
After treatment ended, tumor size increased rapidly (day 42).  B)  CT scans of the 
mandibular lymph nodes (outlined in yellow) demonstrate a clinically measurable  
decrease in tumor size prior to treatment (day 0) and one week after S-PAC-1 
administration (Day 7).  
 
 
 
A) B)
Patient dog 1
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Given the small number of patients included in this clinical study to date, anti-tumor 
activity of PAC-1 and S-PAC-1 cannot be conclusively determined. Nonetheless, it is clear from 
the four dogs treated with PAC-1, that although two patients responded to treatment with stable 
disease, a comatose neurologic response is of great concern and further investigation is necessary 
to determine a safe dosing strategy (Table 3.2.). In the six patients treated with 1X S-PAC-1, one 
patient (dog 1) showed a partial response with a ׽30% reduction in both caliper RECIST score 
and the mandibular lymph node measurements by CT scan over the course of the 4-week 
treatment (Figure 3.2). I was present for the recording of one RECIST measurement for dog 1. 
After discontinuation of S-PAC-1 treatment, the RECIST scores for dog 1 increased dramatically 
(days 36 and 42, Figure 3.2A). In addition to this partial response, three patients showed stable 
Table 3.2. Results for clinical trial of pet dogs with lymphoma 
Dog 
Patient
Name Breed Weight (lbs) Compound Treatment Side Effects Response
1 Heidi Schnauzer 19 PAC-1 1X, 4 x 48h No Progression
2 Clifford Beagle 39 PAC-1 1X, 4 x 48h No Progression
3 Brodie Golden Ret. 128 PAC-1 2X, 4 x 48h Yes Stable
4 Ares Rottweiler 130 PAC-1 3.3X, 4 x 48h Yes, Death Death (after treatment #2)
1 Zombie Mixed 79 S-PAC-1 1X, 4 x 24h No Partial response
2 Sophie Choc. Lab. 89 S-PAC-1 1X, 4 x 24h No Stable
3 T.J. Newfoundland 160 S-PAC-1 1X, 4 x 24h No Stable
4 Cinnamon Corgi 30 S-PAC-1 1X, 2 x 72h No Stable
5 Shelby Golden Ret. 80 S-PAC-1 1X, 2 x 72h No Progression
6 Scooby Doo Boxer 59 S-PAC-1 1X, 2 x 72h No Progression
7 Gizmo Mixed 52 S-PAC-1 2X, 4 x 24h No Stable
8 Max Labrador 98 S-PAC-1 2X, 4 x 24h Yes, Severe Stable (euthanize after #2)
9 Sport Mixed 48 S-PAC-1 2X, 4 x 24h No Stable
10 Ellie Mae Mixed 38 S-PAC-1 3.3X, 4 x 24h Yes, Severe Response
11 Thane Doberman Pin 116 S-PAC-1 3.3X, 4 x 24h Yes, Death Response
12 Coco Poodle 80 S-PAC-1 3.3X, 4 x 24h Yes, Slight Progression
13 Serena German Shep 78 S-PAC-1 3.3X, 4 x 24h Yes, Severe Progression
14 Beaner Austr Shep 56 S-PAC-1 2.25X, 4 x 24hx Yes, Death N.D.
1X PAC-1 = 2 mg/kg loading dose, 0.6 mg/kg/h maintenance dose
1X S-PAC-1= 7mg/kg loading dose, 3 mg/kg/h maintenance dose, with slight variation in Dog #1. 
N.D.= Not determined
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disease (patients 2, 3, and 4), whereas two patients showed disease progression (patients 5 and 
6), as indicated in Table 3.2. The rapid increase in RECIST scores after drug withdrawal shown 
in patient 1 is representative of the effect of drug withdrawal in all patients. Furthermore, the 
most dramatic response to date is 3.3X S-PAC-1 dog patient 10: tumor size was measured to 
have been reduced by 34% (by RECIST score) after one treatment, and the dog’s life has been 
prolonged for eight months after the treatments, at the time of this writing. As additional patients 
are enrolled for treatment, procaspase-3/caspase-3 levels in their tumor aspirates before and after 
treatment will be assessed, and these levels, as well as subtype of lymphoma may play a role in 
the different responses in the dogs regarding safety and efficacy. Together, these data suggest 
that clinically relevant concentrations of PAC-1 and S-PAC-1 can be achieved relatively safely 
in actual client-owned pet dogs with lymphoma, and that these compounds have the capability of 
eliciting a disease response in a number of the patients, and further testing in these animal 
models will aid in the development of procaspase activating compounds in humans. 
3.3. Cell permeability and blood-brain barrier permeability of PAC-1 and S-PAC-1 
PAC-1 and S-PAC-1 have different toxicities in vivo: PAC-1 at concentrations of 30 
mg/kg or higher induces a neurotoxic response (seizures and ataxia), while S-PAC-1 can be 
safely administered at high doses without the same side effects. In this section is described the 
use of a cell permeability experiment, a comparison of calculated logBB values, and an in vivo 
blood-brain barrier study to characterize the neurotoxic differences between PAC-1 and S-PAC-
1.  
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3.3.1. Cell permeability of PAC-1 and S-PAC-1 
The divergent in vivo neurotoxicity induced by PAC-1 and S-PAC-1 may be attributed to 
differences in the ability to penetrate neuronal cell membranes, or differences in blood-brain 
barrier (BBB) permeability.149 To explore the first hypothesis, collaborator Dr. Tim Fan and Dr. 
Diana Thomas treated Neuro-2a murine neuroblastoma cells with either PAC-1 or S-PAC-1 
(both in HPCD) at 50 µM for 30 minutes. Following compound exposure and cell lysis, the 
lysates were analyzed by HPLC for intracellular compound concentration. Both PAC-1 and S-
PAC-1 were detected in the cell lysates at equivalent concentrations (PAC-1: 29.4 ± 6.5 µM and 
S-PAC-1: 29.4 ± 5.7 µM) (Figure 3.3A). These results demonstrate that both PAC-1 and S-PAC-
1 are equally capable of penetrating neuronal cell membranes, and suggest that cell permeability 
does not play an essential role in the different in vivo neurotoxicity exhibited by the two 
compounds. 
3.3.2. Calculated LogBB value as a predictor of PAC-1 and S-PAC-1 blood-brain barrier 
permeability 
Given the known affinity of PAC-1 for zinc in vitro,161 and the data suggesting that PAC-
1 binds cellular zinc (Chapter 2), the current hypothesis is that the neurotoxicity observed in 
mice and dogs administered PAC-1 in HPβCD is caused by the chelation of intracellular zinc at 
N-methyl-D-aspartic acid (NMDA) receptors within the central nervous system.149 This 
hypothesis is consistent with data from in vivo studies of other zinc chelators that induce a 
neurologic phenotype reminiscent of what we observed with PAC-1.200, 201 The calculated logBB 
is an in silico predictive value of the partitioning across the BBB based on the ClogP of a 
compound and its total polar surface area.202, 203 Indeed, PAC-1 has a calculated logBB value of 
−0.07 (ratio of PAC-1 concentrations in brain:blood of 46:54). This logBB suggests that a 
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significant amount of PAC-1 may enter the central nervous system. Conversely, S-PAC-1 has a 
highly negative calculated logBB value of –1.26 (ratio of S-PAC-1 concentrations in brain:blood 
of 4:96), supporting the hypothesis as a lower concentration of S-PAC-1 is likely to enter the 
brain, and thus may explain why S-PAC-1 is non-neurotoxic. Furthermore, several studies have 
indicated that the chelation of intracellular zinc stores relieves tonic suppression of NMDA 
receptors, resulting in neuronal hyperexcitation.201, 204  
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Figure 3.3. Neuronal cellular membrane and BBB permeabilities of PAC-1 and S-
PAC-1.  A) Mean concentrations of intracellular PAC-1 or S-PAC-1 within Neuro-2a 
cells following incubation with 50 µM PAC-1 or S-PAC-1 for 30 minutes. Experiment 
performed in triplicate. B,C) To measure the BBB capacity of PAC-1 and S-PAC-1, 
C57BL/6 mice received PAC-1 or S-PAC-1 at 75mg/kg dissolved in HPBCD via lateral 
tail vein injection.  Concentrations of PAC-1 and S-PAC-1 within serum (B) and brain 
tissue (C) 5 minutes post-injection. Cohort size per group (n=4). Error bars indicate 
standard deviation.  
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3.3.3. BBB penetrance of PAC-1 and S-PAC-1 in mice 
An in vivo study of BBB penetrance was performed by collaborator Dr. Tim Fan and Dr. 
Diana Thomas in which two cohorts of four C57/BL6 mice were injected with 75 mg/kg PAC-1 
or S-PAC-1 (both formulated in HPCD) via the lateral tail vein and subsequently sacrificed 5 
minutes post-injection. Immediately following sacrifice, both serum and perfused brain samples 
were submitted for HPLC analysis of PAC-1 and S-PAC-1 concentration. While PAC-1 and S-
PAC-1 serum concentrations differed by approximately 2-fold (70.4 ± 20.7 µM versus 35.8 ± 6.8 
µM, respectively), the concentration of PAC-1 in the brain was 62 times greater than S-PAC-1 in 
the brain (47.3 ± 5.4 ng/mg versus 0.76 ± 0.05 ng/mg tissue, respectively)  (Figure 3.3B,C). 
These data support the hypothesis that PAC-1 and S-PAC-1 have significantly different 
permeability to the BBB, as well as confirm the predictive power of the logBB calculations for 
these compounds. These results strongly suggest that the BBB penetration contributes to the 
observed neurotoxicity of PAC-1 when high concentrations are administered in vivo.  
3.4. Short exposure cytotoxicity phenotype of PAC-1 
Various cell culture experiments can serve as useful surrogates for in vivo dosing 
strategies. For example, as described earlier in this chapter, continuous cell culture cytotoxicity 
IC50 values provide a starting point for ranges of target peak plasma concentrations of a drug in 
vivo. In this section, a simple short exposure cytotoxicity experiment is presented as a starting 
point for potential dosing strategies. The experiment involves the treatment of cancer cells with 
the compound for various exposure times. Next, the cells are washed in order to remove 
compound, incubated in fresh cell culture media for another period of time, and cell viability is 
assessed. This protocol mimics a bolus treatment of a drug in vivo, in which the tumor cells are 
exposed to drug for a period of time before the drug is metabolized or cleared through the 
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system. Especially given that the pharmacokinetic half-life of PAC-1 is about 3.5 h in mice and 
dogs, it would be promising if short exposures of PAC-1 could induce potent cell death with this 
surrogate experiment. In this chapter, the initial findings of PAC-1 in a short exposure 
experiment are reported, followed by a study into the effect of assay conditions including serum 
levels in the cell culture media and method of compound addition, and the results from an 
optimized short exposure assay are described.   
3.4.1. Sufficiency of short exposures of PAC-1 to induce potent cell death 
 The ability of PAC-1 to induce cell death in cancer cells was first explored and 
characterized with lymphoma cell lines. EL4 murine lymphoma cells in 990 µL of media (RPMI 
1640 supplemented with 10% fetal bovine serum, FBS) were treated with 100 µM PAC-1 by 
direction addition of 10 µL of a 10 mM stock of PAC-1 in DMSO. The cells were exposed to 
PAC-1 at this high concentration for various times from 15 min to 2 h, washed once with media, 
and incubated for the remainder of 24 h at 37 ºC. Cell viability was assessed with flow cytometry 
in annexin-V/propidium iodide double stained cells. In this experiment, approximately the same 
amount of potent cell death was observed at 24 h after a 15 min compound exposure (Figure 
3.4A). The experiment was repeated for a range of cell lines, including human lymphoma cell 
lines U-937, CA46, as well as canine lymphoma cell lines OSW, GL-1, 17-71 (Figure 3.4B). The 
short exposure phenotype was also observed in adherent cell lines such as cervical HeLa and 
glioma GL-261. When cells were treated with PAC-1 that was pre-mixed with ZnSO4, the cells 
remained as viable as the control cells. However, this lack of phenotype may be due to cell 
impermeability of the PAC-1:zinc complex as opposed to any actual inhibitory effect of zinc, 
since zinc does not inhibit the phenotype when cells are pretreated with ZnSO4.          
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Figure 3.4. Direct addition short exposure cytotoxicity induced by PAC-1.   
Mean percent cells in the apoptotic/late apoptotic-necrotic cell population was 
determined by flow cytometry of annexin-V and propidium iodide double stained cells 
24h after compound exposuure A) EL4 cells were exposed to PAC-1 for various times. 
At 24h, the majority of the cell population was apoptotic/late apoptotic-necrotic. B) 
Various lymphoma cell lines respond dramatically to PAC-1 exposure of 15 min, most 
cells are non-viable at 24h. Experiment performed with at least three replicates. Error 
bars indicate standard deviation.  
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3.4.2. Uniqueness of PAC-1 pulse phenotype compared to other cytotoxins.  
 PAC-1 derivatives. The ability of short exposures of 100 µM PAC-1 to induce potent cell 
death had clinical significance in potential bolus dosing of the compound. At the time of the 
discovery of this short exposure phenotype, PAC-1 derivatives S-PAC-1 and PAC-1-II-12 were 
being developed for in vivo testing in mice because of their potential as non-neurotoxic PAC-1 
derivatives. First, 100 µM S-PAC-1 was tested for its ability to induce cell death at exposure 
times ranging 15 min to 2 h in EL4 cells. While ~10% or less of the cells remained viable with 
PAC-1 short exposure treatments, greater than 75% of cells remained viable with 100 µM S-
PAC-1 treatments at exposures as long as 2 h (Figure 3.5). This would suggest that a short bolus 
dose of S-PAC-1 in vivo would not be amenable, and indeed, a continuous constant rate infusion 
dosing of S-PAC-1 was pursued in animal studies (see above). The fact that structurally similar 
compounds would behave so differently in this short exposure assay was intriguing, although 
research efforts later determined that high concentrations of PAC-1 induced ER stress, another 
distinguishing factor compared to S-PAC-1 (see Chapter 2).    
Colleague Quinn Peterson tested a panel of PAC-1 derivatives for their ability to induce 
potent cell death in U-937 cells, assessing cell viability by late apoptotic/necrotic stain propidium 
iodide alone by flow cytometry. Of the 20 PAC-1 derivatives tested, 9 compounds were potent 
(less than 50% cell remained viable after the assay). Of these, PAC-1-II-12 was identified a lead 
compound for investigation because of its negative logBB value of –0.7 (for structure of PAC-1-
II-12, see Figure 3.5). Therefore, I performed short exposure studies to determine the exposure 
time- and dose dependence of PAC-1-II-12. Less than ~20% of EL4 cell remained viable at any 
of the treatment times ranging 15 min to 2 h when treated with 100 µM PAC-1-II-12 (Figure 
3.5). Also, concentrations as low as 50 µM PAC-1-II-12 were able to induce potent cytotoxicity 
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(less than 50% viable cells) at 1 h and 2 h exposure times. While constant rate infusion dosing 
strategies have been developed for both PAC-1 (low non-neurotoxic dose) and S-PAC-1 for a 
clinical trial of pet dogs with lymphoma,z149, 199 PAC-1-II-12 was not moved forward in efficacy 
studies; in a pharmacokinetic study of the compound in mice, collaborator Dr. Tim Fan observed 
slight neurotoxicity upon treatment with 90 mg/kg PAC-1-II-12 and the peak plasma 
concentration was 2 µg/mg, too low to take advantage of the short exposure phenotype without 
safety concerns. With the realization that some, but not all, PAC-1 derivatives share the unique 
phenotype, efforts toward the discovery of other PAC-1 derivatives that induce cytotoxicity with 
short exposures will be discussed in Section 3.5. 
Figure 3.5. Short exposure cytotoxicity of PAC-1, S-PAC-1, and PAC-1-II-12.   
Representative populations of cell population in a flow cytometry experiment of cells 
that are double stained with annexin-V and propidium iodide 24h after compound 
exposure for PAC-1, S-PAC-1, and PAC-1-II-12. Cells in the lower left quadrant are 
considered viable, while cells in the lower right and upper quadrants are considered 
apoptotic/late-apoptotic necrotic. PAC-1 and PAC-1-II-12 elicit a strong cytotoxic 
response in this assay, but S-PAC-1 does not.  
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Known cytotoxins. While it was surprising to discover that some PAC-1 derivatives did 
not share the short exposure phenotype of PAC-1, it was hypothesized that many known 
cytotoxins would be cytotoxic with short exposures death simply due to the fact that many of the 
compounds are potently cytotoxic in a continuous exposure assay with IC50 values at 24 h in the 
nanomolar range. The results of short exposure cytotoxicities of known cytotoxins are presented 
in Table 3.3. Indeed, some compounds shared the short exposure phenotype of PAC-1 with less 
than 50% of cells remaining viable after a 1 h exposure, such as topoisomerase II inhibitor 
etoposide,205 Ca2+/calmodulin-dependent protein kinase inhibitor and general kinase inhibitor 
staurosporine,206 and DNA alkylator MNNG (Table 3.3).207  
Table 3.3. Cytotoxic compounds and their potency in EL4 murine lymphoma cells 24h after 1h compound exposure
Compound
24h IC50
(µM) [Compound] (µM) Exposure time (min) % Viable cells at 24h
PAC-1* 11.0 ± 2.3 100 60 10.5 ± 5.3
Etoposide* 4.8 ± 2.6 50 60 44.8 ± 3.9
100 60 31.2 ± 4.9
Doxorubicin 0.08 ± 0.06 1 60 80.5 ± 0.5
Daunorubicin 0.2 ± 0.06 2 60 71.1 ± 6.2
Cisplatin N.D. 100 60 86.63 ± 4.9
Colchicine 0.2 ± 0.06 100 60 66.7 ± 0.9
Staurosporine* N.D. 100 60 1.4 ± 1.3
MNNG* 8.1 ± 0.4 100 60 8.8 ± 8.9
S-PAC-1 6.4 ± 0.8** 100 60 85.6 ± 10.0
TPEN 5.3 ± 1.4*** 100 60 89.7 ± 1.4
Thapsigargin* 0.4 ± 0.2 100 60 7.5 ± 6.1
Tunicamycin* N.D. 100 60 12.1 ± 1.9
(*)Indicates compounds that induce potent cytotoxicity (less than 50% viable cells remaining at 24h)
(**)Indicates a 72h IC50 value in U-937 cells, reported in Can. Res., 2010, 70, 7232.
(***) Obtained by SRB assay
N.D. Not determined
24h IC50 values determined by MTS assay, cell viability assessed at 24h by annexin V/propidium iodide
Error is S.E.M. 
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Among some of the cytotoxins that were not cytotoxic with short exposures were 
doxorubicin, daunorubicin, and colchicine. PAC-1 is known to chelate zinc (see Chapter 2),161 
and surprisingly, potent zinc chelator TPEN did not induce short exposure cell death in the EL4 
cells. Evidence of PAC-1’s role as a putative ER stress inducing compound was presented in 
Chapter 2, and interestingly, ER stress inducing compounds thapsigargin and tunicamycin (tested 
at 100 µM) both were cytotoxic with short exposures. The short exposure effect of thapsigargin 
and tunicamycin has also been noted by others.208, 209 These data indicate that while some 
compounds are quite toxic to cancer cells, only some share the short exposure phenotype of 
PAC-1, making this phenotype a relatively unique one.  
3.4.3. Effect of compound addition and serum levels on short exposure assay 
  The short exposure assay as performed as described above (direct addition of 10 µL of 
compound from a 10x DMSO stock into 990 µL of cells in RPMI 1640 media with 10% FBS) is 
highly reproducible as evidenced by the standard error of the means reported for the cell viability 
data in PAC-1-treated cells from multiple cell lines, and for cell viability in cells treated with 
multiple compounds using the same assay. Nonetheless, when small changes in the protocol 
were made in the method of compound addition or levels of FBS (serum) in the media, the potent 
short exposure cytotoxicity of PAC-1 was either attenuated or no longer observed.  
 A small change in the method of compound in which involved the addition of 500 µL of 
a 2x concentrated solution of PAC-1 pre-mixed in RPMI 1640 media (10% FBS) to 500 µL cells 
in media strongly affected the results of the short exposure assay compared to those of the direct 
addition method of compound addition. The pre-mixed addition of compound is thought to be a 
more gentle exposure of the cells to compound, possibly resembling more closely the exposure 
of tumor cells to compound that is diffused in the blood stream, compared to the direct addition 
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method. First, at exposure times up to 2 h, cells treated with 100 µM in a pre-mixed compound 
addition were generally as viable at 24 h as DMSO treated control cells (Figure 3.6). The short 
exposure cytotoxicity was observed in the pre-mixed treatment in RMPI 1640 (10% serum) only 
when the PAC-1 concentration was increased to 200 µM (Figure 3.7).   
Figure 3.6. Effect of method of compound addition and serum levels on the short 
exposure cytotoxicity assay with PAC-1 in U-937 cells. U-937 cells were treated with 
PAC-1 in either a direct addition or pre-mixed addition treatment for 2h. 24h after this 
exposure time, a flow cytometry experiment was performed in which the cells that are 
double stained with annexin-V and propidium iodide. PAC-1 was cytotoxic (shown as 
remaining viable cells) with direct addition treatment or in the absence of serum in the 
media. Even in the direct addition treatment, a slight increase in viable cells is observed 
as serum levels are increased, n=3  
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Figure 3.7. Dose and time dependence of PAC-1 pre-mixed treatment in GL-1 
cells. GL-1 cells were treated with PAC-1 by pre-mixed addition for 1-3h. 24h after this 
exposure time, a flow cytometry experiment was performed in which the cells that are 
double stained with annexin-V and propidium iodide. PAC-1 was cytotoxic (shown as 
remaining viable cells) with a concentration of 200 µM. n=1  
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those seen in the cells treated by direct addition (see Chapter 2). Finally, in a confocal 
microscopy experiment, the onset of punctate mitochondrial staining by Mitotracker Red in 
PAC-1 treated HeLa cells was slightly delayed when PAC-1 was added by pre-mixed addition. 
The punctate phenotype, which is described in more detail in Chapter 2, was observed within the 
first 5 - 10 min of direct addition PAC-1 treatment, compared to 30 min with pre-mixed 
treatment. It should be noted that these confocal experiments were performed in standard buffer 
conditions, with HBSS (in the absence of media, Figure 3.8C). The remarkable difference in the 
short exposure phenotype with a change in compound addition suggests that pre-mixed 
compound exposure could be due to more diffuse exposure of compound lending to a necessity 
for longer exposure times. Furthermore, PAC-1 might be bound more readily by serum (10% 
FBS) in the media when pre-mixed, and thus may not be as effective in inducing short exposure 
cytotoxicity, as in a direct addition treatment. 
 To test the possibility that serum levels might play a role in the dramatic difference in the 
short exposure phenotype of PAC-1 in a pre-mixed compound addition method versus direct 
addition method, U-937 cells were treated with 100µM PAC-1with both compound addition 
methods using media with varying amounts of serum. Following the 2 h compound exposure, 
cells in all treatment groups were washed and incubated with RPMI 1640 media containing 10% 
FBS until cell death was assessed at 24 h. Both direct addition and pre-mixed treatments 
displayed potent cytotoxicity at 24 h in the absence of serum (Figure 3.7). However in the 
presence of 10% and 20% FBS, the cells remained greater than 90% viable in the pre-mixed 
PAC-1 treatment group. Interestingly, the direct addition PAC-1 treatment was quite cytotoxic in 
all three serum levels tested, however, with increasing serum levels in the media, the cytotoxicity  
82 
 
Figure 3.8. Effect of directed addition PAC-1 on cellular and mitochondrial 
morphology. T.E.M. images of U-937 cells treated with a direct addition of 100 µM 
PAC-1 for 5 minutes. A) PAC-1 treated cell has complete absence of mitochondria, 
dilated ER, enlarged lysosomes, and compromised nuclear and cellular membrane (5 
kx magnification), inlay: zoomed image of the severely compromised membrane (17kx 
magnification). B) Differences in lysosome size in PAC-1 and control cells (in two white 
boxes), both images taken at 10kx magnification, shown next to each other for 
comparison. Images are representative of several cells, n = 1 experiment. C) Live HeLa 
cells treated with either pre-mix or direct addition 100 µM PAC-1. Mitotracker Red 
(mitochondria, pseudo-colored red) and SYBR green (nuclei, pseudo-colored blue). 
Onset of punctate mitochondrial morphology (white arrows) is observed sooner in cells 
where PAC-1 was directly added, compared to pre-mixed addition PAC-1-treated cells. 
Magnification is 40x, representative cell population, n=3.  
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increasing levels of serum also lead to a decrease in the cytotoxicity of PAC-1. However, 
although longer exposure times are necessary for a pre-mixed treatment PAC-1 in using standard 
cell culture conditions of RPMI 1640 media with 10% FBS, a unique cytotoxic response is still 
observed in this assay.    
Figure 3.9. Dose and time dependence of PAC-1 pre-mixed treatment in GL-1 cells 
in HBSS (absence of serum). GL-1 cells were treated with PAC-1 by pre-mixed 
addition for 1-3h. 24h after this exposure time, a flow cytometry experiment was 
performed in which the cells that are double stained with annexin-V and propidium 
iodide. PAC-1 was cytotoxic (shown as remaining viable cells) with a concentration of 
100 µM and 200 µM. n=1  
 
 
3.4.4. Optimized short exposure assay 
In order to characterize how long of a compound exposure is sufficient to induce potent 
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µM S-PAC-1, and DMSO for various exposure times for up to 12 h. After treatment, the cells 
were washed and incubated in fresh media. At 24 hours, the cells were stained with AV/PI to 
assess cell viability by flow cytometry. While PAC-1 and S-PAC-1 induced death with a similar 
potency in a 24- or 72-hour continuous exposure,149 100 µM PAC-1 induced large amounts of 
cell death at exposure times as short as 4 hours; this effect was not observed with 100 µM S-
PAC-1 (Figure 3.10). This data is consistent with data previously obtained by Quinn Peterson, in 
which 12 h was crucial for PAC-1 and S-PAC-1 induced cytotoxicity in U-937 cells.149 
Therefore, 100 µM PAC-1 exposures as short at 4 h in a pre-mixed addition short exposure 
experiment (in the presence of 10% FBS) were sufficient to induce potent loss of cell viability.  
Figure 3.10.  Pre-mix exposure to PAC-1 induces cell death.  U-937 cells were 
treated with 100 µM PAC-1, 100 µM S-PAC-1, or DMSO for various exposure times, and 
cell viability was assessed by flow cytometry of the cells double stained AV/PI. Shown 
are the percent viable cells at 24h averaged over triplicate data. Error bars indicate 
standard error of the mean.  
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3.4.5. Implication of short exposure phenotype for in vivo dosing regimens  
The sufficiency of short exposures of compounds to trigger death is unusual, but can be 
an attractive feature of anticancer drugs. For example, the frequency of dasatinib dosing was 
reduced for treatment of chronic myeloid leukemia after the discovery that the compound is 
cytotoxic and effective after short exposures.210, 211  With the current formulation of PAC-1 in 
HPBCD, it would be difficult to avoid neurotoxicity in vivo and obtain high enough peak plasma 
concentrations of PAC-1 in order to use the short exposure phenotype for a bolus dosing 
regimen. Therefore, a PAC-1 derivative with a highly negative logBB that induces cancer cell 
death with short exposures could be a potent and effective antitumor agent. 
3.5. Search for a next-generation PAC-1 derivatives 
The ability of short exposures of PAC-1 to induce potent cell death is an attractive feature 
that could translate in a clinical setting to short, pulse, bolus treatments of the drug instead of 
longer, continuous treatments. One major limitation of PAC-1 is its neurotoxicity in murine and 
canine studies in its current formulation at doses of 30 mg/kg or higher. A number of PAC-1 
derivatives from a structure-activity relationship study were examined as promising drug 
candidates.148 As it became apparent that the possibility of using a short exposure assay to 
differentiate between PAC-1 derivatives would be an indicator of a dosing strategy, a few PAC-1 
derivatives were tested for their ability to induce potent death with short exposures. Azide-
containing derivative PAC-1-II-12 was found to be cytotoxic with a short compound exposure in 
lymphoma cells (above), however peak plasma concentrations were found to be too low for an 
effective short exposure dose, and slight neurotoxicity was observed in vivo. Therefore, a 
compound that is non-neurotoxic and is able to induce cell death with short exposures is a goal in 
the development of next-generation PAC-1 derivatives.     
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3.5.1. Parallel synthesis of PAC-1 derivatives 
In an effort to search for new next-generation procaspase activating compounds, I 
synthesized ~860 PAC-1 derivatives by series of parallel synthesis reactions along with Dr. 
Danny Hsu. The building blocks were selected and synthesized based on the available body of 
knowledge of PAC-1’s in vitro activity and cell culture toxicity, but building blocks were 
completed before the discovery of PAC-1’s in vivo neurotoxicity (see above). Therefore, while a 
number of the PAC-1 derivatives have negative logBB values and would be predicted to be non-
neurotoxic in vivo, the majority of derivatives have logBB values comparable or more positive 
than PAC-1. Dr. Hsu synthesized the modified hydrazides through the coupling of various aryl 
chlorides that were available in the Hergenrother laboratory with hydrazine. The condensation 
reaction between the modified hydrazides and modified salicylaldehydes yields various PAC-1-
like hydrazones (Figure 3.11). Dr. Hsu and I carried out the condensation reactions in parallel 
with a slight access of hydrazide (1.7 eq.) in 1-ethoxyethanol with catalytic amounts of HCl, 
shaking on a parallel synthesizer at 110 ºC. The formation of the derivatives products were 
monitored by mass spectrometry. The reactions were quenched upon addition of polystyrene-
benzaldehyde resin, which reacted with remaining hydrazide. The resin was filtered out through 
a cotton plug. Most products were liquid, and after evaporating the ethoxyethanol overnight by 
vacuum, solid PAC-1 derivative products were obtained with masses ranging 2-10 mg. In cases 
where a solid product precipitated in the reaction, the product was filtered, and PS-benzaldehyde 
resin was added to the mother liquor, then subsequently filtered through the cotton plug. The 
precipitated solid, as well as that which was evaporated from the liquid reaction mixture, was 
dried by vacuum. The purities of the compounds were determined by HPLC by Dr. Hsu, and 
were found to be 90% pure or greater throughout the entire library. Dr. Hsu and I reconstituted 
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~2-5 mg of the compounds into 10 mM stocks with DMSO. It should be noted that a few of the 
reactions did not go to completion, and the products were not formed for PAC-1 derivatives: 
L4R21, L7R23, L16R27, L16R28, L21R27, L26R10, L30R23, L30R24, L30R25, and L30R26.   
 
Figure 3.11.  Combinatorial synthesis of PAC-1 derivatives. The condensation 
reaction between 31 hydrazides and 28 aldehydes leads to 868 total PAC-1 derivatives.  
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3.5.2. Screen of PAC-1 derivative cytotoxicity in a continuous assay 
Dr. Hsu performed the primary screen of the ~860 PAC-1 derivatives for compounds that 
were cytotoxic in U-937 cells 24 h after a continuous exposure at a concentration of 20 µM. Cell 
viability was assessed by flow cytometry in cells that were double stained with FITC-annexin V 
and propidium iodide. Sixty-three compounds were more cytotoxic than PAC-1 (tested at the 
same concentration) in this initial screen. I re-tested the compounds and found that most of the 
63 compounds were indeed cytotoxic in U-937 cells at 20 µM, and the top six most potent 
compounds (less than 10% cells were viable at 24 h) were tested for 24 h and 72 h cytotoxicity 
IC50 values were obtained by Isabel Neacato. Surprisingly, the compounds had 24 h and 72 h 
IC50 values that were generally comparable to (or slightly lower than) PAC-1 as assessed by the 
SRB assay.  Three of the most potent compounds, L5R8, L14R8, and L27R8, were moved 
forward in animal studies, with hopes that their increased cytotoxicity would allow dosing at low 
enough concentrations to avoid any potential neurotoxic response.  
In the preliminary toxicity study performed by colleagues Quinn Peterson and Rachel 
Botham, PAC-1 derivatives L5R8 (logBB 0.14), L14R8 (logBB 0.42), and L27R8 (logBB 0.02) 
were administered i.p. in a single mouse at 150 mg/kg. With logBB values greater than that of 
PAC-1, it is not surprising that the mice treated with these three derivatives displayed a 
neurotoxic response including ataxia, lethargy, and some hyperexcitation over the course of 18h, 
resulting in death (Table 3.4). A study to determine the pharmacokinetics and maximum 
tolerated dose of these compounds is planned; if the mice can achieve a high enough plasma 
concentration predicted to be effective without neurotoxicity, the compounds will be pursued for 
further testing in efficacy studies.    
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3.5.3. Screen for short exposure cytotoxic PAC-1 derivatives 
PAC-1 has a unique phenotype in which short exposures (~4 h) of high concentrations of 
the compound are sufficient to induce potent cell death in multiple cell lines at 24 h. This could 
be an attractive feature of an anticancer drug because it could translate clinically to a dosing 
strategy that is a pulse bolus dose that would be sufficiently cytotoxic to tumor cells. However, 
due to the neurotoxicity observed with doses of PAC-1 higher than 30 mg/kg (see above), to treat 
a patient with a high bolus dose of PAC-1 is not safe with the current formulation of the 
compound. Therefore, efforts are currently underway to identify new PAC-1 derivatives that 
share the same short exposure phenotype that would be predicted to be non-neurotoxic in vivo. 
The same library of ~860 PAC-1 derivatives that was tested for continuous cytotoxicity (above) 
was screened for the ability to induce potent cell death at 24 h with a short 1 h compound 
exposure at 100 µM. For the ease of the assay screen, the compound was added by the direct 
Table 3.4. Lead PAC-1 derivatives from the continuous cytotoxicity screen and their toxicity in mice.
Compound Structure 72h IC50 value 
(µM)
Calculated
LogBB
value
Mouse toxicity
(150 mg/kg)
L5R8 0.7 ± 0.04 + 0.14 Yes, severe, fatal
L14R8 1.4  ± 0.6 + 0.42 Yes, severe, fatal
L27R8 1.4  ± 0.6 + 0.02 Yes, severe, fatal
IC50 assay: Performed by Isabel Neacato, SRB assay
Mouse toxicity: Performed by Quinn Peterson and Rachel Botham; n=1 mouse per compound
N
N
N
H
N
O
HO
OMe
OMe
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addition method of 5 µL of 10 mM stock in DMSO into U-937 cells in 490 µL RPMI 1640 
media (10% FBS), similar to initial PAC-1 short exposure assays, and PAC-1 and DMSO were 
used as controls. After exposure for 1 h, the cells were washed and incubated in fresh RPMI 
media for the remaining 23h. Cell viability was assessed by flow cytometry of cells that were 
double stained FITC-annexin V/prodium iodide using an automated 96-well plate sampler. From 
this initial screen, 86 compounds were identified to induce cell death higher than 50% at 24 h 
after 1 h compound exposure. Interestingly, five of the most potent six compounds from the 
continuous 20 µM cytotoxicity assay were among compounds that were also potently cytotoxic 
after a 1 h exposure, indicating that there was some, but not complete, overlap between the hits 
from both cytotoxicity screens.  
3.5.4. Correlation between short exposure compounds and mitochondrial morphology 
At high concentrations, PAC-1 has a unique cytotoxic phenotype as well as cellular and 
mitochondrial phenotype compared to S-PAC-1. As described in Chapter 2, HeLa cells treated 
with 100 µM PAC-1 (pre-mixed in HBSS) had a distinct punctate mitochondrial staining that 
occurred within 30 min of treatment. This punctate staining was also observed with a 
thapsigargin treatment, although onset of the phenotype with this ER stress inducing compound 
did not occur until 60 min. There were no changes in mitochondrial morphology observed with 
S-PAC-1 treatment, up to 12 h, when cell viability was compromised. These studies in 
mitochondrial morphology prompted further investigation into the possible correlation between 
compounds that induce continuous cytotoxicity or short exposure cytotoxicity and a punctate 
mitochondrial phenotype. Live HeLa cells were treated for up to 2 h with 100 µM of a selection 
of 4 derivatives that were the most potent and exclusively cytotoxic in the continuous assay and 
10 derivatives that were the most cytotoxic in the short exposure assay. Mitochondrial 
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morphology was assessed using Mitotracker Red stain. Indeed, every short exposure PAC-1 
derivative displayed the same mitochondrial phenotype as PAC-1 by 2 h, while no change in 
mitochondrial morphology was observed for every exclusively continuous exposure PAC-1 
derivative (Table 3.5). Further testing of all compounds that are cytotoxic in each assay is 
warranted to fully establish the potential positive correlation between short exposure of 
cytotoxicity and mitochondrial morphology. Furthermore, the mitochondrial phenotype may also 
point to a potential ER stress mechanism, as described in Chapter 2.   
3.6. The development of PAC-1 derivative L28R8 
 Some properties for a next-generation PAC-1 derivative include a compound that 
activates procaspase-3 in vitro through the chelation of inhibitory zinc ions, induces potent cell 
death with short exposures in cell culture, has a comparable continuous cytotoxicity to PAC-1, 
and is non-neurotoxic in vivo. In the efforts described in the previous section, ~860 PAC-1 
derivatives were synthesized and were tested for their ability to induce cell death in U-937 cells 
with continuous and short exposures. One compound that induced potent death in the short 
exposure assay is PAC-1 derivative L28R8. L28R8 is a particularly attractive next-generation 
PAC-1 derivative because it not only shares many characteristics of PAC-1 in vitro and in cell 
culture, it also has a negative calculated logBB value, which predicts it to be non-neurotoxic. In 
this section, efforts toward the characterization of L28R8 are described. 
3.6.1. Continuous and short exposure cytotoxicity profile 
 L28R8 was found to be potent in a screen of ~860 PAC-1 derivatives in a short exposure 
cytotoxicity assay (Figure 3.12A). In the screen, U-937 cells were treated with 100 µM L28R8 
for 1 h, and 6% of the cells remained viable at 24 h. Retesting the direct addition treatment again, 
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3% of the cells remained viable at 24 h, confirming that L28R8 was quite potent. Since it was 
determined that the optimal short exposure assay exposes the cells to compound that is pre-
mixed in RPMI 1640 (10% FBS) media, L28R8 was tested in this optimized assay at longer 
exposure times. From exposure times ranging 4 h to 24 h, 100 µM L28R8 induced potent cell 
death when pre-mixed with media (Figure 3.12B). It should be noted that these experiments used 
the 10mM DMSO stock of L28R8 that I synthesized by parallel synthesis with ~90% purity with 
Dr. Danny Hsu (described above), and the compound was found to be somewhat insoluble in its 
stock solution. Although the compound was well dissolved for the experiment, questions 
remained about the solubility. Therefore, colleague Howard Roth synthesized and purified 
L28R8 (>95% purity), and this resynthesized compound had improved solubility in DMSO and 
in aqueous media (such as cell culture media). A 4 h exposure of the compound was sufficient to 
induce potent cell death, therefore, U-937 cells were exposed to L28R8 (newly synthesized) at a 
range of concentrations for up to 4 h. Less than 50% of cells remained viable upon 2 h exposure 
of L28R8 at 100 µM, and both 50 µM and 100 µM L28R8 was potently cytotoxic with a 4 h 
exposure (Figure 3.12C).  
 L28R8 was not initially identified to be potently cytotoxic in a continuous exposure 
screen of the PAC-1 derivative library at 20 µM for 24 h, as performed by Dr. Danny Hsu. 
However, upon further investigation of this derivative, colleague Rachel Botham determined the 
72 h continuous cytotoxicity IC50 value for L28R8 to be 7.0 ± 0.5 µM (SRB assay), quite 
comparable to that of PAC-1. Together, preliminary cell culture data on L28R8 suggests that 
shorter exposures are sufficient to induce cell death than PAC-1, and that L28R8 and PAC-1 
both induce cell death with similar potency in a continuous treatment assay. 
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Figure 3.12.  L28R8 time and concentration dependence in a short exposure 
assay. A) Structure of L28R8 and logBB value, B) Timecourse exposure up to 24 h of 
100 µM L28R8 in U-937 cells using library stock of the compound, n=3, C) Timecourse 
exposure and dose response up to 4 h of resynthesized L28R8, n=1.  
 
3.6.2. Mitochondrial morphology of L28R8 
 The mitochondria of live HeLa cells, stained with MitoTracker Red, displayed a distinct 
punctate mitochondrial phenotype within 30 minutes of cellular exposure to a pre-mixed solution 
of 100 µM PAC-1 in HBSS (see Chapter 2). This phenotype was not shared with S-PAC-1, and 
was observed with ER stress inducer thapsigargin, suggesting a possible link between 
mitochondrial phenotype and ER stress. L28R8 was selected in a group of compounds that 
induced short exposure cytotoxicity, and indeed, punctate mitochondrial morphology was 
observed by 2 h (above). Therefore, a confocal microscopy experiment was performed to 
examine the timing of the appearance of the punctate staining. HeLa cells were stained with 
MitoTracker Red (for mitochondria) and SYBR green (for nuclei) and treated with 100 µM 
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L28R8 and imaged every 10 min. A dramatic punctate mitochondrial phenotype was observed 70 
min after compound exposure (Figure 3.13). If mitochondrial phenotype is related to an ER 
stress response, it is interesting that L28R8 induces a delayed phenotype relative to PAC-1. 
However, given the appearance of the phenotype, future experiments examining a possible ER 
stress mechanism for L28R8 are warranted.  
Figure 3.13. Mitochondrial morphology of HeLa cells treated with 100 µM L28R8. 
Live cells were stained with MitoTracker Red (mitochondria) and SYBR Green (nuclei) 
and imaged every tem minutes following compound addition. Punctate mitochondrial 
staining was not observed until 70 minutes, n=3.  
 
3.6.3. Preliminary studies on L28R8 safety in mice 
  One attractive feature of L28R8, compared to other PAC-1 derivatives that can also 
induce short exposure cell death and a change in mitochondrial morphology, is that its calculated 
logBB value is –0.86. A highly negative logBB value predicts that the concentration of L28R8 in 
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the blood will be much higher in the brain, thus, L28R8 is expected to be non-neurotoxic. Quinn 
Peterson and Rachel Botham administered L28R8 (formulated in HPBCD) i.p. in C57/BL6 mice 
and observed no side effects other than mild lethargy up to 200 mg/kg in healthy mice. However, 
in a different study conducted by Dr. Tim Fan, EL4 lymphoma tumor-bearing C57/BL6 mice 
displayed dramatically lowered animal weight when treated with 200 mg/kg L28R8 daily; these 
mice were euthanized after 4 treatments. These results suggest that L28R8 can be administered at 
high doses safely in vivo, however the frequency of such a high dose in tumor-bearing mice 
needs further examination. Future pK and efficacy studies will be inform whether this short 
exposure safe PAC-1 derivative will be the next-generation PAC-1 derivative for personalized 
cancer therapy.  
3.7. Conclusions 
PAC-1 and S-PAC-1 have been well characterized in vitro and were moved forward into 
murine and canine models of cancer to study the safety, pharmacokinetics, and efficacy of the 
compounds. PAC-1, at 30 mg/kg or higher, was found to be neurotoxic, eliciting a short-lived 
seizure and ataxia in mice and dogs.149 At lower and safe doses of PAC-1, the compound can be 
administered in vivo through a constant rate infusion,199 and as such, PAC-1 is being pursued 
currently in a clinical trial for pet dogs with lymphoma. Likewise, S-PAC-1 was found to be a 
safe derivative at doses as high as 300 mg/kg in mice and 60 mg/kg in dogs.149 The neurotoxicity 
observed can be explained and predicted by a logBB value for a compound, PAC-1 is predicted 
to be more concentrated in the brain than S-PAC-1, and indeed an in vivo study of BBB 
penetration confirms this. To date, four pet dogs with lymphoma have been enrolled in the 
clinical trial for PAC-1 (at safe low doses), and 14 dogs have been enrolled into the trial for S-
PAC-1. The data from this clinical trial show that S-PAC-1 has a safer therapeutic window than 
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PAC-1, and that while there are some notable adverse side effects, some dogs have responded to 
both PAC-1 and S-PAC-1 treatment with either disease regression or stable disease. These 
results suggest that PAC-1 and S-PAC-1 are worthy for consideration in future clinical studies 
with animal models of cancer, and perhaps in humans.  
One intriguing characteristic of PAC-1 is its ability to induce potent cell death after short 
exposures of 4 h in an optimized assay. As in the example of potent BCR/ABL kinase inhibitor 
dasatinib, the sufficiency of short exposures of compounds can affect dosing strategies for the 
drugs by requiring only short bolus treatments and perhaps even less frequent treatments.210,211 
The ability of 100 µM PAC-1 to induce potent cell death 24 hours after a short compound 
exposure may be linked to ER stress; short treatments of thapsigargin and tunicamycin also have 
been shown to elicit a strong cytotoxic response in the Hergenrother lab as well as in the 
literature.208, 209  
High concentrations (~100 µM) of PAC-1 can be obtained in mice with a 50 mg/kg tail 
vain injection, this concentration is high enough to induce potent short exposure cell death in cell 
culture, but severe neurotoxicity in animals precludes the use of PAC-1 at those doses. 
Therefore, PAC-1 derivative L28R8 was identified from a library of ~860 PAC-1 derivatives as 
a very promising next-generation candidate. L28R8 not only has a short exposure cytotoxicity 
phenotype that could translate to an amenable dosing strategy, but it also has a highly negative 
logBB value (–0.86) and can be safely administered in mice at doses up to 200 mg/kg. Short 
exposure efficacy studies in mice are currently underway and results from that study will shed 
light on L28R8’s potential as a next-generation PAC-1 derivative.  
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3.8. Materials and Methods 
3.8.1. Reagents, Buffers, and Cell Lines 
All reagents, unless otherwise noted, were purchased from Sigma-Aldrich. Compounds 
purchased from other suppliers include: tunicamycin and staurosporine (Tocris), 2-
hydroxypropyl-beta-cylodextrin (CTD). Compounds were dissolved in DMSO (Sigma) for in 
vitro and cell culture studies. PAC-1 and S-PAC-1 were synthesized by colleagues Dr. Danny 
Hsu, Dr. David Goode, Howard Roth, and others as reported.146, 148 Compound L28R8 was 
resynthesized by Howard Roth.  
 Cell lines U-937, HeLa, CA46, EL4, OSW, 17-71, GL-1, and GL-261 were obtained and 
cultured as described in Chapter 2, with the exception of CA46, OSW, and GL-261 were 
obtained from the lab of Dr. Tim Fan. The sulforhodamine B (SRB) and MTS cytotoxicity 
assays and data analysis are described in Chapter 2. Furthermore, the confocal microscopy and 
transmission electron microscopy experiments are described in Chapter 2 as well.  
3.8.2. Formulation of PAC-1 and S-PAC-1 for in vivo studies  
For all in vivo experiments, PAC-1 and S-PAC-1 were freshly reconstituted to a stock 
concentration of 15 mg/mL. Briefly, 200 mg/mL of solublizing agent (2-hydroxypropyl-β-
cyclodextrin) was dissolved in 70% of the final volume of sterile water for injection. An 
appropriate mass of PAC-1 or S-PAC-1 was added to this solution and the pH adjusted to 1.5-2 
at which PAC-1 is fully soluble. After complete dissolution of PAC-1 in the 2-hydroxypropyl-β-
cyclodextrin solution, the pH is restored to 5-6. This solution is then sterile filtered and stored at 
4 °C until use. The stability of this stock solution was followed by LC-MS over 5 days and 
exhibited no degradation products during this time. For i.p. and i.v. injections of these drugs in 
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mice, the drug was delivered directly from this stock concentration or was diluted in sterile water 
for injection to achieve lower doses. For administration to dogs in a continuous infusion, the 
drug stock was diluted 1:1 in a saline solution. 
3.8.3. Pharmacokinetics of PAC-1 and S-PAC-1 in healthy research dogs and in patient 
dogs with lymphoma 
Healthy male hound dogs, bred for research purposes, weighing at least 30 kg were used 
for all preclinical pharmacokinetic studies. All procedures involving care and handling of the 
dogs followed guidelines set forth by the University of Illinois Animal Care and Use Committee. 
All dogs received a single dose of PAC-1 or S-PAC-1 via i.v. injection. After a 2-week washout 
period, three dogs received a dosing regimen predicted to achieve and maintain a steady-state 
plasma concentration of 10 μL, that is, i.v. PAC-1 or S-PAC-1 delivered as a constant-rate 
infusion comprising a 10-minute loading dose, followed by a constant maintenance dose for 24 
hours. Dogs with lymphoma were treated with i.v. PAC-1 or S-PAC-1 in a constant rate infusion 
for either 24 or 72 hours. For all dogs and dosing strategies, blood was drawn from the lateral 
saphenous vein and centrifuged, and plasma was stored at −80°C until analysis. Pharmacokinetic 
analyses were performed by Levent Dirikolu (UIUC Veterinary Biosciences), using a nonlinear 
regression program (Winnonlin, version 5.1) (Pharsight Corporation, Cary, NC). 
3.8.4. Antitumor assessment of PAC-1 and S-PAC-1 in dogs with lymphoma 
Caliper measurement was performed according to the Response Evaluation Criteria in 
Solid Tumors (RECIST) method.212 Briefly, the longest linear length measurement was recorded 
for four pairs of peripheral lymph nodes (mandibular, prescapular, inguinal, and popliteal), with 
the summation of these values giving a RECIST score. In addition to caliper measurements for 
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all four sets of peripheral lymph nodes, computed tomography (CT) scans were performed on the 
mandibular lymph nodes in every patient, allowing for accurate and objective measurement of 
maximal lymph node linear length. 
3.8.5. In Silico LogBB Predictions 
The following equation was used to determine the LogBB: 
LogBB = -0.0148 (PSA) + 0.152 (ClogP) + 0.139 
ClogP was determined using ChemDraw Ultra 12, and polar surface area (PSA) was determined 
using the Daylight web-based software: www.daylight.com/meetings/emug00/Ertl/tpsa.html. 
3.8.6. Short exposure cell cytotoxicity assay 
The direct addition protocol is described as follows: U-937 cells were harvested and 
transferred to a 24-well plate at 500,000 cells/well in 990 µL RPMI 1640 media with 10% FBS 
(some experiments were performed in the absence of FBS, or in HBSS). Compounds tested were 
added directly to the well in a 10µL from DMSO stock solutions to obtain the desired compound 
concentration in 1% DMSO. The contents of the well were mixed 2 – 3 times by manual pipette.  
The pre-mixed addition protocol is described as follows: U-937 cells were harvested and 
transferred to a 24-well plate at 500,000 cells/well in 500 µL RPMI 1640 media with 10% FBS 
(some experiments were performed in the absence of FBS, or in HBSS). Compounds were added 
at 10 µL from DMSO stocks to 490 µL media as 2x pre-mixed concentrated solutions. 500 µL 
compound solutions were added to the wells with cells, so that the final concentration of 
compound was obtained in 1% DMSO.  
The cells were exposed to compound for various times from 15 min to 24h. Following 
compound exposure time, the cells were centrifuged in the 24-well plate at 1000xg, washed once 
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in 500 µL RPMI 1640, centrifuged again, and resuspended in 500 µL RPMI 1640. At 24h, all 
cells from all treatment groups were pelleted and stained with FITC-annexin V/propidium iodide 
and cell viability was assessed by flow cytometry using the LSR II cytometer (BD Biosciences). 
Data collected from at least 10,000 cells was analyzed using the BD FACSDiva Software, with 
percentage of whole cells with negative staining for FITC-annexin V and propidium iodide 
reported as viable cells. 
3.8.7. Parallel synthesis of PAC-1 derivatives  
Thirty-one hydrazides and 28 aldehydes were collected or synthesized by Dr. Danny Hsu. 
The condensation reaction to obtain ~860 PAC-1 derivatives was performed on a parallel 
synthesizer. Briefly, 1.1 eq. of the hydrazide and 1 eq. of the aldehyde was added to 2-
ethoxyethanol with catalytic amounts of HCl into 1-inch diameter glass tubes. Approximately 96 
reactions were performed at once at 100 ºC overnight to 3 days, shaking on the parallel 
synthesizer with a cool lid to avoid evaporation of products. The formation of the products for 
each tube was monitored by low resolution ESI/MS (analysis for product formation by Dr. 
Danny Hsu). Next, polystyrene-benzaldehyde resin was added to each reaction mixture and 
allowed to shake up to 2 days at room temperature to scavenge excess hydrazide. The resin was 
filtered out with a cotton plug, and the ethoxyethanol was evaporated from the product over 
several days by vacuum. ~2-10 mg product was obtained from this procedure, at a purity of 
>90% (purity was analyzed by Dr. Danny Hsu by HPLC).  
3.8.8. Continuous and short exposure cytotoxicity screen of PAC-1 derivatives 
Dr. Danny Hsu tested ~860 PAC-1 derivatives in a continuous exposure screen in U-937 
cells. Compounds (10 µL) were added in singlet by direct addition to a well containing 490 µL 
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RPMI 1640 media (10% FBS) at a final compound concentration of 20 µM. After incubation for 
24 h, the cells were transferred to flow cytometry tubes, washed, and resuspended in Annexin V 
binding buffer. The cells were treated with FITC-Annexin V and propidium iodide and a cell 
population of at least 10,000 events was collected by the LSR II flow cytometer. I rested 63 of 
the most potent compounds in the same assay to confirm their potency. 
A short exposure cytotoxicity screen was carried out as follows: U-937 cells in 490 µL 
RPMI 1640 media (10% FBS) in a 24-well plate were tested in singlet with 10 µL PAC-1 
derivatives by direct addition at a final concentration of 100 µM. After a 1 h exposure, the cells 
were centrifuged in their plates and washed once with RPMI 1640 media. At 24 h after 
compound addition, the samples were centrifuged and resuspended in 100 µL/sample of Annexin 
V binding buffer pre-mixed with propidium iodide and FITC-Annexin V. The samples were 
transferred to 96-well plates and read on the LSR II flow cytometer using an automated plate 
sampler. At least 10,000 events were collected per sample.   
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Chapter 4: Discovery of novel procaspase activating 
compounds 
 
All experiments, unless otherwise noted in the chapter, were performed in full by Diana West. 
Experimental methods from experiments performed by colleagues other than myself are not 
included in the Materials and Methods section.  
  
4.1. Introduction 
 Procaspase activating compound PAC-1 and its derivatives, hold considerable promise as 
anticancer therapeutics. Described in more detail in Chapters 2 and 3, the PAC-1 compounds 
developed in the Hergenrother laboratory activate procaspases in vitro, induce apoptotic death in 
cell culture, and are effective in murine and canine tumor models.146, 148, 149, 161, 199 PAC-1, a zinc 
chelator, activates procaspase-3/-7 and caspase-3/7 by binding to inhibitory zinc and restoring 
the enzyme’s activation. These executioner caspase activating compounds serve as the first 
procaspase activating compounds, and PAC-1 and its derivatives have been forwarded into 
animal studies and a clinical trial for pet dogs with lymphoma. Another procaspase-activating 
compound, 1541, was developed in the Wells laboratory,147 and is able to activate procaspase-3 
and procaspase-6.  
To date, selective procaspase activating compounds have not been developed. Although 
inactivating mutations for caspase-3 are rare, there are instances where it is either not expressed 
or barely detectable in cancer cell lines.116, 213, 214 In MCF-7 breast cancer cells, for example, a 
47bp deletion in exon 3 of the CASP-3 explains the absence of the procaspase-3.213, 214 In 
instances where procaspase-3 is not expressed or observed to have low levels in cancers, a 
selective procaspase-6 or procaspase-7 activating compound would serve to trigger apoptotic cell 
death in these cancer cells. Selective compounds would not only serve as potential anticancer 
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agents, but would also be useful chemical tools in biochemistry, for example, to study 
procaspase enzyme activation mechanisms and enzyme kinetics, or in cell biology to elucidate 
mechanisms of various caspases in cellular pathways. It is thought that caspase-3 and caspase-7 
share many redundant intracellular substrates in the apoptotic death program. In this situation, a 
procaspase-7 or procaspase-3-selective small molecule activator would be advantageous to 
elucidate the roles of each caspase in the cell.  
In this chapter, efforts toward the identification of procaspase-7 and procaspase-3-
selective activating compounds are described. First, a high-throughput screen for procaspase-7 
activators yielded three lead compounds. The novel compounds activate procaspase-7, and are 
likely to be zinc chelators. Next, a short discussion of zinc chelators as anticancer agents will be 
presented. Lastly, the search for novel non-zinc-chelating and selective activators of procaspase-
3 and -7 is presented in which previously identified procaspase activators as well as lead 
compounds from a second high-throughput screening campaign will be examined. 
4.2. High-throughput screen for procaspase-7 activating compounds  
4.2.1. Assay development 
 As described in Chapter 2, procaspase-7 can be recombinantly expressed in E.Coli, and 
the activity can be monitored with a caspase activity assay in which procaspase-7 cleaves the 
colorimetric substrate Ac-DEVD-pNA, releasing p-nitroaniline (405 nm). The use of the Ac-
DEVD-pNA substrate is amenable for use in high-throughput screening because large quantities 
of it can be synthesized via a solution-phase peptide synthesis.215 Chronologically speaking, the 
assay and screen for procaspase-7 was optimized and performed shortly before PAC-1 was 
discovered to activate procaspase-3/-7 by chelating inhibitory zinc ions. Therefore, the buffers 
used in the procaspase-7 activity assay closely resemble what had been used previously in the 
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Hergenrother lab,146 as well as in literature,82 without regard for the presence of zinc and other 
divalent metals. The procaspase-7 assay buffer included CaCl2, Hepes (buffering agent), CHAPS 
(mild detergent for protein folding), β-mercaptoethanol (BME), and glycerol.  
4.2.2. Primary procaspase-7 screen  
The screening library used for the discovery of procaspase-3 was a ~22,000-membered 
library that was assembled in the Hergenrother laboratory that included purchased compounds, 
compounds collected from synthetic efforts in the laboratory, as well as archived compounds in 
the Department of Chemistry Marvel Storeroom. At the time of the procaspase-7 screen, the 
Hergenrother compound library was incorporated into the collection of screening compounds at 
the High-throughput Screening Facility (HTSF) at the University of Illinois, a library totaling 
about ~200,000 compounds. The screen for procaspase-7 activators was performed at the HTSF 
using a 384-well plate format and the facility’s automated liquid handler for compound, protein, 
and substrate addition and automated plate stacker for the spectrophotometer. First, ~500 384-
well plates were preloaded with 25 µL of procaspase-7 assay buffer and HTSF library 
compounds (single compound/well) were added with a pin transfer device for a final assay 
concentration of compound to be ~50 µM. The plates were sealed and stored at –80 ºC until they 
were needed.   
 Procaspase-7 was expressed in E.Coli in large quantities and purified enzyme was flash 
frozen at –80 ºC. Approximately 20 to 60 plates were assayed per day; procaspase-7 and 
prepared compound plates were thawed to room temperature. Procaspase-7 was diluted in assay 
buffer and 20 µL/well was added by liquid handler so that the final concentration of protein was 
100 nM. PAC-1 control and DMSO were pin-transferred into control wells manually. The 
enzyme was incubated with compound for 2 h at 37 ºC, after which 5 µL Ac-DEVD-pNA 
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substrate (diluted in assay buffer) was transferred by liquid handler and the plate was 
immediately read on the spectrophotometer kinetically over 10 min at 405 nm.  
Immediately after reading the plate, possible hit compounds from a brief glance at the 
progress curves on Softmax Pro software were noted on a spreadsheet, as well as wells identified 
to contain bubbles, which could read as false positive hits. The rigorous identification hit 
compounds from each plate was performed using Microsoft Excel: the slopes of the progress 
curves were calculated, and compounds in wells in which the procaspase-7 activity slopes were 
greater than or equal to two standard deviations above DMSO control wells were considered hit 
compounds. From this primary screen for procaspase-7 activators, 753 compounds were 
identified as hits. 
4.2.3. Confirmation of hit compounds  
A secondary screen for procaspase-7 activators was performed in which the 753 primary 
hit compounds were selected from HTSF compound plates manually and tested against 
procaspase-7 in singlet in a 384-well plate using the caspase activity assay with the same assay 
conditions as the screen. From this secondary screen, 66 compounds were confirmed as 
procaspase-7 activating compounds. The structures of these compounds were classified into 
various compound classes including: PAC-1-like N-acyl-hydrazones; hydrazones that were N-
functionalized with pyridyl, pyrimidinyl, or related heterocyles; sulfonamidyl- and 
hydroxyquinolines, thioureas, pyrazolo pyrimidinones, among others (Table 4.1). Five of the 66 
compounds were identified as strongly activating compounds in the in vitro assay with greater 
than a 3.5-fold enhancement in procaspase-7 activity. Interestingly, PAC-1 was a compound that 
was included the screening library that was not identified as a hit in the primary screen, although 
other hit compounds share similar hydrazone motifs, mentioned above. Upon inspection, none of 
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the 66 confirmed hits appeared to meet the criteria for promiscuous non-specific enzyme 
activators that was developed in the Hergenrother laboratory, mainly a polar or charged 
headgroup attached to a large hydrophobic tail.216 
 
4.2.4. Procaspase selectivity of confirmed hit compounds 
To determine the potential selectivity of the 66 confirmed hit compounds for procaspase-
7, recombinantly expressed procaspase-3 was incubated with the compounds using the same 
buffer and experimental conditions as the procaspase-7 hit confirmation assay.  When tested for 
activation of procaspase-3, none of the 66 confirmed hits activated procaspase-3 above the level 
observed for PAC-1. In the assay conditions tested, the compounds activated procaspase-7 
selectively. 
 
Table 4.1. Confirmed procaspase-7 activators grouped in various compound classes.
Confirmed procaspase-7 activators Number of 
compounds
PAC-1-like hydrazones:
o-hydroxy N-acyl hydrazones* 5
N-pyridyl (or pyrimidinyl/heterocycle) hydrazones* 11
Quinolines:
8-hydroxy quinolines* 19
8-sulfonamidyl quinolines* 5
8-ether, 8-ester or 8-thioether quinolines* 5
Thioureas* 9
Pyrazolo pyrimdinones* 3
Uncategorized structures 9
(*) Known metal binding motif
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4.2.5. Cytotoxicity screen of hit compounds 
Since the aim of this particular procaspase-7 screen was to identify compounds that not 
only activated procaspase-7, but also could be forwarded as potential anticancer therapeutics, the 
next assay that was utilized to identify a few lead compounds was a cytotoxicity assay in HL-60 
leukemia cells. Briefly, the 66 compounds were selected from the HTSF compound plates and 1 
µL was added to a 96-well plate containing HL-60 cells in triplicate, at a final concentration of 
(~ 1 µM). The cells were incubated with compound at 37 ºC for 72 h, after which an MTS assay 
was performed and cytotoxicity relative to DMSO (live control) and 100 µM PAC-1 (death 
control) was calculated.  The level of in vitro procaspase-7 activation did not necessarily 
correlate with potency in the cytotoxicity assay (Figure 4.1). Compounds named 102 C21, 206 
M19, and 392 M4 (based on their library plate location) were selected as the most cytotoxic and 
were selected for further investigation (Figure 4.2A). 
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Figure 4.1. Relative cytotoxicity of 66 confirmed procaspase-7 activators. The 66 
procaspase-7 activators are listed from left to right on the horizontal axis from most to 
least potent in vitro activator, on the vertical axis is the relative cytotoxicity. Inlayed 
graph: The top seven compounds in the in vitro procaspase-7 fold activity in the 
secondary screen of primary hits (blue graph bars). From this data, the three most 
cytotoxic compounds were selected for further testing: 102 C21, 206 M19, 392 M4.    
 
4.3. Characterization of procaspase-7 activators 102 C21, 206 M19, and 392 M4  
4.3.1. In vitro characterization of procaspase-7 activators 
To characterize the lead compounds, the in vitro dose response activation of procaspase-7 
was first tested. Lead compounds 102 C21, 206 M19, and 392 M4 were compounds in the HTSF 
library that were members of a purchased library. Therefore, individual powdered compounds 
were purchased from ChemBridge for testing and reconstituted in 5 or 10 mM DMSO stocks. 
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First, the compounds were tested for their ability to activate procaspase-7 in a dose-dependent 
manner. Indeed, when procaspase-7 was treated with varying concentrations of the three 
compounds, an increase in activity was observed with increasing concentrations in the caspase 
activity assay (Figure 4.2B). However, the solubility of compound 206 M19 was diminished at 
concentrations higher than 10 µM in the assay buffer and the dose-response was only observed 
up to the point of insolubility. Additional in vitro results in a variation of the procaspase-7 assay 
will be addressed in Section 4.4.4. 
Figure 4.2. Procaspase-7 activators 102 C21, 206 M19, 392 M4. A) Structures of 
three lead procaspase-7 activators, B) Dose-dependence of three procaspase-7 with 
three activators and PAC-1 in the same buffer and conditions as the procaspase-7 
screening campaign. Compound 206 M19 had reduced solubility in the assay buffer at 
concentrations higher than 10 µM.   
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4.3.2. Cytotoxicity of procaspase-7 activating compounds  
To characterize the continuous cytotoxic properties of 102 C21, 206 M19, and 392 M4 
more fully, the cytotoxicity IC50 values for the compounds were determined in a small panel of 
cell lines: suspension cell lines HL-60 (human leukemia) and U-937 (human lymphoma), as well 
as adherent cell lines IGROV-1 (human ovarian cancer) and MCF-7 (human breast cancer) were 
tested. MCF-7 cells do not contain procaspase-3, therefore, if executioner procaspases are 
activated by the compounds to induce cytotoxicity in this cell line, it is likely due to procaspase-
7 (and perhaps procaspase-6, to a lesser extent). Summarized in Table 4.2, are the respective IC50 
values for the three compounds. All compounds are quite cytotoxic, with IC50 values in the 
nanomolar to low micromolar ranges at 24 and 72 h compound exposures.  
 
Table 4.2. Summary of cytotoxicity data for procaspase-7 activating compounds.
Cell Line Compound Average  72h IC50 (µM)
U-937 (MTS) 102 C21 0.5 ± 0.07
Human Lymphoma 206 M19 0.03 ± 0.004
392 M4 0.5  ± 0.2
HL-60 (MTS) 102 C21 0.3 ± 0.07
Human Lymphoma 206 M19 0.03 ± 0.01
392 M4 0.4 ± 0.1
IGROV-1 (SRB) 102C21 3.4 ± 1.2
Human ovarian cancer 206M19 0.2 ± 0.06
392M4 1.3 ± 0.3
MCF-7* (SRB) 102C21 1.4 ± 0.5
Human breast cancer 206M19 0.3 ± 0.1
392M4 0.3 ± 0.2
n ≥ 3 experiments, except (*) n =2
Error reported is standard error of the mean
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 PAC-1 induces cell death after short exposures in cultured cells and this unique 
phenotype can be potentially exploited in an in vivo dosing strategy (see Chapter 3). Therefore 
ability of the three procaspase-7 activators to induce potent cytotoxic death at 24 h after a short 
exposure was tested. EL4 murine lymphoma cells were treated with 100 µM 102 C21, 206 M19, 
and 392 M4 by direct compound addition for 2 h, and after washing the cells and incubating 
them in RPMI 1640 media, cell viability was assessed by flow cytometry using annexin 
V/propidium iodide double staining. Compared to 100 µM PAC-1 in the same assay, compounds 
102 C21 and 206 M19 induced potent cell death, with less than 40% viable cells at 24 h. 
Compound 392 M4 induced modest short exposure cell death (Figure 4.3). Together, these data 
suggest that if these compounds were advanced into in vivo models, assuming favorable 
pharmacokinetic profiles of the compounds, a short bolus dose of compounds may be sufficient 
to induce cancer cell death.   
Figure 4.3. Short exposure cytotoxicity of procaspase-7 activators. EL4 cells were 
exposed to DMSO, or 100 µM PAC-1, 102 C21, 206 M19, 392 M4 for 2h. Shown are 
flow cytometry plots of cell populations stained with annexin-V-FITC (x-axis) and 
propidium iodide (y-axis) assessed at 24h. All three compounds induce short exposure 
cytotoxicity, with 102 C21 and 206 M19 being the most potent in this assay. 
 
4.3.3. Cell cycle arrest of procaspase-7 activators and PAC-1  
One way to characterize the ability of compounds to induce cell death is to determine if 
they arrest the cells in a particular phase of the cell cycle. The three procaspase-7 activators were 
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tested with PAC-1 for their ability to induce cell cycle arrest. U-937 or HL-60 cells were treated 
with 10-50 µM PAC-1 for relatively short exposures of 6-8 h. The cells were then fixed with 
ethanol, and following fixation, were treated with RNase A and stained with propidium iodide 
(DNA marker). The cell populations in the various stages of the cell cycle were determined by 
flow cytometry upon analysis of the intensity of propidium iodide staining using the BD FACS 
Diva software. It was discovered in this experiment that PAC-1 induced cell cycle arrest in the 
G1 phase at all concentrations tested (Table 4.3). Interestingly, potent zinc chelator TPEN has 
been shown by others to also arrest the cell cycle in G1 phase.217 The co-treatment of cells with 
PAC-1 and either ZnSO4 or caspase inhibitor Z-VAD-fmk did not alleviate the cell cycle arrest 
induced by PAC-1.  To test if procaspase-7 activators also induced cell cycle arrest, U-937 cells 
were exposed to the three compounds at a concentration of 50 µM for 8 h. Based on this 
experiment, it appears that 102 C21 may be an S-arrestor, 206 M19 may be a G1-arrestor, and 
392 M4 may be a G2/M-arrestor (Table 4.3).  
4.4. Procaspase-7 activating compounds as zinc chelators 
The discovery of PAC-1’s in vitro mechanism as a chelator of inhibitory zinc to restore 
procaspase-3/-7 (see Chapter 2)161 was concurrent with the efforts to characterize the newly 
discovered procaspase-7 activating compounds 102 C21, 206 M19, and 392 M4 in in vitro and 
cell culture assays. Therefore, the ability of PAC-1 to chelate zinc influenced investigation into 
the procaspase-7 activating compounds’ potential as zinc chelators. 
Table 4.3. Cell cycle analysis of PAC-1 and procaspase-7 activators in U-937 cells (8h treatment).
1% EtOH 10 µM PAC-1 20 µM PAC-1 50 µM PAC-1 50 µM 102 C21 50 µM 206 M19 50 µM 392 M4
% G1 50 61 64 69 47 56 44
% G2/M 21 8 17 16 14 15 28
% S 29 31 19 15 38 29 28
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4.4.1. Known zinc-binding motifs in procaspase-7 activating compounds 
 A number of metal-binding moieties have been identified in the literature, including 
ortho-hydroxy-N-acyl hydrazones,218 8-hydroxy quinolines,219 sulfonamidyl and mercapto 
quinolines,220 thioureas,221 pyrimidinones,222 among others.223 The three lead procaspase-7 
activating compounds of interest contain metal-binding motifs. Compound 102 C21 is a 
sulfonamidyl quinoline, remarkably similar in structure to known non-cytotoxic fluorescent zinc 
sensor TSQ.224  Furthermore, 206 M19 is an N-pyridyl-hydrazone, and 392 M4 is an 8-hydroxy 
quinoline. Revisiting the 66 confirmed procaspase-7 activating compounds, 57 compounds fall 
into these general classes of zinc chelators (Table 4.1). Based on the fact that so many confirmed 
procaspase-7 activators fall into known classes of divalent metal chelators, it is highly probable 
that these compounds chelate zinc.  
 
4.4.2. Effect of Zn2+ on UV absorbance spectra of procaspase-7 activators  
One efficient way of testing if a compound binds to a metal is to visualize a change in the 
UV absorbance spectrum of the compound upon addition to the metal. This experiment was 
Table 4.4. Effect of zinc on UV-vis spectra of the 66 procaspase-7 activators
Observed shift in UV absorbance spectra Number of 
compounds
Shift in UV absorbance spectrum upon addition of ZnSO4 57
Slight shift in UV absorbance spectrum upon addition of ZnSO4 6
No observed shift upon addition of ZnSO4* 2
Not tested upon addition of ZnSO4** 1
(*) These compounds have a known metal binding motif
(**) HTSF compound stock for this compound was depleted, however the structure has a 
known metal binding motif 
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performed previously to demonstrate that PAC-1 chelates zinc.161 First, the 66 confirmed 
procaspase-7 activating compounds were selected from the HTSF compound plates and diluted 
in a 96-well plate in singlet at 1 µM. UV-vis spectra were obtained between wavelengths of 190-
500 nm for all compounds as well as PAC-1 and inactive non-zinc-chelating derivative PAC-
1a.146, 161 Next, the compounds were treated with 10 µM ZnSO4, and UV-vis spectra were 
obtained. Strong shifts in the spectra of 57 compounds, as well as slight shifts for 6 compounds, 
were observed upon addition of zinc (Table 4.4). Only two compounds did not elicit any 
observable shift in their UV spectrum, however, they both have known metal-binding motifs 
(pyrazolo pyrimidinone and 8-hydroxy quinoline, respectively). The three lead compounds 102 
C21, 206 M19, and 392 M4 had shifts in UV absorbance spectra in this assay upon exposure to 
75 µM ZnOTf, and a more detailed UV-vis spectrum was obtained for each compound using a 
Varian Carey 4000 spectrophotometer. Both compounds 102 C21 and 206 M19 had shifts in 
their spectra, however, the shift in the spectrum obtained for 392 M4 was not as remarkable as in 
the previous UV absorbance experiment (Figure 4.4). Finally, compound 206 M19 is a red color, 
and a visual change in compound color to violet was noted upon addition of ZnSO4 (Figure 
4.4B).  
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Figure 4.4. Shift in UV-vis spectra of three lead procaspase-7 activators with 
addition of ZnSO4. A) Shift in spectrum of 102 C21, B) Shift in spectrum of 206 M19, 
inlay: change in color visually observed upon addition of zinc, C) Slight shift in spectrum 
of 392 M4 and D) more pronounced shift observed for 392 M4 when tested among the 
66 procaspase-7 activating compounds.  
 
4.4.3. Effect of procaspase-7 activators in zinc-free procaspase-7 activity assay 
 If the procaspase-7 activators are zinc chelators, it is expected that they will not be able to 
activate procaspase-7 in a zinc-free caspase activity assay, analogous to results for PAC-1 (see 
Chapter 2.161 This hypothesis was tested with all 66 confirmed procaspase-7 hit compounds. 
Indeed, when 100 nM procaspase-7 in Chelex® resin-treated zinc-free Hepes/NaCl buffer was 
exposed with these compounds at ~50 µM, none of the compounds were able to activate 
procaspase-7 two standard deviations above DMSO control activity. This suggests that the 
compounds rely on the presence of metal in order to affect an enhancement in procaspase-7 
activity in vitro.   
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4.4.4. Procaspase-7 activators relief of zinc-mediated caspase-7 inhibition  
 It is predicted that zinc-chelating compounds will activate procaspase-7 by chelating 
inhibitory zinc and restoring enzyme activity, like PAC-1 (see Chapter 2).161 Therefore, in one 
experiment, 5 µM procaspase-7 uncleavable triple mutant (D23A/D198A/D206A; called PC7 
TM in Figure 4.5A) was inhibited by 10 µM ZnSO4, and increasing concentrations of compound 
102 C21 rescued ~100% activity of the enzyme (Figure 4.5A). In the absence of zinc, there was 
not any considerable change in the enzymatic activity of procaspase-7 regardless of 102 C21 
concentration (Figure 4.5A). Compound 102 C21 elicited a strong relief zinc-mediated inhibition 
in a similar assay with caspase-7, however, compounds 206 M19 and 392 M4 did not restore the 
activity as powerfully (Figure 4.5.B-D). Therefore, another assay was conducted with caspase-7 
at 100 nM and a lower concentration of inhibitory zinc (500 nM), and compounds 206 M19 and 
392 M4 both enhanced activity of caspase-7 over DMSO control (Figure 4.5E).  Together, the 
three lead procaspase-7 activators have metal chelating motifs, shifts in their UV-vis spectra 
upon addition to zinc, are unable to activate procaspase-7 in zinc-free assay conditions, and 
restore the activity of zinc-inhibited caspase-7. These data suggest that these activators, like 
PAC-1, activate procaspase-7 through the relief of zinc-mediated enzyme inhibition.     
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Figure 4.5. Relief of zinc-mediated inhibition of procaspase-7 and caspase-7. A) 
Compound 102 C21 rescues procaspase-7 activity in the presence of zinc, B-D) 
Compounds 102 C21, 206 M19, and 392 M4 relieve zinc-mediated inhibition of 
caspase-7 to varying degrees, E) with a lower concentration of zinc, compounds 206 
M19 and 392 M4 display a more pronounced rescue of zinc inhibition of caspase-7.  
 
4.4.5. Comparison of PAC-1 and procaspase-7 activators to other zinc-chelators 
A number of divalent metal chelating compounds have been investigated as potential 
anticancer compounds, such as TPEN, clioquinol, pyrithione, tachpyridine, o-hydroxy n-acyl 
hydrazones (such as 311, PIH, and SIH), thioureas Dp44mT and Triapine, DFO, among 
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others.223, 225-227 Procaspase activating compounds PAC-1 and PAC-1 derivatives, as well as 
those discovered in the screen for procaspase-7, 102 C21, 206 M19, and 392 M4 are potential 
new zinc binding compounds that are thought to chelate inhibitory zinc and restore caspase 
activity. A small investigation into the effect of a few known divalent metal binding compounds 
on cancer cells was performed to compare to PAC-1 and procaspase-7 activators. 
Known zinc-binding compound TPEN, zinc ionophore clioquinol, and iron-binding 
compounds pyrithione and Dp44mT were selected for a continuous cytotoxicity study with U-
937 cells. Summarized in Table 4.5, are the 24 and 72 h cytotoxicity IC50 values. The potency of 
the compounds range from low micromolar (in the case of TPEN, clioquinol, and pyrithione) to 
nanomolar (Dp44mT), and these cytotoxicities are comparable to those obtained for PAC-1 and 
procaspase-7 activators. Cell cycle analysis in U-937 cells was performed TPEN, clioquinol, and 
pyrithione (Dp44mT was not included because it was fluorescent), and only TPEN was able to 
induce G1 arrest similar to PAC-1, a result others have observed as well.217 Conclusive cell cycle 
arrest data was not obtained in this experiment for the other chelators, and further investigation is 
warranted. TPEN and PAC-1 both arrest the cell cycle in the same phase and have similar 
cytotoxic potency, however, TPEN binds to zinc much more tightly (KD of 2.6 x 10-16)173 than 
PAC-1 (KD ~ 50nM).161 This may suggest that affinity for zinc may not necessarily correlate 
with cellular function of the metal chelator.    
4.5. Search for non-zinc chelating activators of procaspase-3 and procaspase-7 
The lead compounds from two different screening campaigns to identify novel 
procaspase-3 and procaspase-7 activating compounds in the Hergenrother laboratory are zinc 
chelating compounds. These compounds activate procaspases by rescuing zinc-mediated 
inhibition, are cytotoxic in cancer cells, and procaspase-3 activators PAC-1 and S-PAC-1 have  
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shown considerable promise in vivo. Nevertheless, compounds that directly active procaspases 
independent of the chelation of inhibitory zinc would be of great use for additional study of the 
biochemical characteristics and cellular mechanisms of procaspases. Therefore, an effort was 
conducted in the Hergenrother laboratory to identify non-zinc-chelating procaspase-3 and 
procaspase-7 activating compounds. In this section, a brief study of existing procaspase-3 
activating compounds will be described, followed by the efforts in a high-throughput screening 
campaign for novel activators.  
4.5.1. Examination of previously identified procaspase-3 activating compounds 
 In the original procaspase-3 activator screen, PAC-1 was selected as a lead compound of 
four confirmed procaspase-3 activators because of its ability to activate procaspase-3 in a dose-
dependent manner.146 Based on the body of knowledge accumulated about zinc-chelating 
Table 4.5. Summary of cytotoxicity data for known zinc 
chelating compounds in U-937 human lymphoma cell line
Compound Exposure time (h)
Average 
IC50 (µM)
Clioquinol 24 14.7 ± 1.5
72 3.4 ± 0.06
Pyrithione 24 8.3 ± 1.7
72 0.4 ± 0.06
TPEN 24 5.3 ± 0.9
72 2.1 ± 0.6
Dp44mT 24 0.006 (n=1)
72 0.01 ± 0.005 (n=2)
n ≥ 3 experiments, unless otherwise noted, assessed by SRB 
assay, Error reported is standard error of the mean
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procaspase activators such as PAC-1, revisiting the remaining three initial procaspase-3 
activating compounds from the original screen146 was warranted. These three compounds, 
5841384, 5881914, and 5879057 were ordered from ChemBridge corporation for investigation 
(Figure 4.6A). It should be noted that these compounds were originally found to activate 
procaspase-3 in the original screening conditions (different buffer components and in the likely 
presence of divalent metals).146 The compounds were first tested for their ability to activate 
procaspase-3 by relief zinc-mediated inhibition. Procaspase-3 uncleavable triple mutant 
(D9A/D28A/D175A) at 2.5 µM was treated with varying concentrations of the three compounds 
in the presence and absence of 10 µM ZnSO4. If a compound is a zinc-binding compound, such 
as PAC-1, it is predicted that it would restore some level of procaspase activity. In this assay, 
however, none of the compounds activated procaspase-3 (Figure 4.6D). These results suggest 
that the compounds do not bind inhibitory zinc, or that the inhibition of the enzyme by 10 µM 
ZnSO4 could not be overcome.  
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Figure 4.6. Revisiting previously identified procaspase-3 activating compounds A) 
The structures of three procaspase-3 activating compounds that were identified along 
with PAC-1 in the initial procaspase-3 screen, B) 72h cytotoxicity IC50 values in U-937, 
error is standard error of the mean, C) Flow cytometry data for a 100 µM compound 
treatment in a short exposure cytotoxicity assay in EL4 cells, D) Relief of zinc-mediated 
inhibition activity assay in which none of the compounds rescue the activity of 
procaspase-3 triple mutant.  
 
 The continuous and short exposure cytotoxicity of the compounds in cancer cells was 
examined next. In a 72 h continuous exposure MTS assay in U-937 cells, compounds 5841384 
and 5881914 were modestly cytotoxic with mid-micromolar IC50 values, and compound 5879057 
was the most cytotoxic with a low micromolar IC50 value (Figure 4.6B). In a short exposure 
cytotoxicity assay, EL4 murine cells were exposed with the three compounds at 100 µM for 2 h, 
and cell viability was assessed by flow cytometry at 24 h with cells double stained with annexin 
V/propidium iodide. A potent short exposure cytotoxicity was not observed for compounds 
5841384 and 5881914, however, compound 5879057 elicited a very potent cytotoxic response 
(Figure 4.6C). Together with the in vitro assay data, further study of compound 5879057 would 
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be quite informative, given its potent cytotoxicity and the possibility that it may not activate 
procaspase-3 through a zinc-chelation mechanism.       
4.5.2. High-throughput screening campaign assay development  
Drawing from the previous knowledge of procaspase-3/-7’s ability to autoproteolyze 
itself into active caspase-3/-7, two screens were designed using the catalytically active and but 
autoproteolysis-resistant triple mutants of procaspase-3 (D9A/D28A/D175A) and procaspase-7 
(D23A/D198A/D206A) in the zinc-free caspase activity assay (described in Chapter 2). The 
zinc-free HEPES and NaCl standard assay buffer that was used for the zinc chelation studies was 
selected for use in this screen,161 with the addition of Triton X. The use of 0.01% Triton X has 
been shown to reduce the number of false positives in biochemical assays by inhibiting the 
formation of compound aggregates.228 Since the assay is performed with enzyme and buffer in 
which zinc and other metals have been removed, it was not expected that PAC-1 would activate 
in these conditions. Therefore, a 5x increase in the concentration of the enzyme served as a 
“positive control” for the screen. 
4.5.3. Pilot screen for activating compounds 
The off-site screening of the NIH Molecular Libraries Probe Centers Network (MLPCN) 
for non-zinc chelating procaspase-3 and procaspase-7 by collaborators at the Scripps Research 
Institute Molecular Screening Center would be conducted in two screens. First, the entire 
~330,000 compound library would be screened for procaspase-3 activators, and then screened for 
procaspase-7 activators. This would allow for the identification of procaspase-3/-7-selective 
activators as well as dual activators of the enzymes. The screens would be performed in a 1536-
well plate format using automated liquid handlers. Therefore, a small pilot screen for activating 
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compounds in the Hergenrother laboratory was conducted with ten 384-well plates for 
procaspase-3 and procaspase-7 using the zinc-free activity assay to determine if sufficient signal-
to-noise could be achieved in the zinc-free assay conditions.  
Procaspase-3 and procaspase-7, at 1 µM final concentration in 25 µL of zinc-free 
Hepes/NaCl buffer (with 0.01% Triton X), was added to 10 384-well plates containing 20 µL 
zinc-free buffer treated with ~50 µM compounds from 10 compound plates from the HTSF 
(originally from the former Hergenrother ChemBridge library plates CH1 through CH10) by pin 
transfer device. Positive control, 5 µM procaspase-3/-7 was also added to the wells as well as 
DMSO control. The plates were incubated at 37 ºC for 1 h, and 200 µM Ac-DEVD-pNA was 
added to the wells and the absorbance at 405 nm of the plates was recorded kinetically over 10 
minutes. A compound was considered a hit compound when it elicited a percent change in 
procaspase activity over 10 minutes that was greater than or equal to 3x the standard deviation of 
the percent activity in the control wells. In the pilot screens of procaspase-3 and procaspase-7, 
the positive control wells were consistently identified to have an activity greater than the hit cut-
off, and some of the compounds were observed to be hit compounds as well (Figures 4.7 and 
4.8). 
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Figure 4.7. Procaspase-3 pilot screen plates. Red dotted lines indicate the hit cut-off 
(3 times the standard deviation) of basal procaspase-3 triple mutant activity. The blue 
dots are individual compounds, and the red dots are positive control 5 µM procaspase-3 
triple mutant.    
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Figure 4.8. Procaspase-7 pilot screen plates. Red dotted lines indicate the hit cut-off 
(3 times the standard deviation) of basal procaspase-7 triple mutant activity. The blue 
dots are individual compounds, and the red dots are positive control 5 µM procaspase-7 
triple mutant.  
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4.5.4. Primary screen for procaspase-3 and procaspase-7 activators 
 I and colleague Rachel Botham prepared materials for the high-throughput screening for 
procaspase-3 and procaspase-7 activating compounds. Twenty liters of Chelex®-treated 
Hepes/NaCl (0.01% Triton X) buffer, flash frozen zinc-free recombinantly expressed 
procaspase-3 (D9A/D28A/D175A) and procaspase-7 (D23A/D198A/D206A) at a 100X 
concentrated stock, synthesized 100mM Ac-DEVD-pNA stock in DMSO, were all prepared in 
the Hergenrother laboratory and shipped to the Scripps Molecular Screening Center.  
Collaborator Ania Knapinska recapitulated the 384-well plate pilot assay for both 
enzymes and also miniaturized the assay for a 1536-well plate format (5 µL total volume/well) 
without significant loss of signal-to-noise (Figure 4.9). One major change in the assay was that 
the absorbance at 405 nm was not tracked kinetically; rather, the absorbance was measured after 
the addition of Ac-DEVD-pNA and then again 2 h later. The Z-prime value is a measurement of 
the general signal-to-noise quality of a screen, and an assay with a Z’ value greater than 0.5 is 
considered to be of modest to good quality.229 The Z’ value for a single miniaturized assay plate 
was determined to be 0.7, indicating that the assay was suitable for a screening campaign and 
that hit compounds could be identified with high confidence. The ~330,000 compounds were 
tested in both screens at a concentration of 8.5 µM. Hit compounds from the primary screen were 
deposited into the PubChem database (procaspase-3 screen AID463141; procaspase-7 screen 
AID463210). The total primary hit compounds totaled 350 for the procaspase-3 screen and 302 
for the procaspase-7 screen. 
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Figure 4.9. Miniaturization of 384-well to 1536-well plate assay. A) Sample 384-well 
pilot assay plate for procaspase-3. Red dotted lines indicate the hit cut-off (3 times the 
standard deviation) of basal procaspase-3 triple mutant activity. The blue dots are 
individual compounds, and the red dots are positive control 5 µM procaspase-3 triple 
mutant. B) Sample 1536-well plate (from collaborator Ania Knapinska). Shown in black 
boxes are positive controls, buffer reference, pinning controls, and individual wells of 
basal procaspase-3 triple mutant activity at 1 µM. 
 
4.5.5. Secondary screens for selective and dual procaspase-3/-7 activators 
Primary screen hit compounds for both screens were lead through a series of 
counterscreens (summarized in a diagram in Figure 4.10). Briefly, of hit compounds from both 
the procaspase-3 and procaspase-7 screens, 131 were redundant hits. Therefore, in a search for 
selective procaspase-3 activators, 210 of the remaining 219 selective primary screen hits were 
available for ordering and testing. Collaborator Ania Knapinska performed two secondary 
screens: a confirmation screen for procaspase-3 activators (18/210 were confirmed hits), and a 
counterscreen with procaspase-7 (6/210 activated procaspase-7). The procaspase-3 and 
procaspase-7 hit compounds (25 total) were available, ordered, and dose response was 
performed. From this analysis, 5/25 procaspase-3 compounds and 4/25 procaspase-7 compounds 
were dose dependent, and 1 selective procaspase-3 compound was discovered. The analysis for 
procaspase-7 activating compounds was performed in a similar way, however, instead of 
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studying only procaspase-7-selective compounds, the initial dual procaspase-3/-7 activating 
compounds were also tested in secondary assays. In this study, 289 of the 302 procaspase-7 hit 
compounds (including those that overlapped with procaspase-3 activating primary hits) were 
available for ordering. In a confirmation screen for procaspase-7 activation, 4/289 compounds 
were active. In a procaspase-3 counterscreen, 5/289 compounds were identified. Using a more 
lenient cut-off of one standard deviation above the average control activity, 17/19 compounds 
were available and ordered for dose-response testing. Only one compound was found to be dose-
dependent in the procaspase-7 assay and one compound in the procaspase-3 assay.  
Figure 4.10. Funnel diagram of the procaspase-3 and procaspase-7 activator 
screens. On the left is the process by which procaspase-3-selective compounds were 
identified through the procaspase-3 primary screen. On the right is the process by which 
procaspase-7-selective compounds and dual activating compounds were generated 
from the procaspase-7 primary screen. Both screens yielded 24 compounds for further 
investigation.  
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A collection of 24 compounds were moved forward for further testing based on their 
ability for selective or partial selective activation of procaspase-3 and procaspase-7, as well as 
compounds that serve as dual activators of both enzymes. The most potent hit most selective 
procaspase-3 activator is compound 5574594, the most selective procaspase-7 activator is 
compound 2925038, and the most potent dual activating compound is compound 865262 (Figure 
4.11, compound names are PubChem CID numbers). Colleague Rachel Botham observed that 
many of the 24 compounds were colored, and in the assay are false positive hits when the 
absorbance of the compound is not taken into account. Testing of these compounds in caspase 
activity assays and cytotoxicity testing is currently underway.   
Figure 4.11. Top hits from procaspase-3 and procaspase-7 zinc-free screens. A) Top 
procaspase-3-selective compound, B) top procaspase-7-selective compound, and C) 
most potent dual activating compound.  
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4.6. Conclusions 
 Since the discovery of PAC-1 and PAC-1 derivatives as procaspase activating 
compounds, a goal in the Hergenrother laboratory has been to identify other novel procaspase 
activators, specifically compounds that are procaspase-selective or act by a mechanism other 
than relief of zinc-inhibited procaspase activity. Toward this aim, two separate screening 
campaigns were conducted. First, procaspase-7 was screened in similar conditions to the original 
procaspase-3 screen. Three lead compounds, 102 C21, 206 M19, and 392 M4, were identified 
from this screen and were found to be quite cytotoxic in cancer cells. Like PAC-1, the three 
procaspase-7 activators most likely activate procaspase-7 by chelating inhibitory zinc and 
rescuing the activity of the enzyme. This hypothesis is supported by the fact that all three 
procaspase-7 activating compounds have known metal-binding motifs, exhibit a shift in their 
UV-vis spectra upon addition of zinc, and can relieve the activity of zinc-inhibited caspase-7 to 
varying degrees. The realization that the novel procaspase-7 activators have a similar in vitro 
mechanism to PAC-1 prompted a small study into some of the characteristics of known metal 
chelators as well.  
 Given the development of PAC-1 and PAC-1 derivatives in vivo, as well as the potential 
for general zinc chelators to be cytotoxic in cancer cells, the zinc chelating procaspase activators 
have promise as anticancer agents. Future studies warranted are the further characterization of 
the selectivity of 102 C21, 206 M19, and 392 M4 for procaspase-7, a determination of their zinc 
binding affinities, the synthesis of the compounds, confirmation of the their ability to activate 
procaspase-7 in the cell, and the toxicity of the compounds in mice. If the compounds are 
forwarded into animal models, the potential neurotoxicity of zinc chelating procaspase activators 
and their interaction with NMDA receptors to control muscle function would be a concern (see 
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Chapter 3). Fortunately, the calculated logBB value for each compound is quite negative (102 
C21 logBB:–0.63; 206 M19 logBB:–0.28; 392 M4 logBB:–0.39), suggesting that they may be 
neurologically safe in vivo.   
 An effort was undertaken to identify novel procaspase activating compounds that activate 
the enzymes by a different mechanism that is not zinc-dependent. First, three previously 
identified procaspase-3 activating compounds were examined. One compound in particular, 
5879057, was cytotoxic with low micromolar IC50 values. The three compounds failed to relieve 
the zinc-mediated inhibition of procaspase-3, which make them candidates for further study. A 
detailed study of the compounds’ ability to activate procaspase-3 (and other procaspases) in the 
absence of zinc is necessary to move forward. Secondly, an extensive high-throughput screening 
campaign was performed with the NIH MLPCN for non-zinc-dependent selective procaspase-3, 
selective procaspase-7, and dual procaspase-3/-7 activators. Two primary screens and a series of 
secondary screens yielded 24 compounds for examination. While many of the compounds may 
be false positives due to their intrinsic increase in absorbance in vitro, at the time of this writing, 
a study of the promising candidates is currently being conducted by colleague Rachel Botham. 
The obstacle of false positive hits due to colored compound absorbance is one that could be 
potentially remedied by a blank screening of the MLPCN library in our assay buffer over time to 
determine if any compounds have an intrinsic increase in absorbance at 405 nm; this would 
allow various problematic compounds to be ruled out immediately, and the activating 
compounds could be reanalyzed. If none of the hit compounds from the MLPCN screen are 
confirmed to activate procaspase-3 or -7 in the Hergenrother lab, it may raise the question as to 
whether non-zinc chelating procaspase activating compounds could be discovered. The greatest 
evidence that this goal is achievable the identification of a procaspase-3/-6 activating compound 
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1541 from a screening of ~62,000 compounds conducted in the laboratory of Jim Wells.147 
Therefore, even in the event of a pessimistic scenario regarding the hit compounds from the 
MLPCN screen, it is possible for procaspase activators to be identified and have a novel in vitro 
mechanism of activation compared to PAC-1 and the procaspase-7 activating compounds. 
Furthermore, one improvement to the discovery of novel procaspase-3 activators could be the 
use of novel compound libraries of diverse and complex chemical structures, such as the libraries 
currently being developed in the Hergenrother laboratory. Together, the studies in this chapter 
show that novel procaspase activating compounds can be identified through high-throughput 
screening, and the future results will determine if the compounds will serve as anticancer agents 
and chemical tools for the study of procaspases.  
4.7. Materials and Methods 
4.7.1. Reagents, buffers, cell lines 
All reagents, unless otherwise noted, were purchased from Sigma-Aldrich. Compounds 
purchased from other suppliers include: 102 C21, 206 M19, 392 M4, 584184, 5881914, and 
5879057 (ChemBridge); TPEN (Tocris), and Dp44mT (EMD). Compounds were dissolved in 
DMSO or ethanol (Sigma) for in vitro and cell culture studies. Caspase-7 activity buffer used for 
HTSF procaspase-7 activity screen (5mM CaCl2, 100 mM Hepes (pH 7.0), 0.1% CHAPS, 5mM 
β-mercaptoethanol (BME), 10% glycerol) was used for the primary screen and some of the 
follow-up experiments. The zinc-free Hepes/NaCl buffer described in Chapter 2 was used for the 
remaining in vitro experiments, except for the MLPCN screen in which 0.01% Triton-X was 
added.  Cell lines U-937, HL-60, IGOV-1, MCF-7, and EL4 were obtained and cultured as 
described in Chapters 2 and 3.  
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4.7.2. Primary HTSF screen for procaspase-7 activating compounds 
 The UIUC High-Throughput Screening Facility (HTSF) ChemBridge compound 
collection of 469 plates was screened at ~50 µM. 2.5 µL of compounds were transferred by 
liquid handler to a 384-well plate containing 20 µL of caspase-7 activity buffer. The 
Hergenrother laboratory ChemBridge and Marvel libraries (incorporated into the HTSF library) 
were screened at ~50 µM and compounds were pin transferred into 22.5 µL of caspase-7 activity 
buffer. The compound plates were sealed and frozen at –20 °C. 
 Procaspase-7 was recombinantly expressed as described in Chapter 2 and 100 mL 
aliquots were flash frozen in liquid nitrogen and stored at –80 °C. Thawed procaspase-7 was 
diluted in caspase-7 activity buffer to a concentration at which the enzyme would be 100 nM in a 
50 µL well final volume in a 384-well plate. 22.5 µL of the enzyme-buffer solution added to 
each well of strips 1-23 and the top eight wells of strip 24 of the plate and 22.5 mL of caspase-7 
activity buffer was added manually to the bottom eight wells of strip 24 with a multichannel 
pipette. Each plate was incubated for two hours at 37 °C. A 100 mM stock of Ac-DEVD-pNA 
substrate in DMSO was diluted in caspase-7 activity buffer so that the final concentration of 
substrate in the plate would be 20 µM. 5 µL of diluted substrate was added by liquid handler and 
the plate was immediately read kinetically for 10 minutes at 405 nm on the Spectra Max Plus 
plate reader. The slope of the change of absorbance in each compound well was compared to that 
of vehicle control wells, and a relative activation in terms of fold increase was determined.  
4.7.3. Procaspase-7 activators secondary screen  
 The secondary screen followed a similar protocol to the caspase-7 activity assay for the 
initial library screen. The 753 putative hit compounds were hand pipetted (~50 µM compound 
per well: 2.5 µL of HTSF ChemBridge compounds and 0.5 µL of Hergenrother ChemBridge and 
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Marvel library compounds) into 22.5 µL of caspase-7 activity buffer into three 384-well plates. 
20 µL of procaspase-7, diluted in caspase-7 activity buffer for a final concentration of 100 nM 
was added to each well by a multichannel pipette. The plates incubated for two hours at 37 °C, 
then 5 µL of Ac-DEVD-pNA, diluted in caspase-7 activity buffer to obtain a final concentration 
of 200 µM, was added by multichannel pipetter. Each plate was read kinetically at 405 nm for 
two hours. 
4.7.4. Zinc-free caspase-7 activity assay for testing of library hit compounds  
 The 66 hit compounds from the secondary screen were added at a final concentration of 
~50 µM to 22.5 µL of Chelex-treated Hepes-NaCl buffer in a 384-well plate. Frozen aliquots of 
zinc-free procaspase-7, prepared as described above, were diluted in Chelex-treated Hepes-NaCl 
buffer to obtain a final well concentration of 500 nM and 20 µL of this protein solution was 
added to each well. This assay was done twice, and three wells on the bottom of strip 7 were 
used for 50 µM PAC-1 control in one assay, and four wells on the bottom of strip 7 were used 
for the same purpose in another trial. After incubation at 37 °C for two hours, 5 µM Ac-DEVD-
pNA (diluted to a final concentration of 200 µM in Chelex Hepes-NaCl buffer) was added and 
the plate was read kinetically at 405 nm for two hours on the Spectra Max Plus 
spectrophotometer.  
4.7.5. UV-vis absorbance of confirmed hit compounds and zinc-free activity assay to test 
zinc inhibition and PAC-1 rescue of procaspase-7 activity 
 The 66 confirmed hit compounds were tested for a shift in their UV absorbance upon 
addition of zinc. In a 96-well plate, 1 µL of compound from HTSF compound plates was added 
to 99 µL water (final concentration of ~1 µM), as well as 1 µM PAC-1 and PAC-1a for controls. 
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All of the compounds were tested except for 186 G12; the HTSF compound plate was depleted 
of this compound. The compounds were tested in singlet. The plate was read on the Spectra Max 
Pro plate reader spectrophotometer scanning wavelengths from 190 to 500 nm. Next, 1 µL of 1 
mM stock of ZnSO4 was added to each well (10 µM final concentration) and the plate was read 
again on the spectrophotometer. Water blank absorbance was subtracted from each well, and a 
shift in UV absorbance was observed for most compounds, using Microsoft Excel plots of 
absorbance vs. wavelength. For a more detailed study of the shift of the UV-vis spectra of the 
three lead compounds, 102 C21, 206 M19, and 392 M4, a Varian Carey 4000 spectrophotometer 
(in the laboratory of Prof. Jeff Moore) was used. The compounds were diluted to 60 µM in zinc-
free Hepes/NaCl buffer in a quartz cuvette. The absorbance at 190 to 600 nm was recorded. 
Next, ZnOTf (5 µL of 3 mM solution) was iteratively added and absorbance spectra were 
recorded, up to a final concentration of 75 µM ZnOTf. The protocol to examine the role of zinc 
inhibition and PAC-1 rescue of procaspase-7 activity was performed as other zinc-free caspase 
activity assays were described in Chapter 2.  
4.7.6. Cytotoxicity assays 
Toxicity screen of 66 procaspase-7 activators. HL-60 cells were harvested and plated at 
10,000 cells/well into a 96 well plate. In triplicate, the 66 hit compounds were added from HTSF 
compound plates at a final concentration of 1 µM in triplicate. DMSO (live control) and 1 µM 
PAC-1 (for comparison) and 100 µM PAC-1 (death control) were also added. The compounds 
incubated with the cells for 72 h, after which the MTS assay was performed.  
For continuous cytotoxicity experiments with compounds to obtain IC50 values, SRB and MTS 
assays were performed as described in Chapter 2. For short exposure cytotoxicity experiments, 
the compounds were added by direct addition to the cells in a protocol described in Chapter 3.  
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4.7.7. Cell cycle arrest experiment 
A cell count of 106 to 2x106 U-937 or HL-60 cells were exposed to compounds in DMSO 
or ethanol for 6 to 8 h in triplicate. Following compound exposure, the cells were pelleted by 
centrifugation, washed with PBS, and fixed in ice-cold ethanol overnight at 4 ºC. Next, the fixed 
cells were incubated at 4 ºC with 100 µg/mL RNase A, followed by room temperature incubation 
with 50µg/mL propidium iodide. Cells were analyzed by flow cytometry, collecting at least 
10,000 events per sample on the LSR II cytometer, and the cell cycle stages were assigned using 
BD FACS Diva software.  
4.7.8. Pilot screens of procaspase-3 triple mutant and procaspase-7 triple mutant for the 
MLPCN screen 
The assay for the pilot screen of 10 former-Hergenrother ChemBridge library plates for 
procaspase-3 and procaspase-7 was conducted using the caspase activity assay with the same set 
up as the HTSF procaspase-7 screen (described above) with the following exceptions: First, the 
buffer used was a zinc-free Hepes/NaCl buffer with 0.01% Triton-X. Secondly, 5 µM enzyme 
was used as a positive control in the assay. Third, the compounds were added by pin transfer 
device, which deposited ~50 µM compound in the assay and incubated with the enzyme for 1 h. 
Hit cut-off was set at 3 times the standard deviation of basal procaspase activity. The absorbance 
of DEVDase activity was recorded kinetically over 10 minutes. 
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Chapter 5: The future for personalized procaspase activating 
compound therapies: Identifying human patient populations 
with elevated procaspase-3 levels 
 
All experiments, unless otherwise noted in the chapter, were performed in full by Diana West. 
Experimental methods from experiments performed by colleagues other than myself are not 
included in the Materials and Methods section.  
 
5.1. Introduction 
 A personalized anticancer drug is one that targets specific abnormalities in the tumor 
cells to induce cell death or halt cell growth and proliferation selectively with little to no effect 
on healthy non-cancerous cells. Tumor cells can be selectively targeted using different 
approaches: First, the tumors may have different general characteristics, such as a hypoxic 
metabolism that can be exploited therapeutically.230 Secondly, driver mutations in cancer cells 
lead to the expression of cancer-specific and targetable proteins, such as BRL-ABL in chronic 
myeloid leukemia, or HER-2/neu in breast cancer, among others.231 Another abnormality that 
exists in cancer cells is the elevation of levels of various targetable proteins, such as EGFR in 
non-small cell lung cancer.231 Procaspase-3 was chosen as a target for small molecule activation 
in the Hergenrother laboratory because of its predominant role in executing apoptotic cell death 
downstream of defective apoptotic machinery, as well as its elevated levels in cancer cells, 
compared to non-cancerous cells.146  
In its initial report, PAC-1 induced potent cell death in cells isolated from primary human 
resected colon and lung cancer tumors, and the potency of cytotoxicity correlated with levels of 
procaspase-3 that were measured in the cells.146 Likewise, this correlation was also observed in 
numerous cancer cell lines. Furthermore, cancerous cells (either cell lines or primary tissue), 
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were generally found to have higher procaspase-3 concentrations than non-cancerous cells.146 
These data support the growing body of evidence, discussed in Chapter 1, that procaspase-3 is 
elevated in many cancer types. Therefore, the use of small molecule procaspase activators is 
predicted to be selective for tumor cells of patients with elevated procaspase-3 levels.  
Since the discovery and identification of caspase-3 and its precursor procaspase-3 in the 
mid-1990s, a number of studies have been conducted identifying elevated levels of procaspase-3 
and caspase-3 in primary tissue from patients of certain lymphomas and leukemias, as well as 
cancers of the lung, colon, breast, prostate, pancreas, skin, stomach, central nervous system, 
liver, esophagus and tongue, and endometrium. In most of these studies, immunohistochemical 
analysis of procaspase-3 was performed to draw the conclusion that procaspase-3 levels were 
elevated; however, these antibodies recognize epitopes for both procaspase-3 and active caspase-
3. The same can be said of the assessment of procaspase-3 levels in the initial PAC-1 report;146 
procaspase-3 content was analyzed in colon and lung tissue by flow cytometry using an antibody 
that recognizes both the proenzyme and active caspase-3 forms. Some studies in other 
laboratories addressed the relative procaspase-3 and active caspase-3 levels in closer detail by 
using Western blot analysis of human patient samples or cell lines,120, 123, 131, 136, 138, 232 and found 
procaspase-3 to be the predominant caspase-3 species in the cancers studied. For example, in 
gastric cancers, active caspase-3 was not detected in cancerous tissue (but was observed in non-
cancerous tissue) by a Western blot in one study.232 In a different report, procaspase/caspase-3 
(non-specific) as well as active caspase-3 (specific) levels were analyzed in gastric cancer tissue 
by immunohistochemistry; Is inferred that the low level of active caspase-3 staining in the 
samples was due to a predominance of procaspase-3 compared to active caspase-3.135 A review 
of these experiments is included in Section 5.2 of this chapter. 
139 
 
 A study of procaspase-3 and active caspase-3 ratios in common cancers, as well as an 
immunohistochemical study probing procaspase-3 specifically would complement the many 
studies mentioned above. Described in this chapter are the efforts toward a detailed 
immunohistochemical study of procaspase-3 levels in resected and archived tumor tissue from 
human colon, lung, and breast cancer patients. Such a study will shed light on procaspase-3 
levels in these cancers; furthermore, an evaluation of the pathological features of the patient 
population will also be performed in order to determine if there is a correlation between 
procaspase-3 levels and patient or tumor characteristics. These studies will provide information 
that may lead to the identification of a patient population that would most benefit from the 
anticancer treatment of a procaspase activating compound.  
5.2. Literature review of procaspase-3 level assessment in cancerous tissue 
Lymphomas and leukemias. A number of studies examining the levels of procaspase-3 in 
various lymphomas have been conducted. An immunohistochemical study of procaspase-3 in 
two subtypes of Hodgkin’s disease (using an antibody that stains both proenzyme and active 
caspase-3) revealed that procaspase-3 was expressed in all cases studied of classical Hodgkin’s 
disease (HD), but procaspase-3 expression was not observed in those with the nodular 
lymphocyte predominant Hodgkin’s disease subtype (NLPHD).115 A separate 
immunohistochemical study, again using an antibody that recognizes both pro- and active 
caspase-3, confirmed detected procaspase-3 in HD patients and cell lines, but procaspase-3 was 
detected in only a few samples from NLPHD patients in cell lines.116 Procaspase-3 levels (as 
recognized by a non-specific procaspase-3 antibody) were detected in 84/85 malignant non-
Hodgkin’s lymphoma samples, and strong immunohistochemical staining was observed most 
often in high-grade lymphomas.117 Procaspase-3 levels and localization in B-cell diffuse large-
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cell lymphoma (DLCL) were studied by Pringle and co-workers by immunohistochemistry.118 In 
the 54 high-grade samples studied, lower procaspase-3 levels were found to associate with a poor 
prognosis. Furthermore, diffuse procaspase-3 staining in the cytosol correlated with a poor 
prognostic factor, while punctate procaspase-3 staining tracked with a favorable prognosis and 
complete response to CHOP chemotherapeutic treatment. Nakazato and co-workers also studied 
DLCL, examining active caspase-3 levels in DLCL of the central nervous system(CNS) and non-
CNS DLCL. Using an antibody that only recognizes active caspase-3, immunohistochemical 
analysis revealed that active caspase-3 levels were significantly higher in CNS DLCL compared 
to non-CNS DLCL.119 In a study of procaspase-3 levels by Western blot in acute myelogenous 
leukemia by Kornblau and co-workers, increased levels of procaspase-3 (compared to active 
caspase-3) associated with a lower survival rate while high levels of active caspase-3 associated 
with improved survival for the 185 patients studied.233  
Lung cancers. Pääkö and co-workers observed strong procaspase-3 immunoreactivity in 
49% of lung adenocarcinomas and 64% of squamous cell carcinomas in a study of non-small cell 
lung carcinomas (NSCLCs), using an antibody that recognizes both zymogen and active caspase-
3.121 In a study utilizing Western blot, real time RT-PCR, and DEVDase caspase activity, 
expression and immunodetection of procaspase-3 was found to be elevated in NSCLC cell lines 
from patient samples.120 Although the procaspase-3 antibodies used were not stated to be specific 
for only procaspase-3 staining, the Western blots in this study reveal that the vast majority of 
caspase-3 detected is in the zymogen form and that processing of the zymogen could be 
visualized upon treatment with granzyme B, indicating that the antibody recognizes both pro- 
and active forms of caspase-3.  
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Colorectal cancers. Kuppen and co-workers studied levels of caspase-3 activity in colon 
cancers.122 The DEVDase activity of 60 colon cryostat sections was compared with pathological 
factors and immunoreactivity of p53, b-catenin, and markers of tumor infiltrating cells. High 
caspase-3 activity (as determined as 1374 pmol AMC/min/mg tumor) correlated significantly 
with right-side colon tumors, tumor infiltrating cells, and increased risk of recurrence. While 
caspase-3 is known to have a 200-fold increase in catalytic activity compared to an uncleavable 
mutant of procaspase-3 in vitro,159 Ac-DEVD-AMC is a substrate for both pro- and active 
caspase-3. Furthermore, pro- and active caspase-7 activity can be detected by this same 
fluorimetric substrate. Therefore, the activity measured in this study cannot be solely attributed 
to caspase-3. A Western blot study of 20 colon cancer samples was conducted by Nicholson and 
co-workers.123 Procaspase-3 was found to be the predominant caspase-3 form and generally 
increased in the tumor samples, up to 6-fold procaspase-3 elevation in one patient. 
Breast cancers. Reed and co-workers studied the levels of apoptosis-related proteins in 
invasive breast cancer or carcinoma in situ patients and cell lines. Procaspase-3 
immunoreactivity was analyzed by immunohistochemistry using an antibody that recognizes 
both zymogen and active procaspase-3. Procaspase-3 levels were observed to be higher in the 
invasive cancers compared to normal tissue.132 In a separate immunohistochemical study, Soini 
and co-workers observed a significant correlation between strong procaspase-3 staining in 
carcinoma in situ samples and high grade, but no correlation was observed between procaspase-3 
staining and tumor grade in invasive carcinomas.133 Using RT-PCR, Western blotting, and 
caspase DEVDase activity, procaspase-3 levels were studied in breast cancer by Duffy and co-
workers.131 In this study, breast carcinomas, fibroadenomas, and normal breast samples 
displayed similar levels of caspase-3 mRNA, but pro- and active caspase-3 were both observed 
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at significantly higher levels in the cancerous tissue. There was also a noted significant 
correlation for pro- and active caspase-3 levels in ductal carcinomas (compared to lobular 
carcinomas).  
Prostate cancers. An immunohistochemical analysis of pro- and active caspase-3 levels 
(using an antibody that recognizes both caspase forms) of resected prostates displaying prostate 
carcinoma or benign prostatic hyperplasia was conducted by Watson and co-workers.130 Stronger 
procaspase-3 staining was observed in the benign prostatic hyperplasias and low/moderate grade 
prostatic carcinomas, while little to no procaspase-3 was detected in high grade prostastic 
carcinomas. It was also observed that procaspase-3 was detected in basal and secretory epithelial 
cells, and that lower amounts of these cells were observed in the high grade tumors. Since 
procaspase-3 levels are found to be generally higher in the prostate epithelial cells of healthy 
individuals compared to most organs,234 a decreased expression or loss of basal and secretory 
cells in high-grade patients may point to a mechanism to evade apoptosis in prostate cancer.  
Pancreatic cancers. In an immunohistochemical study of apoptosis-related proteins in 87 
pancreatic carcinomas, Soini and co-workers detected procaspase-3 expression in 80% of the 
cases, with strong staining in 26% of the positive cases.125 An apoptotic index of each sample 
was determined by TUNEL staining, and did not significantly correlate with procaspase-3 
expression. Is noted that an increase in expression of procaspase-3 might cause cells to be more 
susceptible to apoptosis, but not necessarily correlate with apoptosis occurring in the cell 
population. Since the procaspase-3 antibody used recognizes both pro- and active caspase-3, the 
fact that apoptotic index did not significantly correlate with procaspase-3 staining could suggest 
that the zymogen was the predominant species of caspase-3 stained in the samples. In a study of 
samples of pancreatic duct cell carcinomas and intraductal papillary-mucinous tumor of the 
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pancreas (IPMT), Shimosegawa and co-workers sought to determine if procaspase-3 expression 
levels were related to noninvasive and invasive IPMT cases.129 Using RT-PCR and 
immunohistochemistry (with an antibody that recognizes both pro- and active caspase-3), 
procaspase-3 was found to be overexpressed in both pancreatic duct cell carcinomas as well as 
IPMT patients. Cytoplasmic staining of procaspase-3 was related to invasive tumors of both 
pancreatic cancer types, and furthermore, was significantly correlated with tumor grade.     
Skin cancers. A Western blotting study was conducted by Jansen and co-workers 
examining established melanoma cell lines for procaspase-3 and procaspase-7. Increased 
procaspase-3 and -7 was detected compared to a normal melanocyte cell line. In a different study 
of squamous cell carcinoma of the head and neck, a caspase-3 single nucleotide polymorphism 
was identified to be related to a increased risk for that particular cancer.137 
Gastric cancers. In an immunohistochemical study of caspase-3 levels in 60 gastric 
cancers, Lee and co-workers observed that 57 samples were detected by an antibody that 
recognizes the large subunit of procaspase-3 and active caspase-3.235  In a different study, 
elevated procaspase-3 levels in gastric cancers were determined by immunohistochemistry using 
an antibody that recognizes pro- and active caspase-3, as well as an antibody that recognizes 
active caspase-3.135 Konturek and co-workers examined procaspase-3 and caspase-3 levels by 
Western blot and mRNA analysis.232 In this study, procaspase-3 was observed to be the 
predominant form in cancer tissue, while normal tissue contained mostly active caspase-3. While 
these studies support the elevated protein levels of procaspase-3 in gastric cancers, it should be 
noted that caspase-3 expression was also found to be down-regulated in an mRNA in situ 
hybridization study of gastric cancers conducted by Li and co-workers.236 
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Cancers of the central nervous system. In a study of 52 neuroblastoma samples, a 
Western blot was performed to observe the relative presence of the procaspase-3 enzyme in the 
samples.138 Elevated procaspase-3 levels were found to be correlated positively with a number of 
factors including lower stage of tumors, favorable prognostic outcome, and younger age. In an 
immunohistochemical study of active caspase-3 levels in glioma, Nakayama and co-workers 
found that patients of one glioma subtype had significantly greater survival with higher cleaved 
caspase-3 levels.139 
Other cancers. In an immunohistochemical study of endometrial carcinoma and normal 
endometrial tissue by Löhrs and co-workers, elevated procaspase-3 levels were observed in the 
carcinomas compared to the nonneoplastic tissue.134 Furthermore, patients with >50% 
procaspase-3 positive cells had a shorter survival rate. A study of active caspase-3 levels was 
conducted for hepatocellular carcinomas by Rashid and co-workers.124 In this 
immunohistochemical and Western blotting study, caspase-3 levels were found to be elevated in 
68% of hepatocellular carcinomas examined compared to normal liver parenchyma. In an 
immunohistochemical study of esophageal squamous cell carcinoma, Miaw and co-workers 
found that elevated procaspase-3 levels significantly correlated with a favorable patient 
prognosis.126 Furthermore, in a separate study of esophageal cancer, elevated procaspase-3 levels 
correlated with increased overall patient survival.127  
5.3. Primary resected colon and lung tissue 
 Resected human tissue samples provide opportunities to isolate cancer and non-cancerous 
cells for studies of protein levels. In this section, the acquisition of primary resected lung and 
colon tissue, and the preparation of the samples for a large Western blot surveying the ratio of 
procaspase-3 to active caspase-3 levels, will be discussed.  
145 
 
5.3.1. Patient consent and sample acquisition  
The Hergenrother laboratory has established a relationship with Carle Foundation 
hospital, and is fortunate to have three projects for the acquisition fresh tumor and non-cancerous 
resected tissue from surgical procedures, as well as samples of archived paraffin-embedded 
tissue. For the studies involving resected colon and lung tissues, patient consent was required 
prior to the surgery, and the patients’ identities were protected by the Health Insurance 
Portability and Accountability Act (HIPAA) regulations. The attending surgeon or pathologist 
set aside both cancerous and surrounding non-cancerous tissue sample for the research project, 
and I obtained the tissue within hours of the patients’ surgery. To date, 14 lung and 65 colon 
tumor samples have been collected.  
5.3.2. Sample preparation and fixation 
 Once the samples were obtained from Carle Foundation hospital, I immediately prepared 
the samples for digestion to single cells. Briefly, the tissue was examined: any attached adipose 
tissue was cut away with a sterile razor and discarded, and hard tan-grey masses were cut from 
the tissue as the tumor sample, and remaining soft epithelial or mucosal tissue was set aside as 
the non-cancerous sample. Next, the cancer and non-cancerous samples, in their respective cell 
culture dishes, were minced and treated with dispase and collagenase to digest the samples into 
single cells for up to ~6h. The tissue was filtered through sterile cheesecloth, and the isolated 
cells were pelleted by centrifugation and washed. In order to preserve the cells for Western blot 
analysis of procaspase-3 and caspase-3 levels, the cells were fixed in ice cold ethanol, and stored 
at –20 ºC.  
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5.3.3. Optimization for a Western blot and future directions 
 A single Western blot using an antibody that recognizes procaspase-3 and active caspase-
3 will be used to determine the ratio of procaspase-3 to active caspase-3 levels in the isolated 
cells from resected cancer and surrounding non-cancerous tissues from the various colon and 
lung cancer patients. Since this Western blot may use all, if not most, of the existing fixed cell 
samples, it is critical to optimize a Western blot protocol that will achieve a strong enough 
staining signal from the cell lysate for analysis. To this aim, the U-937 cell line was tested as a 
surrogate for the isolated cancer cells, and the cell lysate was stained for procaspase-3 and 
caspase-3.  
Briefly, 107 cells were counted and exposed to 50 or 100 µM etoposide for up to 12 h. 
Following treatment, the cells were harvested, washed with PBS, and lysed by sonication in PBS 
containing a protease inhibitor cocktail. Following clarification by centrifugation, the soluble 
protein was boiled in SDS loading dye containing BME, and 20 – 75 µg denatured protein 
sample was run by SDS-PAGE. Following transfer onto PVDF membrane, the blot was blocked, 
and stained sequentially with an antibody that recognizes both procaspase-3 and active caspase-
3, then secondary horse-radish peroxidase (HRP)-conjugated antibody. After addition of HRP 
substrate, the blot was imaged by autoradiography, and films were scanned with the original blot 
to visualize the protein standard ladder. It is expected that a band for procaspase-3 (~32kDa) 
would be observed in control samples, and that some procaspase-3 and processed active caspase-
3 (~17kDa, ~10kDa) bands would be observed in the etoposide-treated samples. From this 
experiment, a clear signal for procaspase-3 could be observed in both the control and 50 µM 
etoposide treatments; however, in the 100 µM etoposide treatment, there is barely any detectable 
signal for procaspase-3 and no signal was observed for active caspase-3 bands (Figure 5.1). This 
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loss of the procaspase-3 form and lack of detectable active caspase-3 bands has been observed by 
other colleagues and collaborators. One explanation is that the antibody may stain the epitope 
better when procaspase-3 is in its zymogen form compared to active form. Another explanation 
is that once procaspase-3 is activated to caspase-3, the active form acts rather quickly in the cell, 
and then is degraded.  Regardless, the optimization of Western blotting conditions with different 
procaspase-3 antibodies warrants further investigation.     
Figure 5.1. Western blots for procaspase-3 and active caspase-3 in U-937 cell 
lysate. A) Cells were treated over the course of 12 h with DMSO or 50 µM etoposide, 
20 µg were loaded/well, the Western was stained for an antibody that recognizes both 
pro- and active caspase-3.  B) U-937 cells were treated for 12 h with 100 µM etoposide 
and 75 µg lysate was loaded/well, the Western blot was performed with the same 
antibody as in A), faint active caspase-3 bands were observed in this experiment.  
 
5.4. Immunohistochemical study of paraffin-embedded sections from human colon, lung, 
and breast cancer patients. 
 Carle Foundation hospital archives patients’ resected tumor/non-cancerous tissue samples 
and biopsy samples that formalin-fixed, dehydrated, and embedded in paraffin, for at least a 
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decade for analysis in the case that a patient relapses after treatment or surgery. With a 
collaborative protocol, the repository of archived paraffin-embedded tissue is available for 
research purposes, and the blocks of tissue can be cut and mounted on glass slides for assessment 
by immunohistochemistry. Described in this section is the current progress on collecting patient 
samples for an immunohistochemical study of procaspase-3 levels in human colon, lung, and 
breast cancer patients. Briefly, de-identified pathological reports were examined and slides were 
cut of two archived paraffin-embedded tissue blocks, one resected tumor sample and one non-
cancerous tissue sample, for each patient. The slides were stained with hematoxylin and eosin 
and sent to collaborator Dr. Luke Borst (North Carolina State University College of Veterinary 
Medicine) for pathological confirmation of cancer and non-cancerous tissue. Next, sets of slides 
were cut from the confirmed tissue blocks and immunohistochemically stained for procaspase-3.   
5.4.1. Selection of patient samples 
The surgical and biopsy tissue for patients at Carle Foundation hospital is well 
documented in pathological reports. Through the collaboration with the hospital, I obtained de-
identified pathological reports for 44 colon cancer, 37 lung cancer, and 54 breast cancer patients 
who had undergone surgical tumor resections between the years 2006 and 2010. The 
pathological reports contain information pertaining to the patient, such as age and gender, as well 
as the cancer tissue itself, such as tumor stage and grade and cancer type. Furthermore, most of 
the pathological reports have a description of the tissue blocks that were archived in the hospital 
repository. Summarized in Table 5.1 are the different pathological characteristics of the various 
patients that were examined. The available archived tissue blocks were requested from Carle 
Foundation hospital, and 0.3 – 0.4 µm-thick tissue slides were prepared on poly-L-lysine charged 
slides by the Histology Department at Carle Foundation. 
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Table 5.1. Pathological data for cancer patients
Colon cancer Lung cancer Breast cancer
%
Patients 
n = 44
% 
Patients
n = 37
% 
Patients
n = 54
Patient Age Under 30 0 Under 30 0 Under 30 0
31 – 50 6.8 31 – 50 5.4 31 – 50 11.1
51 – 70 47.7 51 – 70 51.4 51 – 70 63
71 – 90 45.5 71 – 90 43.2 71 – 90 25.9
Gender Male 52.3 Male 54.1 Male 0
Female 47.8 Female 46.9 Female 100
Stage TX 2.3 TX 8.1 TX 0
TI 15.9 TI 35.1 TI 63
TII 4.6 TII 37.8 TII 35.2
TIII 70.5 TIII 8.1 TIII 1.9
TIV 4.6 TIV 10.8 TIV 0
Grade I 15.9 I 48.7 I 50
II 36.4 II 5.4 II 38.9
III 38.6 III 29.7 III 11.1
IV 9.1 IV 16.2 IV 0
Tumor area Cecum 22.7 Upper lung 43.2 Upper-inner 
breast
18.5
Ascending 
colon
18.2 Lower lung 40.5 Upper-outer 
breast
44.4
Transverse 
colon
6.8 Hilius 2.7 Lower-Inner 
breast
1,9
Descending
colon
2.3 NOS 5.4 Lower-Outer 
breast
7.4
Sigmoid 
colon
20.5 Overlapping 
lesion
2.7 Overlapping
lesion
9.3
Rectum 4.6 Middle lung 5.4 NOS 14.8
NOS 4.6 Central portion 5.6
Rectosigmoid 11.4
Hepatic 
Fixture
9.1
150 
 
5.4.2. Confirmation of cancerous and non-cancerous tissue. 
 Hematoxylin and eosin (H&E) double staining of the tissue slides is a common way that 
pathologists diagnose cancers and other diseases clinically.237 Hematoxylin mainly stains nuclei 
and eosin stains the cytoplasm, allowing for pathologists to examine general tissue structure, 
cellular morphology such as cell border integrity, and nuclear features such as nuclear diameter 
and nuclear crowding. With this information, the presence of cancerous cells can be identified as 
well as the cancer type, stage, and grade. I manually stained the tissue slides with hematoxylin 
and eosin at the Histology Laboratory at the UIUC College of Veterinary Medicine along with 
undergraduate colleague Arabella Lazar. Briefly, the slides were deparaffinized and cleared with 
xylene and rehydrated with ethanol. Next the slides were stained with hematoxylin and washed 
with water, and then subsequently stained with eosin. After washes with ethanol and xylene, a 
coverslip was added to the slide with mounting medium, to preserve the permanently stained 
slides. After drying for 24 h, the slides could be visualized and imaged using a light microscope 
or automated slide imager (Figure 5.2A-D).  
 In order to confirm the presence of cancerous and non-cancerous tissues in the samples 
that I selected from the pathological reports, collaborator Dr. Luke Borst, a veterinary clinical 
pathologist, microscopically examined the slides. To date, 92 H&E slides (from 46 patients) have 
been examined by Dr. Borst. On the slides, if both cancerous tissue and non-cancerous tissue 
were observed on the same slide, the cancerous tissue was outlined with a permanent marker 
(Figure 5.2E); this is for me to distinguish cancerous areas when surveying levels of procaspase-
3 in the future immunohistochemical analysis of the slides. Of the slides examined, 12 (from 6 
patients) were found to have a discrepancy compared to the pathological reports (either both 
patient slides were cancerous, or no cancerous tissue was observed on either slide), and these 
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samples were removed from the study. The confirmation of cancerous and non-cancerous tissue 
from the various patients allows for the continuation of the study for the immunohistochemical 
staining of procaspase-3.  
Figure 5.2. H&E staining of tissue slides. A-B) Cancerous tissue from a male colon 
cancer patient, section of the tumor from the ascending colon, visualized at 4x (A) and 
10x (B) magnification. C-D) Non-cancerous colon tissue from the same patient, 
uninvolved mucosa imaged at 4x (C) and 20x (D). E) Sample H&E slide where 
cancerous material was encircled with a permanent marker by Dr. Luke Borst.  
 
5.4.3. Optimization of an immunohistochemical staining protocol for procaspase-3 in 
paraffin-embedded sections. 
 The efforts to survey the levels of procaspase-3 in paraffin-embedded sections of human 
patients with colon, lung, and breast cancer will focus on differences between procaspase-3 
levels in cancerous and non-cancerous tissue in the same patient, as well as overall procaspase-3 
levels in the cancers, specifically as they relate to pathological features such as cancer stage and 
grade. Since many procaspase-3 antibodies recognize epitopes on both procaspase-3 and active 
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caspase-3, a selective procaspase-3 rabbit monoclonal antibody was chosen from Abcam 
(Cambridge, MA) for the immunohistochemical studies. To confirm the specificity of the 
antibody, a Western blot was performed on recombinant procaspase-3 autoproteolysis-resistant 
triple mutant (D9A/D28A/D175A) and recombinant active caspase-3. The antibody is predicted 
to recognize only the procaspase-3 triple mutant, and not caspase-3. Indeed, while the same 
amount of 20 µg of procaspase-3 triple mutant and active caspase-3 were loaded onto the SDS-
PAGE gel and transferred to the PVDF membrane (Figure 5.3A), the signal from the Western 
blot was strongest for the ~32kDa band for procaspase-3 (Figure 5.3B). There was also a very 
faint single for a lower molecular weight band ~10kDa in both procaspase-3 triple mutant and 
caspase-3 lanes. Possible explanations for this faint band could be non-specific binding of some 
sort of caspase cleavage product (not likely since procaspase-3 triple mutant does not process 
itself), or general non-specific binding. Therefore, the Abcam procaspase-3-specific antibody 
was selected for the immunohistochemical study.  
Figure 5.3. Confirmation of procaspase-3-specific antibody. A) SDS-PAGE gel 
analysis of recombinantly expressed procaspase-3 triple mutant D9A/D28A/D175A 
“D3A” and active caspase-3, stained with Coomassie. B) The corresponding Western 
blot for procaspase-3 using the Abcam procaspase-3 antibody of the same protein stock 
(SDS PAGE gels were run at the same time) shows a strong band in the lane containing 
procaspase-3, and a faint non-specific band in both lanes.  
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 Human tonsil tissue is known to express relatively high levels of procaspase-3. The tissue 
is also readily available at Carle Foundation hospital for preparing slides for 
immunohistochemical staining. Therefore, 0.3 – 0.4 µm-thick tonsil tissue slides were prepared 
by Carle Foundation for the optimization of an immunhistochemical protocol for procaspase-3. I 
worked with the Histology Laboratory to establish a procaspase-3 staining procedure in which 
the slides were first deparaffinized and hydrated in xylene and ethanol, respectively. Next, the 
slides were incubated in 0.01 M citrate in a steamer for 1 h for antigen retrieval, and endogenous 
peroxidases were blocked with a hydrogen peroxide solution for 20 min. Following a protein 
block step, the tissue was stained with primary procaspase-3 antibody, then with polymer-HRP 
secondary antibody. The areas of procaspase-3 staining were visualized upon addition of HRP 
substrate, chromogenic diaminobenzidine (DAB). Individual cells could be identified by their 
nuclei using a hematoxylin counterstain, and the glass coverslips were mounted on the slides 
following ethanol and xylene wash steps. Shown in Figure 5.4A are various dilutions of primary 
procaspase-3 antibody that were tested on the tonsil tissue. It was determined that a dilution of 
1/250 to 1/350 would be a suitable primary antibody dilution.  
5.4.4. Procaspase-3 staining of patient samples 
 With an optimized immunohistochemical procedure at hand, I requested slides to be 
prepared from archived paraffin-embedded tissues from patients with colon, lung, and breast 
cancer for the study, as well as some trial slides. There were four slides requested per patient: a 
slide for procaspase-3 staining of cancerous tissue and positive control tonsil tissue, a slide for 
procaspase-3 staining of non-cancerous tissue and positive control tonsil tissue, a slide for 
negative control rabbit IgG of cancerous tissue, and a slide for negative control rabbit IgG of 
non-cancerous tissue (Figure 5.4B). Unfortunately, a number of tissue blocks were either 
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completely exhausted or not available for request and the total number of full sets of patient 
slides prepared decreased to 22 colon, 5 lung, and 16 breast cancer patients. 
I stained the trial slides with either procaspase-3 or rabbit IgG to assure the optimized 
protocol was effective with actual cancer samples. The study slides were then taken to the 
Veterinary Medicine Diagnostic Laboratory (UIUC) where they were stained on an automated 
slide stainer using the protocol that was developed by I. The primary antibody concentration 
used for the automated staining was a 1/250 dilution because some of the trial samples stained 
slightly lighter with the automated staining compared to manual staining. Complete sets of H&E-
stained slides and procaspase-3 positive and negative slides for each patient were compiled for a 
qualitative assessment of procaspase-3 levels by Dr. Luke Borst.  
Figure 5.4. Immunohistochemistry of procaspase-3. A) Optimization of procaspase-
3 staining on control human tonsil tissue, compared to isotype control Rabbit IgG 
staining. B) Scheme of the four slides for immunohistochemistry requested for each 
patient.  
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5.5. Future directions for procaspase-3 assessment in primary resected and paraffin-
embedded tissue 
5.5.1. Qualitative and quantitative evaluation of procaspase-3 levels 
A Western blot is planned for procaspase-3/caspase-3 ratio in resected colon and lung 
tissue. First, continued experiments are necessary to optimize Western blotting conditions for the 
primary tissue. After the Western blot is run for all of the samples simultaneously, densitometry 
can be used to quantitate procaspase-3 and caspase-3 levels the patients.   
The immunohistochemical assessment of procaspase-3 levels can be carried out 
qualitatively and quantitatively. The qualitative assessment is done by a microscopic 
examination of the tissue slides stained with procaspase-3 by a pathologist. Dr. Luke Borst will 
analyze the slides and rank them according to subjective criteria of weak, moderate, or strong 
procaspase-3 staining. This qualitative technique is used often for assessment of protein staining 
by immunohistochemistry.238 I will conduct a quantitative assessment of procaspase-3 levels 
using densitometry.239 A defined area of tissue of most saturated procaspase-3 staining will be 
identified and red-green-blue densitometry and will be used to quantify the brown-colored 
staining for each sample. A percentage of staining compared to positive and negative controls 
(assessing defined areas of most saturated brown staining) will be calculated, and these values 
can be analyzed among cancerous and non-cancerous tissue among all the patient samples.   
5.5.2. Pathological correlation to procaspase-3 levels 
If there is a trend for elevated (or decreased) procaspase-3 in colon, lung, and/or breast 
cancers, then correlations between procaspase-3 levels as pathological indicators such as age, 
gender, tumor stage and grade, will be investigated. The acquisition of more patient samples per 
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cancer type is currently underway; about 30 patients’ samples per cancer is desired, in order to 
have a varied distribution of pathological features, as well as for increased statistical power in the 
study. The average procaspase-3 levels among the cancer types can be compared to the 
pathological features using statistical software (SAS statistical analysis software, SAS Institute, 
Cary, NC) to perform tests such as the Wilcoxon rank-sum test (for two independent groups of 
data) that have been used in other studies of protein levels, including caspase-3,138 with similar 
sized cancer patient groups.240, 241   
5.6. Conclusions 
The efforts toward a procaspase-3-specific immunohistochemical study in colon, lung, 
and breast cancer, as well as a study of procaspase-3/caspase-3 relative levels in colon and lung 
cancers, may support the prevailing thought that procaspase-3 levels are upregulated in cancer. 
To the best of I’s knowledge, this study will be the first examination of procaspase-3 specifically 
in primary tissues, and one of just a few studies that addresses the procaspase-3/caspase-3 ratio 
in samples as well. The paradoxical elevation of procaspase-3 levels in cancers has been 
observed in several cancer types, and has been linked to various pathological and prognostic 
factors. While most of these studies are immunohistochemical evaluations using a non-specific 
procaspase-3/active caspase-3 antibody, a few Western blot and immunohistochemical studies 
lend evidence that the proenzyme form, indeed, is elevated in cancers.138,120,123,232,131,136  
Konturek  and co-workers observed elevated levels of survivin in addition to procaspase-3 in 
gastric cancers, and they speculate that the increase in levels of this endogenous caspase inhibitor 
in cancer may be one reason why the caspase-3 species is exclusively procaspase-3 in gastric 
cancer compared to non-cancerous tissue.232 However, the increase in survivin protein levels in 
cancer, does not adequately explain how an increase in mRNA caspase-3 expression levels has 
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been observed in pancreatic duct cell tumors129 where the overexpression of caspase-3 correlated 
with increased tumor invasiveness. Therefore, and the driving force for this apparent 
upregulation of procaspase-3 remains unknown.  
The Hergenrother laboratory has developed a series of procaspase activating compounds 
including PAC-1,146, 148, 161, 199 S-PAC-1,148, 149 other PAC-1 derivatives (see Chapter 3 and 
reference 148), and novel activators of procaspase-3/-7 (see Chapter 4). Furthermore, a 
procaspase-3/-6 activating compound, 1541, was developed by others.147 Together, this 
collection of procaspase activating compounds is a promising arsenal for potentially selective 
therapies in patients with high procaspase levels in their cancers. The assessment of pathological 
features will determine if procaspase-3 levels serve as a useful prognostic marker in cancer, as 
well as identify a patient population that could most benefit from a personalized anticancer 
treatment with procaspase activating compounds.  
5.7. Materials and Methods 
5.7.1. Reagents, buffers, and cell lines 
All reagents, unless otherwise noted, were purchased from Sigma-Aldrich. Compounds 
purchased from other suppliers include: dispase I and collagenase IV (Worthington), procaspase-
3/caspase-3 rabbit polyclonal antibody (sc-7148, Santa Cruz Biotechnologies), procaspase-3-
specific rabbit monoclonal antibody [E85-103] (Abcam), Chrompure Rabbit IgG - whole 
molecule (Jackson Immunoresearch Labs), polymer-HRP and Power Block were supplied in the 
Biogenex Human HRP polymer kit (Biocare), diaminobenzine (DAB, Chromogen). All materials 
for manual H&E staining or manual/automated immunohistochemistry not mentioned above 
were supplied by the Histology Laboratory or the Veterinary Medicine Diagnostic Laboratory at 
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the UIUC College of Veterinary Medicine. Human lymphoma cell line U-937 was obtained and 
cultured as described in Chapters 2 – 4.   
5.7.2. Acquisition and processing of primary resected colon and lung tissue 
 HIPAA-protected cancer patients consented to the use of their colon or lung tissue for 
research purposes prior to their surgical procedure at Carle Foundation. The attending 
surgeon(s), resected both cancerous tissue and attached or adjacent non-cancerous tissue. The 
tissue was stored at 4 ºC in a saline solution and I obtained the de-identified tissue sample within 
hours of the surgery. The tissue was removed from the saline solution and firm grey-tan 
cancerous matter was separated from soft epithelial/mucosal non-cancerous matter with a 
sterilized razor into two separate cell dishes. Discarded portions of tissue include any tissue that I 
was not certain of cancer/non-cancerous classification and yellow adipose tissue. The separated 
cancerous and non-cancerous tissue was minced coarsely and incubated for 60 min to up to ~6 h 
in a sterilized solution of ~8 mg of dispase I and collagenase IV dissolved in 10 mL/tissue dish 
RPMI 1640 media (10% FBS) at 37 ºC. After this digestion step, the cellular material was 
filtered through sterilized cheesecloth and washed with media. The cells were fixed by vortexing 
the cell pellet while adding ice-cold ethanol drop-wise. The cells were stored at –20 ºC and 
collected for all patients for a future Western blot analysis.  
5.7.3. Western blots for procaspase-3 and caspase-3 
   Human lymphoma U-937 cells were counted and 107 cells/well in 10 mL RPMI media 
were added to 6-well cell culture dishes. At various timepoints, the cells were treated with 1% 
DMSO, and 50 µM and 100 µM etoposide by direct addition. After exposure times, the cells 
were harvested and washed in PBS, and resuspended in PBS treated with protease inhibitor 
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cocktail IV. Next, cells were lysed by sonication, and the lysates were clarified by centrifugation 
13,000 x g for 15 min. The soluble protein was quantified by the Edelhoch technique (see 
Chapter 2), and further diluted in to equal amounts in PBS. The proteins were denatured in 2X 
SDS loading dye (with BME) and boiled for 5 min. For the Western blot shown in Figure 5.3, 20 
µg of protein was loaded into each well, and for the gel shown in Figure 5.3, 75 µg of protein 
was loaded into the 4-20% gradient polyacrylimide gel for SDS-PAGE. The recombinant 
expression of procaspase-3 triple mutant (D9A/D28A/D175A) and caspase-3 is described in 
Chapter 3. Frozen aliquots of these proteins were thawed and denatured in SDS-loading dye 
(with BME). The protein was loaded (20 µg) onto the 4-20% gradient SDS-PAGE gel.  
 The protein from the SDS-PAGE gels were transferred onto PVDF membrane at 60V for 
1 to 2 h in cold Towbin transfer buffer. The membranes were blocked overnight with 1-5% 
powdered milk in TBST at 4 ºC. Next, the membranes were incubated with primary antibody 
(1\100 – 1\500 dilutions) for 1 h at 4 ºC. After three wash steps in TBST, secondary antibody 
anti-rabbit HRP (1\10,000 to 1\20,000 dilution) was added to the membranes in TBST for 1 h at 
4 ºC. After three more wash steps in TBST, SuperSignal West Pico chemiluminescent HRP 
substrate (Pierce) was added to the membrane, and the blot was imaged by autoradiography. The 
autoradiographs were scanned into a digital image with the blot behind them in order to visualize 
the protein standard ladder.    
5.7.4. Paraffin-embedded section selection for pathological reports 
 The patients for the paraffin-embedded section study were protected by HIPAA, however 
patient consent was not required for use of the archived tissue. I obtained de-identified 
pathological reports for colon, lung, and breast cancer patients who had surgical resections 
between the years 2006 and 2010 for selection of cancerous and non-cancerous tissue blocks. A 
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Microsoft Excel spreadsheet was created with pathological information for each patient in the 
study, including age, gender, race/ethnicity, tumor description, area of tumor, tumor stage and 
grade, and requested cancerous and non-cancerous tissue blocks. The pathological reports often 
described the cancerous tissue as an “area of induration” or “area of tumor,” while non-
cancerous tissue was described as “uninvolved margins.” The tissue blocks were requested from 
Carle Foundation, and staff at the Histology Department obtained the tissue blocks, de-identified 
the patients, and prepared 0.3 to 0.4 µm-thick tissue sections mounted on positively charged 
slides for H&E or immunohistochemical staining.   
5.7.5. H&E staining of paraffin-embedded tissue 
 I manually stained of the paraffin-embedded tissue along with Arabella Lazar at the 
Histology Laboratory at the UIUC College of Veterinary Medicine. The tissue slides were 
deparaffinized in xylene and hydrated in ethanol washes (2 to 5 min). Next, the sections were 
stained for 2 min in Harris hematoxylin, followed by a 2 minute wash in acidic/alcohol solution, 
neutralized in a 1% ammonia solution, and washed gently in tap water.   The slides were then 
stained with eosin, washed and dehydrated in graded ethanol, and cleared in xylene (all 1 to 2 
min). Glass coverslips were mounted on the slides using Permount, and the slides were dried 
horizontally for 24 h. Some of the slides were imaged using a light microscope fitted with a 
camera available at Veterinary Medicine, however, most slides shown in this Chapter were 
imaged with the Nanozoomer (Hamamatsu) automated slide imager available at the Institute for 
Genomic Biology, UIUC. To confirm that the tissues selected from the pathological reports were 
indeed cancerous or non-cancerous, the slides were sent to Dr. Luke Borst for pathological 
examination. Any cancerous tissue that was identified on the slides was outlined with a black 
permanent marker.  
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5.7.6. Immunohistochemistry on trial and patient slides 
 To optimize a protocol for immunohistochemistry using a procaspase-3 specific antibody 
(Abcam), human tonsil tissue slides were prepared by Carle Foundation for manual 
immunohistochemistry performed by I. The same protocol (other than varying primary antibody 
dilutions) was used for actual patient slides containing a sample of non-cancerous tissue with 
tonsil positive control tissue or cancerous tissue with tonsil positive control. Furthermore, the 
same protocol was used, other than the use of identical rabbit IgG concentrations in place of 
procaspase-3 primary antibody, for human tonsil trial slides as with patient negative control 
cancerous and non-cancerous tissue slides. 
 Briefly, the slides were deparaffinized and hydrated in xylene and ethanol, respectively 
with 2 to 5 min wash steps. Next, antigen retrieval was performed using a steamer, incubating 
the slides in a Copeland jar with 0.01 M citrate buffer (pH 6) for 1 h. Blocking steps include a 20 
minute endogenous peroxidase block in 3% hydrogen peroxide, followed by a 30 minute protein 
block with Power Block (Biocare) in a humidified slide chamber. The slides were washed three 
times in TBST, and incubated in a humidified slide chamber with either procaspase-3 primary 
antibody or rabbit IgG for 30 min. The slides were washed with TBST and then incubated with 
secondary antibody polymer HRP (Biogenex) for 20 min. The HRP substrate DAB (Chromagen) 
was added to the slides for 5 min. After development of the dye, the slides were counterstained 
with hematoxylin (as in above H&E procedure), washed in ethanol and xylene, and coverslipped.  
 The automated immunohistochemical staining of the slides was carried out by the 
Veterinary Medicine Diagnostic Laboratory, UIUC, using the same antibodies and rabbit IgG 
supplied by I. The laboratory also used the Biocare kit for the study. The protocol closely 
followed the manual protocol described above with the following exceptions: no Power Block 
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step was performed on the slides, and the primary antibody concentration used was a 1\250 
dilution.  
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Appendix 
Appendix A.1. Summarized details from patient pathological reports for an 
immunohistochemical study for procaspase-3 
 
 
 
Study # Area Description of Block Requested From Pathological Report Primary Site Grade Stage Block Age Gender 
061008 Lung Tan-gray lymph node Lung, lower lobe T2 IIIA Cancer C1 80 Male
061008 Lung Lobe of lung with black anthracotic pigmentation Lung, lower lobe T2 IIIA Cancer D3 80 Male
061018 Lung Tan-gray to red-brown spngy fragment of lung Lung, lower lobe T1 IA Cancer B2 60 Female
061018 Lung Bronchial margin Lung, lower lobe T1 IA Normal B1 60 Female
061020 Lung Tan-gray mass and adjacent lung parenchyma several with pleural surface Lung, upper lobe T1 IA Cancer A4 47 Female
061020 Lung Uninvolved lung parenchyma Lung, upper lobe T1 IA Normal A7 47 Female
061025 Lung White underlying tumor Lung, upper lobe T2 IB Cancer B2 73 Female
061025 Lung Bronchial and vascular margins Lung, upper lobe T2 IB Normal B1 73 Female
061043 Lung Light tan tumor Lung, lower lobe T1 IA Cancer D1 73 Female
061043 Lung Uninvolved lung parenchyma Lung, lower lobe T1 IA Normal D5 73 Female
061045 Lung Lobe of purple to black lung Lung, lower lobe T2 IB Cancer E2 64 Female
061045 Lung Uninvolved portion of lung parenchyma Lung, lower lobe T2 IB Normal E9 64 Female
061062 Lung Light tan lung with black anthracotic pigmentaion Lung, upper lobe T1 IA Cancer A1 82 Female
061062 Lung Left upper lobe margins Lung, upper lobe T1 IA Normal F1 82 Female
061076 Lung Pleural surface is tan-gray to purple with area of puckering on pleural surface over a palpable tumor Lung, upper lobe T3 IIIA Cancer C2 67 Female
061076 Lung Bronchical margin Lung, upper lobe T3 IIIA Normal C1 67 Female
061090 Lung White stellate tumor Lung, upper lobe T2 IB Cancer A2 76 Male
061090 Lung Uninvolved lung parenchyma Lung, upper lobe T2 IB Normal A5 76 Male
061099 Lung Areas of tumor are pale and possibly necrotic Lung, hilus of T3 IIB Cancer C3 64 Male
061099 Lung Uninvolved lung parenchyma Lung, hilus of T3 IIB Normal C7 64 Male
0610111 Lung Tan-gray to black, rubbery lymph node Lung, upper lobe T1 IA Cancer B1 73 Male
0610111 Lung Margin Lung, upper lobe T1 IA Normal A1 73 Male
0610116 Lung Light tan mass beneath pleural surface Lung, upper lobe T2 IB Cancer C3 70 Male
0610116 Lung Bronchial margin Lung, upper lobe T2 IB Normal C1 70 Male
0610225 Lung Paratracheal lymph node, small fragments of red soft tissue Lung, upper lobe T2 IIIA Cancer A1 82 Female
0610225 Lung Irregular fragments of red soft tissue Lung, upper lobe T2 IIIA Normal B1 82 Female
0610230 Lung Fragments if tan-pink, irregularly shaped soft tissue Lung, NOS T4 IV Cancer A1 66 Female
0610230 Lung Fragments if tan-pink, irregularly shaped soft tissue Lung, NOS T4 IV Normal A1 66 Female
0610229 Lung Pink-tan, focally red-brown irregular fragments of soft tissue Lung, lower lobe T4 IIIB Cancer A1 55 Male
0610229 Lung Pink-tan, focally red-brown irregular fragments of soft tissue Lung, lower lobe T4 IIIB Normal A1 55 Male
0610228 Lung Tan-white, ill-defined nodule Lung, upper lobe T1 IV Cancer B1 67 Male
0610228 Lung Suture margin transversely sectioned Lung, upper lobe T1 IV Normal B5 67 Male
0610227 Lung Tan-brown puckered area on the pleural surface Lung, upper lobe T2 IB Cancer A2 55 Female
0610227 Lung Remainder of specimen Lung, upper lobe T2 IB Normal A9 55 Female
0610226 Lung Tan-brown, firm and bulging mass Lung, lower lobe T1 IA Cancer C2 64 Female
0610226 Lung Grossly uninvolved lung parenchyma Lung, lower lobe T1 IA Normal C9 64 Female
0610214 Lung Tan-gray to black rubbery , well circumscribed mass Lung, lower lobe T2 IB Cancer A3 71 Male
0610214 Lung Lung parenchyma Lung, lower lobe T2 IB Normal B1 71 Male
0610218 Lung Gray soft tumor Lung, lower lobe T1 IA Cancer C2 66 Male
0610218 Lung Section of uninvolved lung parenchyma and small section of calcified nodule Lung, lower lobe T1 IA Normal C8 66 Male
0610219 Lung Minute fragments of soft white tissue Lung, lower lobe T1 I Cancer A1 72 Female
0610219 Lung Minute fragments of soft white tissue Lung, lower lobe T1 I Normal A1 72 Female
0610216 Lung Red to light tan friable soft tissue fragments Lung, lower lobe TX IIIB Cancer A1 64 Male
0610216 Lung Red to light tan friable soft tissue fragments Lung, lower lobe TX IIIB Normal A1 64 Male
0610217 Lung Tan-gray ragged tissue cores Lung, upper lobe T2 IIIA Cancer A1 68 Male
0610217 Lung Tan-gray ragged tissue cores Lung, upper lobe T2 IIIA Normal A1 68 Male
0610215 Lung Tan-gray to red ragged tissue cores Lung, overlapping lesion T3 IV Cancer A1 81 Male
0610215 Lung Tan-gray to red ragged tissue cores Lung, overlapping lesion T3 IV Normal A1 81 Male
0610220 Lung Tan-brown, irregularly-shaped fragments of soft tissue Lung, right middle lobe TX I Cancer A1 66 Male
0610220 Lung Tan-brown, irregularly-shaped fragments of soft tissue Lung, right middle lobe TX I Normal A1 66 Male
0610221 Lung Minute fragments of tan-pink soft tissue Lung, middle lobe T2 IV Cancer A1 70 Female
0610221 Lung Minute fragments of tan-pink soft tissue Lung, middle lobe T2 IV Normal A1 70 Female
0610222 Lung Tan-pink to tan-brown, shpaed fragments of soft tissue Lung, upper lobe T1 IA Cancer FSA1 74 Male
0610222 Lung Tan-pink to tan-brown, shpaed fragments of soft tissue Lung, upper lobe T1 IA Normal FSC1 74 Male
0610223 Lung Not described Lung, upper lobe T1 IIIB No info 41 Male
0610223 Lung Not described Lung, upper lobe T1 IIIB No info 41 Male
0610224 Lung Not described Lung, lower lobe T2 IV No info 75 Male
0610224 Lung Not described Lung, lower lobe T2 IV No info 75 Male
0610231 Lung Not described Lung, upper lobe T4 IV No info 61 Female
0610231 Lung Not described Lung, upper lobe T4 IV No info 61 Female
0610233 Lung Pale tan minute particulate fragments Lung, NOS T2 IIIA Cancer A1 70 Female
0610233 Lung Pale tan minute particulate fragments Lung, NOS T2 IIIA Normal A1 70 Female
0610234 Lung Not described Lung, lower lobe TX IIIA No info 72 Male
0610234 Lung Not described Lung, lower lobe TX IIIA No info 72 Male
0610235 Lung Pink-tan , focally red-brown irregular fragments of soft tissue Lung, lower lobe T4 IIIB Cancer A1 55 Male
0610235 Lung Pink-tan , focally red-brown irregular fragments of soft tissue Lung, lower lobe T4 IIIB Normal A1 55 Male
0610129 Lung Gray-white tumor Lung, lower lobe T1 II Cancer B1 75 Female
0610129 Lung Frozen section staple margin Lung, lower lobe T1 II Normal B2 75 Female
0610128 Lung Adenocarcinoma, moderately differentiated, with areas of bronchiovascular growth pattern Lung, upper lobe T2 I Cancer B2 67 Male
0610128 Lung Uninvolved lung parenchyma between tumor site and bronchial margin Lung, upper lobe T2 I Normal B7 67 Male
0610232 Lung Pink-tan to red-tan irregular fragments of soft tissue Lung, upper lobe T2 IIIA Cancer B1 87 Male
0610232 Lung Pink to yellow-tan irregular fragments of soft tissue Lung, upper lobe T2 IIIA Normal C1 87 Male
0610250 Lung Firm, rubbery nodule on the fringe Lung, lower lobe T1 IA Cancer A2 83 Female
0610250 Lung Frozen section of pink lung tissue Lung, lower lobe T1 IA Normal A1 83 Female
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061007 Colon tan-gray ulcerated lesion showing thickened bowel wall Rectum, NOS T3 IIA Cancer A3 78 Male
061007 Colon Proximal margin long segment Rectum, NOS T3 IIA Normal A1 78 Male
061009 Colon Entire polupoid lesion and attached bowel wall Sigmoid, NOS T1 IIIA Cancer A2 78 Female
061009 Colon Distal and proximal margins of resection Sigmoid, NOS T1 IIIA Normal A1 78 Female
061010 Colon Sections of tumor, adjacent mucosa, and full thickness bowel wall Colon, ascending T3 IIIC Cancer A2 76 Male
061010 Colon Uninvolved right colon mucosa Colon, ascending T3 IIIC Normal A7 76 Male
061011 Colon Center of tumor Rectosigmoid, NOS T3 IIIB Cancer A3 59 Male
061011 Colon Distal and proximal margins of resection Rectosigmoid, NOS T3 IIIB Normal A1 59 Male
061013 Colon Entire fungating polyp from cecum Cecum T1 IIIA Cancer A2 77 Female
061013 Colon Distal and proximal margins of resection Cecum T1 IIIA Normal A1 77 Female
061017 Colon Tan-brown fungating mass with heaping borders Colon, ascending T3 IIA Cancer A2 69 Female
061017 Colon Margins Colon, ascending T3 IIA Normal A1 69 Female
061023 Colon Tan-gray ulcerated lesions with heaping borders Rectosigmoid junction T3 IIIB Cancer A2 80 Female
061023 Colon Margins Rectosigmoid junction T3 IIIB Normal A1 80 Female
061034 Colon Tan-brown ulcerated lesion with heaping borders Cecum T1 I Cancer A2 86 Male
061034 Colon Margins Cecum T1 I Normal A1 86 Male
061038 Colon Ulcerated tumor with rolled edges Colon, descending T3 IIIB Cancer A2 56 Female
061038 Colon Distal and proximal margins of resection Colon, descending T3 IIIB Normal A1 56 Female
061042 Colon Fungating brown mass Cecum T3 IIIB Cancer A8 58 Female 
061042 Colon Margins Cecum T3 IIIB Normal A1 58 Female 
061046 Colon Wide, circumferential tumor Rectosigmoid junction T3 IIA Cancer A3 58 Male
061046 Colon Uninvolved bowel wall Rectosigmoid junction T3 IIA Normal A7 58 Male
061047 Colon Wide, circumferential tumor Colon, ascending T3 IIA Cancer A2 70 Female
061047 Colon Distal and proximal margins of resection Colon, ascending T3 IIA Normal A1 70 Female
061056 Colon Tan-grey ragged ulcerated lesion Colon, ascending T4 IV Cancer A2 89 Female
061056 Colon Distal margins Colon, ascending T4 IV Normal A1 89 Female
061064 Colon Tan-grey lesion with heaping borders Rectum, NOS T3 IIA Cancer A2 70 Male
061064 Colon Margins Rectum, NOS T3 IIA Normal A1 70 Male
061066 Colon Tan-grey friable polypoid tissue fragments Rectum, NOS T1 I Cancer A3 57 Male
061066 Colon Remainder of tissue Rectum, NOS T1 I Normal A2 57 Male
061072 Colon Right colon-tan-gray fungating circumferential mass Colon, hepatic flexure T3 IIA Cancer A2 70 Female 
061072 Colon Margins negative for tumor Colon, hepatic flexure T3 IIA Normal A1 70 Female 
061079 Colon Tan-brown circumferential mass Colon, hepatic flexure T3 IIIB Cancer A2 82 Female
061079 Colon Margins Colon, hepatic flexure T3 IIIB Normal A1 82 Female
061080 Colon Tan-grey fungating, circumferential mass Sigmoid, NOS T3 I Cancer A5 63 Male
061080 Colon Margins Sigmoid, NOS T3 I Normal A1 63 Male
0610100 Colon Near circumferential tumor Rectosigmoid colon T3 IV Cancer B2 84 Female
0610100 Colon Distal and proximal margins resection portion of bowel Rectosigmoid colon T3 IV Normal B1 84 Female
0610102 Colon Fungating mass Sigmoid, NOS T1 I Cancer A2 56 Female
0610102 Colon Distal and proximal margins of resection Sigmoid, NOS T1 I Normal A1 56 Female
0610103 Colon Ulcerated tumor with rolled edges Cecum T3 IIIB Cancer A2 81 Female
0610103 Colon Distal and proximal margins of resection Cecum T3 IIIB Normal A1 81 Female
0610105 Colon tan-gray, firm, smooth, sessile polyp Colon, ascending T1 I Cancer A2 65 Male
0610105 Colon Margins Colon, ascending T1 I Normal A1 65 Male
0610110 Colon Cecum Cecum T3 IIA Cancer A4 75 Male
0610110 Colon Cecum Cecum T3 IIA Normal A1 75 Male
0610113 Colon Tan-brown circumferential lesion with heaping borders Rectum, NOS T3 IIIC Cancer A3 74 Male
0610113 Colon Proximal margin Rectum, NOS T3 IIIC Normal A1 74 Male
0610114 Colon Tan-brown, bosselated sessile polypoid lesion Rectosigmoid junction T1 I Cancer A2 50 Male
0610114 Colon Margins Rectosigmoid junction T1 I Normal A1 50 Male
0610115 Colon Tan-gray, fungating, circumferential tumor Cecum T3 IIA Cancer A4 75 Male
0610115 Colon Margins Cecum T3 IIA Normal A1 75 Male
0610207 Colon Tan-brown exophytic mass Cecum T3 IIA Cancer A4 88 Female
0610207 Colon Distal Resection Margin Cecum T3 IIA Normal A1 88 Female
0610213 Colon Tan-gray to brown, fungating circumvential mass Sigmoid colon and anastomotiT3 IIIC Cancer A2 67 Male
0610213 Colon Margins long segment Sigmoid colon and anastomotiT3 IIIC Normal A1 67 Male
0610212 Colon Red to tan soft tissue (liver) Ascending colon T2 IV Cancer A1 65 Female
0610212 Colon X Ascending colon T2 IV X 65 Female
0610211 Colon Tan-gray to brown flat lesion with heaping borders Colon, transverse T3 IIA Cancer A2 72 Male
0610211 Colon Margins Colon, transverse T3 IIA Normal A1 72 Male
0610210 Colon Colonic mucosa that has a sessile, non-movable tumor with accompanying translucent blood tinged mucus Colon, transverse T3 IIA Cancer A3 65 Male
0610210 Colon En face margins Colon, transverse T3 IIA Normal A1 65 Male
0610209 Colon Small bowel mucosa with pale tan fibrinopurulent adhesions Cecum T3 IIA Cancer A2 77 Female
0610209 Colon En face margins of resection Cecum T3 IIA Normal A1 77 Female
0610208 Colon Pink-red ulcerated lesion with raised borders Colon, hepatic fixture T4 IIIC Cancer B4 88 male
0610208 Colon Distal Resection Margin Colon, hepatic fixture T4 IIIC Normal B1 88 male
061075 Colon Adenocarcinoma, invading through the muscularis propria into the perirectal soft tissue Sigmoid, NOS T3 II Cancer A2 78 Female
061075 Colon Random uninvolved portion of bowel wall Sigmoid, NOS T3 II Normal A6 78 Female
0610101 Colon Infiltrating adenocarcinoma, oderately differentiated, invading into the muscularis propria Colon, ascending T2 III Cancer A2 54 Female
0610101 Colon Margins Colon, ascending T2 III Normal A1 54 Female
0610125 Colon Adenocarcinoma-circumferential "napkin ring" tumor Sigmoid, NOS T3 II Cancer B4 58 Male
0610125 Colon Uninvolved bowel wall Sigmoid, NOS T3 II Normal B7 58 Male
0610130 Colon Mucinous adenocarcinoma with signet ring carcinoma components, invading into subserosal region Colon, hepatic flexure T3 III Cancer A5 78 Male
0610130 Colon Margins Colon, hepatic flexure T3 III Normal A1 78 Male
0610132 Colon Well-differentiated adenocarcinoma invading through the muscularis propria into the perirectal soft tissue Sigmoid, NOS T3 II Cancer A2 59 Male
0610132 Colon Margins of resection Sigmoid, NOS T3 II Normal A1 59 Male
0610244 Colon Multiple pieces of pale tan soft tissue Cecum TX IV Cancer A1 76 Female
0610244 Colon Multiple pieces of pale tan soft tissue Cecum TX IV Normal A1 76 Female
0610245 Colon Tan-red, ulcerated mass with raised borders *From location T7NO(right colonectomy) Ascending colon T3 IIIC Cancer A3 42 Female
0610245 Colon Colonic resection margin Ascending colon T3 IIIC Normal A1 42 Female
0610246 Colon Raised, rolled edge, centrally ulcerated, apple core tumor Transverse colon T3 IIA Cancer A3 60 Male
0610246 Colon En face margins of resection (*From colon resection) Transverse colon T3 IIA Normal A1 60 Male
0610247 Colon Tam-brown mass with raised borders Cecum T3 IIIB Cancer A4 46 Male
0610247 Colon Colonic resection margin Cecum T3 IIIB Normal A1 46 Male
0610248 Colon Central raised brown tan mass Sigmoid , NOS T2 I Cancer A3 70 Female
0610248 Colon Margin farthest from mass Sigmoid , NOS T2 I Normal A1 70 Female
0610249 Colon Tan-gray to brown fungating circumvential mass Sigmoid T3 III Cancer A2 67 Male
0610249 Colon Margins short segment Sigmoid T3 III Normal A7 67 Male
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061004 Breast Irregular fatty breast mass with an overlying light tan skin ellipse Breast, upper-inner quadrant T2 IIA Cancer A3 52 Female
061004 Breast yellow-tan fibrofatty tissue without area of suspicion Breast, upper-inner quadrant T2 IIA Normal B1 52 Female
061016 Breast Gray-white firm well circumscribed nodule Breast, overlapping lesion T1b I Cancer A2 78 Female
061016 Breast Random sections Breast, overlapping lesion T1b I Normal A10 78 Female
061019 Breast Gray white, firm, well circumscribed mass Breast, upper-outer quadrant T2 IIB Cancer A4 51 Female
061019 Breast Gray white to yellow fibrofatty tissue Breast, upper-outer quadrant T2 IIB Normal B1 51 Female
061021 Breast White indurated tumor with irregular granular cut surface Breast, upper-outer quadrant T1c I Cancer A2 66 Female
061021 Breast Yellow-tan irregular fragment of fibrofatty tissue Breast, upper-outer quadrant T1c I Normal B1 66 Female
061026 Breast Two distinct white stellate tumors Breast, upper-outer quadrant T1c I Cancer A2 54 Female
061026 Breast Random quadrant sections of breast parenchyma Breast, upper-outer quadrant T1c I Normal A5 54 Female
061027 Breast Tan-grey area of rubbery induration Breast, NOS T1c I Cancer A4 70 Female
061027 Breast Tissue adjacent to area of induration Breast, NOS T1c I Normal A8 70 Female 
061028 Breast Irregular area of red-brown hemorrhagic tissue Breast, upper-outer quadrant T2 IIB Cancer A3 64 Female 
061028 Breast Yellow-tan fibrofatty breast tissue Breast, upper-outer quadrant T2 IIB Normal B1 64 Female 
061029 Breast Fibrofatty tissue containing white irregular area Breast, central portion T2 IIA Cancer A2 55 Female
061029 Breast Small fragments of right breat re-excision Breast, central portion T2 IIA Normal B12 55 Female
061035 Breast Yellow-tan fibrofatty cut surface containing a  prior biopsy cavity with surrounding areas of induration Breast, overlapping lesion T1 I Cancer B3 91 Female
061035 Breast Deep margin of resection Breast, overlapping lesion T1 I Normal B2 91 Female
061040 Breast Tan to white stellate tumor Breast, upper-outer quadrant T2 IIIC Cancer C1 79 Female
061040 Breast Various margins Breast, upper-outer quadrant T2 IIIC Normal C10 79 Female
061044 Breast Gray-white, well demarcated indurated mass Breast, upper-outer quadrant T2 IIA Cancer B1 62 Female
061044 Breast Re-excision lumpectomy right breast posterior superior margin Breast, upper-outer quadrant T2 IIA Normal C10 62 Female
061048 Breast Grey-white, firm, indurated mass Breast, NOS T1 I Cancer B2 76 Female
061048 Breast Random sections Breast, NOS T1 I Normal B6 76 Female
061057 Breast Teardrop shaped excision of skin-contains nipple and areola Breast, NOS T2 IIIA Cancer A1 39 Female
061057 Breast Random quadrant sections Breast, NOS T2 IIIA Normal A13 39 Female
061063 Breast Light tan ill defined tumor Breast, NOS T2 IIB Cancer C3 37 Female
061063 Breast Deep margin of resection Breast, NOS T2 IIB Normal C6 37 Female
061068 Breast Hard tumor Breast, upper-outer quadrant T1c I Cancer A1 58 Female
061068 Breast Additional portions of breast tissue near tumor and margins of resection Breast, upper-outer quadrant T1c I Normal A4 58 Female
061070 Breast Entire area of tumor and surrounding margins of breast tissue Breast, NOS T1c IIIA Cancer A1 52 Female
061070 Breast Additional margins Breast, NOS T1c IIIA Normal A10 52 Female
061073 Breast Right breast tissue-white firm tunor Breast, NOS T1c IIIA Cancer A3 64 Female
061073 Breast Deep margin of resection Breast, NOS T1c IIIA Normal A6 64 Female
061074 Breast Left breast tissue-irregular fragment of fibrofatty tissue Breast, upper-outer quadrant T2 IIA Cancer C1 67 Female
061074 Breast Re-excision deep margin Breast, upper-outer quadrant T2 IIA Normal D1 67 Female
061082 Breast Tan brown remarkable skin ellipse Breast, central portion T3 IIB Cancer A2 70 Female
061082 Breast Skin overlying over tumor-tan-grey skin ellipses and underlying soft tissue Breast, central portion T3 IIB Normal E1 70 Female
061085 Breast Yellow fatty mass Breast, upper-outer quadrant T1 IIA Cancer B1 65 Female
061085 Breast Irregular fragment of yellow-tan fibrofatty tissue Breast, upper-outer quadrant T1 IIA Normal D1 65 Female
061088 Breast Well-circumscribed indurated mass Breast, upper-outer quadrant T1b IIA Cancer A1 62 Female
061088 Breast Random sections Breast, upper-outer quadrant T1b IIA Normal B1 62 Female
061095 Breast Irregular gray-tan tumor Breast, NOS T1c IIIC Cancer A3 54 Female
061095 Breast Deep margin of resection Breast, NOS T1c IIIC Normal A2 54 Female
061098 Breast Tan-gray, rubbery indurated well demarcated mass Breast, upper-outer quadrant T1b I Cancer A1 58 Female
061098 Breast Remainder Breast, upper-outer quadrant T1b I Normal A6 58 Female
0610104 Breast Yellow-tan fibrofatty tissue Breast, upper-outer quadrant T2 IIA Cancer A5 62 Female
0610104 Breast Deep margin Breast, upper-outer quadrant T2 IIA Normal D1 62 Female
0610106 Breast Dense white indurated area Breast, upper-outer quadrant T2 IIA Cancer A2 77 Female
0610106 Breast Re-excision right breast lumpectomy Breast, upper-outer quadrant T2 IIA Normal B1 77 Female
0610112 Breast White nodule Breast, upper-outer quadrant T1c I Cancer A1 77 Female
0610112 Breast Additional portions of breast parenchyma and margin Breast, upper-outer quadrant T1c I Normal A7 77 Female
0610117 Breast Gray-white, firm, well circumscribed mass Breast, lower-outer quadrant T1b I Cancer A1 56 Female
0610117 Breast Random sections Breast, lower-outer quadrant T1b I Normal A10 56 Female
0610123 Breast Infiltrating lobular carcinoma Breast, upper-outer quadrant T2 II Cancer B1 71 Female
0610123 Breast Breast, left inferior superficial margin, re-excision Breast, upper-outer quadrant T2 II Normal C1 71 Female
0610206 Breast High grade invasive papillary carcinoma, papillomas, and fibrocystic changes Breast, upper-outer quadrant T2 IIA Cancer C11 63 Female
0610206 Breast Deep margin of resection Breast, upper-outer quadrant T2 IIA Normal C4 63 Female
0610205 Breast Left breast, gray-white yellow tissue core Breast, overlapping lesion T1c I Cancer A1 78 Female
0610205 Breast Left breast, gray-white yellow tissue core Breast, overlapping lesion T1c I Normal A1 78 Female
0610204 Breast Right breast tissue-white tumor Breast, upper-inner quadrant T2 IIA Cancer A6 55 Female
0610204 Breast Deep margin of resection over lower outer quadrant hemorrhagic area Breast, upper-inner quadrant T2 IIA Normal A2 55 Female
0610202 Breast Blood tinged dense fibrous breast tissue with focal areas of califications Breast, upper-outer quadrant T1 I Cancer C7 64 Female
0610202 Breast Lower outer quadrant dense fibrous breast tissue Breast, upper-outer quadrant T1 I Normal C10 64 Female
0610203 Breast Right breast, cores of yellow-tan needle core biopsies of fibrofatty tissue Breast, upper-inner quadrant T1 I Cancer A1 45 Female
0610203 Breast Right breast, cores of yellow-tan needle core biopsies of fibrofatty tissue Breast, upper-inner quadrant T1 I Normal A1 45 Female
0610126 Breast Light tan well circumscribed tumor Breast, upper-inner quadrant T2 IIA Cancer A3 72 Female
0610126 Breast Random quadrant sections Breast, upper-inner quadrant T2 IIA Normal A8 72 Female
0610124 Breast Gray-white firm well demarcated tumor Breast, upper-outer quadrant T2 IIA Cancer A9 66 Female
0610124 Breast Re-excision posterior, superior, lateral and inferior margin Breast, upper-outer quadrant T2 IIA Normal B1 66 Female
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061032 Breast White rubbery tumor Breast, upper-outer quadrant T1a I Cancer A1 56 Female
061032 Breast Additional portions of breast tissue and margin Breast, upper-outer quadrant T1a I Normal A7 56 Female
061093 Breast Gray mass Breast, upper-inner quadrant T1c II Cancer A3 77 Female
061093 Breast Random quadrant sections Breast, upper-inner quadrant T1c II Normal A8 77 Female
061084 Breast Gray-white tumor Breast, upper-inner quadrant T1 I Cancer A5 67 Female
061084 Breast Tumor and anterior Breast, upper-inner quadrant T1 I Normal A4 67 Female
061078 Breast Gray-white firm mass Breast, overlapping lesion T1 I Cancer B1 68 Female 
061078 Breast Random Sections Breast, overlapping lesion T1 I Normal B6 68 Female 
061061 Breast Breast parenchyma with focal ductal carcinoma in situ, high grade with necrosis Breast, central portion T1 I Cancer A1 70 Female
061061 Breast Ductal carcinoma in situ, high grade, comedo and micropapillary patterns-inked margins negative for tumor Breast, central portion T1 I Normal D1 70 Female
061058 Breast Infiltrating ductal carcinoma-White stellate lesion Breast, upper-outer quadrant T1b I Cancer A1 73 Female
061058 Breast Representative portion of additional margins and breast parenchyma Breast, upper-outer quadrant T1b I Normal A4 73 Female
061081 Breast Infiltrating ductal carcinoma-ill defined area of induration Breast, NOS T1b I Cancer A3 40 Female
061081 Breast Re-excision, medial margin, left breast Breast, NOS T1b I Normal D7 40 Female
061049 Breast Invasive and in situ ductal carcinoma, multifocal Lower-inner quadrant T1b I Cancer A1 66 Female
061049 Breast Remainder Lower-inner quadrant T1b I Normal A9 66 Female
061036 Breast Well-differentiated invasive ductal carcinoma-white stellate lesion Upper-inner quadrant T1b I Cancer A1 65 Female
061036 Breast Additional margins of resection and breast parenchyma Upper-inner quadrant T1b I Normal A6 65 Female
061092 Breast Round tumor Breast, overlapping lesion T1b I Cancer A3 84 Female
061092 Breast Random quadrant sections Breast, overlapping lesion T1b I Normal A6 84 Female
0610235 Breast ill-defined, palpably firm tumor Upper-inner quadrant T1c IIA Cancer C2 47 Female
0610235 Breast Dense white fibrous breast tissue Upper-inner quadrant T1c IIA Normal C7 47 Female
0610243 Breast Palpable mass Upper-outer quadrant T2 IIA Cancer C2 73 Female
0610243 Breast Superior medial quadrant Upper-outer quadrant T2 IIA Normal C7 73 Female
0610242 Breast Multiple cores tan-yellow, ultrasound needle core biopsies of fibrofatty tissue Upper-inner quadrant T1b I Cancer A1 73 Female
0610242 Breast Multiple cores tan-yellow, ultrasound needle core biopsies of fibrofatty tissue Upper-inner quadrant T1b I Normal A1 73 Female
0610241 Breast Well-circumscribed the scirrhous white tumor *From location ODSC Lower-outer quadrant T2 IIA Cancer E2 70 Female
0610241 Breast Superior margin Lower-outer quadrant T2 IIA Normal E10 70 Female
0610240 Breast Tan white irregular bordered, firm tumor Upper-outer quadrant T1c I Cancer C1 59 Female
0610240 Breast Medial and lateral margins Upper-outer quadrant T1c I Normal C10 59 Female
0610239 Breast Tan-white focally hemorrhagic mass Upper-outer quadrant T2 IIIA Cancer C2 39 Female
0610239 Breast Upper-outer quadrant Upper-outer quadrant T2 IIIA Normal C6 39 Female
0610238 Breast Focal area of dense white stellate fibrosis Upper-inner quadrant T1b I Cancer A1 61 Female
0610238 Breast Superior margin Upper-inner quadrant T1b I Normal A6 61 Female
0610237 Breast Tan white mass with superior and inferior margins Lower-outer quadrant T1c I Cancer D1 60 Female
0610237 Breast Remainder of specimen Lower-outer quadrant T1c I Normal A2 60 Female
0610236 Breast Tan white, firm, ill-defined and focally hemorrhagic mass Upper-outer quadrant T1a I Cancer C3 58 Female
0610236 Breast Anterior margin Upper-outer quadrant T1a I Normal C10 58 Female
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R1 R2 R3 R4 R5 R6 R7 R8 R9 R10 R11 R12 R13 R14
L1 91% 97% 93% 90% 85% 91% 92% 98% 96% 92% 95% 99% 96% 95%
L2 93% 93% 98% 93% 98% 93% 96% 98% 98% 96% 98% 100% 97% 100%
L3 89% 93% 93% 91% 90% 90% 94% 96% 95% 90% 95% 93% 92% 97%
L4 92% 88% 90% 88% 92% 82% 91% 96% 92% 94% 92% 92% 93% 92%
L5 92% 93% 91% 90% 91% 93% 95% 99% 96% 95% 92% 96% 94% 99%
L6 92% 97% 88% 84% 90% 93% 90% 93% 91% 89% 84% 90% 93% 91%
L7 91% 92% 92% 86% 90% 89% 91% 96% 92% 90% 89% 93% 96% 96%
L8 84% 90% 86% 83% 87% 95% 85% 90% 86% 87% 87% 83% 96% 89%
L9 95% 90% 86% 86% 92% 89% 91% 96% 95% 90% 86% 93% 91% 90%
L10 99% 95% 90% 95% 93% 92% 97% 93% 94% 98% 96% 92% 95% 99%
L11 98% 93% 87% 85% 99% 94% 86% 92% 93% 82% 88% 93% 99% 95%
L12 95% 93% 95% 88% 85% 87% 91% 92% 95% 85% 93% 90% 87% 94%
L13 86% 89% 95% 89% 73% 84% 92% 95% 92% 86% 82% 89% 97% 93%
L14 82% 100% 100% 85% 85% 100% 100% 100% 100% 85% 94% 100% 94% 100%
L15 93% 98% 99% 100% 70% 100% 92% 94% 94% 87% 99% 93% 98% 100%
L16 86% 81% 83% 98% 82% 86% 97% 86% 94% 87% 84% 88% 86%
L17 99% 98% 98% 93% 86% 84% 96% 90% 85% 92% 90% 91% 89% 100%
L18 93% 83% 89% 85% 93% 85% 88% 90% 100% 86% 99% 100% 92%
L19 88% 89% 96% 85% 86% 89% 90% 86% 90% 86% 87% 91% 95% 90%
L20 88% 98% 86% 84% 87% 91% 85% 98% 92% 93% 98% 87% 88% 96%
L21 86% 89% 91% 93% 88% 86% 94% 98% 90% 94% 89% 91% 93% 83%
L22 89% 96% 91% 98% 96% 97% 94% 99% 92% 96% 97% 95% 95% 89%
L23 100% 94% 96% 96% 93% 95% 96% 98% 91% 91% 95% 97% 95% 92%
L24 91% 92% 94% 91% 95% 79% 88% 97% 89% 91% 91% 97% 83% 99%
L25 90% 94% 93% 88% 87% 83% 88% 96% 86% 93% 90% 94% 91% 97%
L26 93% 90% 92% 92% 87% 80% 94% 95% 91% 89% 90% 92% 92% 91%
L27 93% 96% 98% 96% 99% 96% 98% 99% 96% 90% 99% 100% 91% 94%
L28 94% 88% 96% 97% 93% 90% 97% 100% 98% 90% 98% 97% 93%
L29 98% 90% 98% 97% 72% 95% 100% 97% 90% 94% 95% 98% 96% 95%
L30 87% 89% 92% 85% 86% 90% 90% 95% 90% 93% 83% 91% 92% 86%
L31 82% 91% 83% 83% 90% 82% 86% 96% 83% 86% 90% 92% 94% 84%
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R15 R16 R17 R18 R19 R20 R21 R22 R23 R24 R25 R26 R27 R28 Avg
L1 96% 98% 86% 95% 98% 99% 93% 97% 94% 95% 95% 95% 90% 100% 94
L2 94% 98% 83% 96% 97% 97% 86% 92% 86% 100% 93% 99% 89% 96% 95
L3 93% 94% 81% 90% 94% 96% 85% 98% 87% 97% 96% 96% 85% 84% 92
L4 90% 92% 92% 90% 90% 90% 96% 93% 90% 89% 82% 90% 82% 87% 90
L5 93% 91% 86% 90% 93% 71% 93% 90% 91% 91% 95% 93% 96% 96% 92
L6 83% 91% 77% 85% 83% 90% 88% 85% 91% 87% 89% 92% 91% 90% 89
L7 92% 91% 90% 88% 94% 88% 89% 90% 92% 91% 95% 91% 90% 88% 91
L8 85% 81% 86% 86% 94% 82% 86% 100% 87% 90% 87% 90% 88% 83% 88
L9 89% 94% 91% 85% 84% 91% 90% 100% 91% 86% 90% 90% 83% 98% 90
L10 89% 87% 95% 85% 90% 94% 87% 86% 96% 92% 95% 99% 82% 88% 93
L11 82% 87% 84% 90% 88% 96% 92% 100% 90% 91% 91% 90% 93% 98% 91
L12 74% 87% 59% 82% 88% 80% 88% 91% 85% 83% 85% 86% 93% 93% 87
L13 80% 84% 86% 86% 90% 89% 87% 100% 87% 81% 86% 88% 80% 97% 88
L14 100% 100% 52% 100% 100% 83% 85% 100% 71% 94% 88% 100% 91% 95% 92
L15 93% 92% 83% 88% 97% 90% 66% 100% 93% 92% 75% 99% 87% 98% 92
L16 86% 93% 85% 96% 91% 94% 85% 100% 92% 86% 85% 88% 89
L17 98% 90% 86% 89% 99% 92% 86% 99% 85% 95% 86% 99% 90% 87% 92
L18 92% 100% 85% 100% 96% 92% 95% 85% 92% 84% 93% 92% 86% 91
L19 86% 90% 72% 84% 85% 88% 87% 92% 90% 87% 86% 86% 95% 85% 88
L20 81% 88% 90% 86% 96% 85% 90% 100% 91% 97% 83% 84% 81% 90% 90
L21 91% 90% 90% 87% 86% 87% 89% 98% 89% 87% 95% 95% 84% 88% 90
L22 86% 94% 81% 89% 84% 93% 86% 96% 90% 81% 97% 97% 96% 95% 92
L23 92% 95% 82% 90% 90% 86% 87% 94% 89% 90% 93% 94% 92% 88% 93
L24 99% 85% 90% 87% 86% 86% 80% 90% 90% 87% 87% 87% 88% 91% 90
L25 90% 83% 89% 87% 85% 91% 91% 97% 90% 89% 88% 91% 89% 92% 90
L26 88% 94% 89% 90% 90% 95% 91% 94% 90% 90% 88% 89% 82% 95% 90
L27 92% 93% 90% 95% 91% 86% 88% 95% 89% 89% 90% 88% 93% 98% 94
L28 96% 98% 90% 96% 97% 89% 91% 97% 89% 97% 88% 88% 90% 94
L29 96% 92% 100% 100% 95% 80% 92% 92% 85% 97% 95% 92% 83% 89% 93
L30 85% 93% 82% 97% 91% 90% 80% 88% 91% 88% 82% 93% 81% 98% 89
L31 91% 79% 84% 89% 80% 99% 84% 95% 90% 89% 91% 87% 93% 90% 88
